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PREFACE
Neuromyelitis optica has been traditionally considered an inflammatory demyelinating
disease of the nervous system similar to multiple sclerosis but with a poorer outcome.
Early descriptions were made by Albutt in 1870. Subsequently Eugene Devic (1894)
summarised the known cases andliterature and the disease carries his name. There had
been sporadic case reports throughout literature in the last century and small case series.
In 1999 the Mayo Clinic reported
a
large series and suggested diagnostic criteria. Only a
case series has been published from the United Kingdom. This study intended to identify
patients across the United Kingdom, and prospectively follow them up characterising
clinical epidemiological features, treatments and long-term outcomes.
Treatments in NMO are anecdotal. 1 also studied the effects of two treatments —
rituximab and mycophenolate in NMO during myfellowship at the Mayo Clinic, USA.
However, great advances have been made in NMOin thelast five years. A specific
autoantibody -NMO IgG was identified by Vanda Lennonand colleagues at the Mayo
Clinic. Subsequently the antigen to this antibody was found to be a component of the
water channel on the surface of astrocytes, aquaporin-4. More recently glutamate
mediated damage has been identified to be a key mechanism ofinjury. Much has been
learned about the pathogenesis and the pathology of NMO. Howeverthe epidemiology,
long term outcomesandeffective treatmentsare still unclear. I hope this work will might
shed some light on these aspects.
ACKNOWLEDGEMENTS
Neuromyelitis optica (NMO)has been the dominantplayer in mylife for the last six years.
I had stepped into this unwittingly as a research fellow aiming for higher specialist training
in Neurology. Little did I know that I wouldstill be deeply involved in its study for years
to come! I must thank Professor David Chadwick who suggested my name to Dr Mike
Boggild who was planning a UK wide NMO study. Dr Boggild has been a constant
source of support and guidance allowing a free rein. The late lan Hart who was my
supervisor was a great source of wisdom. His achievements in immunology particularly
neuromytonia has been inspirational - my onlyregret is that I could not lear more from
him. Professor Solomon has had a long-term interest in NMOandhas re-entered the fray
as my supervisor to help me complete this work. I have contacted and have been
contacted by several Clinicians across the UK and abroad regarding their patients with
NMO. Their experiences have helped guide this study. The one-year fellowship with
Professor Weinshenker has been a major turning point in my understanding of this
disease. I am particularly grateful to Professor Weinshenker, Doctors Sean Pittock,
Matiello Marcelo and Bruce Cree for permitting me to utilise the Mayo clinic NMO
database and for allowing me toinclude the rituximab and mycophenolate studies done
under their guidance. I have immense gratitude to colleagues at Oxford, (particularly
Professor Angela Vincent) Manchester , Mayo clinic and Newcastle who have assisted
with the immunologic and genetic essays. I am most grateful to Consultant Neurologists
across the UK whohas taken the time to refer patients to this study. This would not have
been possible without the British Neurological Surveillance Unit and Karen Reeves.
Thanks are due to Maria Pybis, Michelle Dennis and Tony Murphy for their
contributions. I am indebted to my family whohave suffered (not in silence though!) my
absences andlate nights! More than one hundred patients and their families have been
contacted multiple times. They have contributed time, effort, money and blood! I am
hopeful that the results of this study will be beneficial to them and their future
management. However there are a few who are now deceased andwill not benefit from
their contributions. It is to these selfless people that I dedicate this work
DECLARATION
I declare that all the work described in this thesis is my own, with the
exceptions mentioned in the acknowledgements.
Abstract
Clinical Epidemiology and Treatment of Neuromyelitis optica
Anu Jacob
Introduction: Neuromyelitis optica (NMO)is an idiopathic inflammatory demyelinating
condition of the central nervous system, which was once considered a variant of multiple
sclerosis (MS), restricted to the optic nerve and spinal cord. We now knowit to be
disease in its own right with striking similarities to MS. There have been remarkable
advances in the understanding of its aetiopathogenesis in the last few years. However its
epidemiology andeffective treatmentsare still uncertain.
Aims:
Identify, characterise and follow up a cohort of NMO patients from the United
Kingdom.
Describe the epidemiology of NMOin Merseyside
Identify new treatments for NVO
Methods:Usingthe British neurological surveillance unit and the electronic records
system of the Walton Centre for Neurology and Neurosurgery, | identified 42 patients
with NMOover a5 year period; 1 documented their history and examination findings,
tested for aquaporin -4 antibodies, oligoclonal bands and autoimmune markers. Using
the electronic records system of the Walton Centre for Neurology and Neurosurgery, |
indentified all patients with NMO in Merseyside, and described the epidemiology. Finally
I examined the role of novel immunomodulatory agents - rituximab (antiCD-20
monoclonal antibody) and mycophenolate in NMO.
Results: 128 patients were seen and 75patientsare still being followed up-a median
(range) of 34 months (0.4-71). Forty-two of these patients satisfy currentcriteria for
NMO or NMOspectrum disorders (NMOSD). 81%were positive for the aquaporin-4
antibody. Ten (24%) patients died andall patients had some disability at their last follow
up.
In the Merseyside region the prevalence of NUO, NMOSDand the combined group was
estimated to be 4.37, 3.49 and 7.86 per million. The incidence was estimated to be 0.52,
0.7 and 1.22 per million peryear respectively. These data suggest that there are at least 369
patients with NMO or NMOSDand 57 new patients/year in the United Kingdom.
Rituximab was found to reducerelapse rates andstabilise or improve disability in a cohort
25 patients. Mycophenolate was found to reducerelapse rates andstabilise disability in a
cohort of 24 patients
Conclusions: Thelargest prospective study to date again show that NMO and NMO
spectrum disorderare disabling conditions with a high mortality and morbidity and
aquaporin-4 antibody positivity is common. NMO is commoner than previously thought
among the Caucasian population. Two ofthelargest retrospective analyses of treatment
efficacy in NMO have shown the benefit of both rituximab and mycophenolate in
reducing relapse rates and preventing the progression ofdisability.
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Chapter1.
Introduction and review ofliterature
Introduction 1.1.
Neuromyelitis Optica (NMO) or Devic’s disease was first described by Allbutt, who in
1870 reported a patient with a “sympathetic disorder of the eye” after an acute episode of
myelitis.(1) A quarter ofa century later Eugene Devic and his student Gault 16 cases from
the literature in addition to one of their own and the syndrome came to be known as
Devic’s disease (2)
Our understanding of NMO did not change greatly over the course next century. It
remained largely regarded as an unusual or severe variant of Multiple Sclerosis. However
the last decade has seen major advances in our understanding of the etiopathogenesis of
NMO.
There are now firm reasons to believe that NMOis a distinct immune mediated, largely
relapsing, inflammatory, demyelinating disease of the central nervous system (CNS). It
most commonly targets the optic nerves and spinal cord, with longitudinally extensive
spinal cord lesions on MRI being recognized as a characteristic and important diagnostic
finding, Wealso now recognizethat brain lesions can occur in NMO,though are usually
atypical for MS. Wealso know that a specific serum antibody (NMO-IgG) whichreacts
specifically with aquaporin 4 (AQP4) is present in up to 70% of patients (3) NMO is the
first and the only CNS inflammatory demyelinating disorder to date in which a specific
immunologic marker andits target have been identified.
1.2 Epidemiology and Genetics
The exact incidence and prevalence data are hard to obtain in western populations as a
result of the rarity of disease in Caucasian populations. In Japan, 15-40%of cases of
Le
demyelinating disease are "optico-spinal" (Kira, 2003). But whether these are truly NVO
or a mix of western type MS, with predominant optic and spinal involvement, and true
NMOis uncertain. In NMO cohorts from Northem Europe and North America non-
Caucasians (African, Hispanic and Asian) are over-represented, though Caucasians still
comprise the majority of patients in these series. It has been estimated that NMO
represents no more than 1% of patients with demyelinating disease in Western
populations.
A recent survey from 2003-2004 covered the Cuban white and non-white population.
Prevalence was 5.1 per 1000,000 for the total Cuban population(4).The estimated average
annual incidence rate was 0.53 per 1000,000. Neither of these rates differed significantly
among whites, blacks, mixed, or non-whites. The number of cases howeveris far too
small to assert the presence or absence of anyracial/ethnic predilection for NMO. The
prevalence rates by gender demonstrated a muchhigher rate in females (9.1) than in males
(1.2). Regardless of geographic variability NMO maystill be an under diagnosed
condition, often mislabelled as MS.It is to be hoped that with increasing awareness and
availability of MRI and NMO-IgGtesting a clearer picture will emerge.
A small number of cases of familial NMO have been reported. The first such case
involving identical twin sisters, one whodeveloped the illness at age 24 and the other at
age 26(5) two sisters with bilateral ON followed by myelitis at 2 and 3 year(6), two
Japanese sisters aged 62 and 67 and two sisters of Spanish-American ancestry, who
developed NMOatages 26 and 28(7, 8)
Amongst Japanese patients HLA DRB1*1501, theallele that is most strongly associated
with MS in western countries, is not associated with OSMS, although it is associated with
Japanese “classical” MS(Q9). HLA DP*0501 has been reported to be over-represented in
16
Japanese patients with OSMS but this allele has a high frequency in the general Japanese
population thus complicating the analysis of such an association(10).
1.3 Clinical Features
NMOis largely relapsing (> 80%) though a minority mayhave only a monophasic course.
Relapsing NMOin the west has a female to male ratio of 5:1. Monophasic NMO affects
both sexes equally. The median age of onset in Caucasians is in the fourth decade.
(11)Paediatric cases have been reported (12, 13)
NMOis characterised by ON and transverse myelitis. The ON can be unilateral or
bilateral, simultaneous or separated by years. It is typically more severe than an ON attack
caused by MS. The myelitis too is usually severe and typically causes substantial disability
at its nadir. Imaging done acutely almost always shows longitudinally extensive myelitis
(LET™), often with cord oedema and gadolinium enhancement.
Brain stem involvement can occur, usually as an extension of a severe cervical myelitis,
and maycause hiccoughs,intractable nausea orrespiratory failure (14)
Clinical brain involvement is uncommon but has been reported particularly in pediatric
populations. Paroxysmal tonic spasms, which are sequelae of the myelitis, are more
common in NMO compared with prototypic MS. Typically these last 10-30 seconds and
are characterized by painful contractions of a limb musculature (they can be mistaken for
partial seizures or may belabelled functional). It is important to recognize these as they
readily respondto small doses of carbamazepine.
NMOcoexists with other auto-immunediseases: thyroid, systemic lupus erythematosus
(SLE), Sjégren’s syndrome (SS), Myasthenia gravis and coeliac disease have all been
reported in association with NMO(15). Non-organ specific antibodies, such as antinuclear
antibodies or SSA are found commonly(16). It is important that neurologists recognize
that the presence of these alone in the absence of clinical symptoms andsigns of their
associated systemic disorders should notlead to a diagnosis of a connective tissue disorder
as the cause of the myelitis or optic neuritis. It is far more likely that they have NMO with
co-existing antibodies reflecting disordered humoral immunity(15). Many of these patients
are seropositive for NMO-IgG.
1.3.2 Neuromyelitis optica in Children
NMOin children is similar to those adults. The frequency of NMO-IgG in both
childhood and adult cases of NMO,andits rarity in paediatric relapsing-remitting
multiple sclerosis, supports the conceptthat these diseases havea similar pathogenesis
in childhood and adulthood. Isolated LETM does not appear to be as predictive of an
NMOspectrum disorder in children as it is in adults.
Treating children with immunosuppressants, steroids or monoclonal antibodies is a
thorny issue without real consensus. (13)
1.4 Diagnostic Criteria
Several diagnostic criteria have been proposed; the most widely accepted are those put
forward by the Mayo group in 1999, which have recently been revised to reflect the
importance of spinal cord MRI findings in this disorder (11). With the availability of
antibodytesting isolated or recurrent episodes of optic neuritis or transverse myelitis
(but not both) associated with the antibody have been brought under the category of
diseases related to NMO. These (ie. ON or TM) have been named NMO spectrum
disorders (NMOSD). They tend to behave like NMO and should be treated as such
(Table1.1)
  
NMO
Optic neuritis
Acute myelitis
And at least two of three supportivecriteria
1. Contiguous spinal cord MRIlesion extending over 3 vertebral segments
2. Brain MRI not meeting diagnostic criteria for multiple sclerosis
3. NMO-IgG seropositive status
NMOSD
Optic neuritis or Longitudinally extensive myelitis
And
Presence of NMO IgG or Antiaquaporin-4 antibody  
Table 1.1Proposeddiagnostic criteria for NMO and NMO SD
1.5 Neuroimaging
Spinal cord MRI undertaken shortly after onset of a sub-acute myelitis (within days to
weeks), typically shows a central cord lesion extending over three or more vertebral
segments. Longitudinally extensive transverse myelitis (LETM) (Figure 1) with cord
oedema and gadolinium enhancementis typical. Follow-up MRI studies may show cord
atrophy, syrinx or complete resolution.
Though at disease onset MRI of the brain is usually normal, over time up to 60% will
develop non-specific findings. In (10%) they fulfill Barkhof criteria for MS (17). These
lesions are largely asymptomatic. Brain stem lesions especially periventricular and
hypothalamic lesions have been noted. These are regions of high AQP4 expression, the
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target antigen for NMO-IgG (18, 19). Transient encephalopathy or endocrinopathies have
been associated with such findings.
Diffusion tensor imaging of normal-appearing brain tissue using has shown abnormal
diffusion in patients with NMO,probably related to secondary degeneration caused by
lesionsin the spinal cord and optic nerve (19)Optic nerve imaging typically shows oedema
and contrast enhancementacutely — which mayextend from orbit to chiasm - and atrophy
at later stages.
1.6 Cerebrospinal fluid
During an acute relapse CSF usually shows a raised total protein with pleocytosis, on
occasion 50-500 cells, often neutrophilic and at times leading to diagnostic confusion.
Eosinophils may also be found in the CSF in NMO(20). Several inflammatory chemo-
attractant cytokines (interleukin [IL]}-17 and IL-8, CSF Eotaxin-2, Eotaxin-3 and
eosinophil cationic protein) have been found elevated in the CSF of NMO/OSMS
patients(21). CSF oligoclonal bands are uncommon, present in only 10-20% patients,
representing another differentiating feature from MS. There are several clinical and
investigational features, which help to distinguish NMO from MS, these are outlined in
table 1.2.
 Feature Multiple Sclerosis Neuromyelitis optica
Part of nervous system
affected Brain and spinal cord
Usually optic nerves and
spinal cord
 
Nonwhite ancestry Uncommon Semen
a Canberelapsing or Monophasic or relapsing
Course _ (progression rare)progressive ;
Occurs earlier (often even
after the
Disability Occurs usually in fi rst event) with severe
’ progressive stage relapses
Brain lesions not typical for
Lesions in brain and small eas aeo ys Longlesions in spinal cordMRI lesions(<2 segments) in_ ? with cordspinal cord swelling (>3 segments)
Spinalfluid oligoclonal
bands Present in >90%
Present in <20%
Present in >70%NMOIG in serum Absent
, . 4 oy 5 , and iplSystemic autoantibodies Infrequent BreUeHE a0 manliple
  Treatment  Interferons, glatirameracetate, natalizumab  Immunosuppressants e.g,:Azathioprine, steroids
Table 1.2: Differences between neuromyelitis optica and typical ‘Western’ MS
Feature MS Neuromyelitis optica
1.7 Pathology
 
NMOpathology is characterized by presence of inflammation demyelination and necrosis
that involves both grey and white matter, often resulting in cavitation. There is presence
of vascular hyalinization and eosinophils may be abundant. Perivascular immune complex
deposition in a ‘rim and rosette’ pattern is seen in the spinal cord, brain and optic nerves.
More recently, widespread absence of stainable AQP4 in NMO lesions has been
demonstrated by several groups (22-24). In some of the lesions described only AQP4 loss
21
(associated with vasculocentric IgG and IgM deposits and complement activation)
without evidence of demyelination or necrosis is seen. This suggests that aquaporin loss
could be the earliest pathogenic event in NMOand supports the contention that NMO-
IgGplays a central role in the etiopathogenesis of the disorder(22).
1.8 Immunology
In 2004 Lennon et al reported the discovery of NMO-IgG, the first ‘disease specific’
antibody in CNS demyelinating disease (3). The antibody, identified by immuno-
fluorescence has a sensitivity of 73% and specificity 91% for NMO.Theantibody is also
positive in a significant proportion of patients deemed to be at high risk of NMO-
spectrum disorders (that is, patients with isolated or recurrent optic neuritis or myelitis)(3).
The specificity of NMO-IgG also called anti AQP4 antibody (in Europe and Japan) has
now been independently validated by several groups (25-28). Immunoprecipitation and
cell based assays have been developed (25). Of the three methods used in the detection of
the antibody, indirect immunofluroscence (NMO IgG), cell based assays and immuno-
precipitation (aquaporin 4 antibody) the cell based assays have the highest sensitivity in
(90%)(29). Whether NMO-IeG titre correlates with disease severity, attack severity or
response to therapy is as yet unknown. Noclinical differences between NMO-IgG
positive and negative patients meeting currentcriteria for NMO have been reported in
series to date.
1.9 The widening spectrum ofNMO
With the availability of NMO-IgG several ‘idiopathic/orphan’ demyelinating entities can
be brought under the NMO ‘umbrella’. These include recurrent myelitis without evidence
of ON and recurrent ON without evidence of myelitis. In 29 consecutive patients
evaluated at Mayo Clinic with a single event of longitudinally extensive transverse myelitis,
22
40% were seropositive for NMO-IgG (30). Of nine seropositive cases followed for 1 year
or longer, 55% (5 patients) had a relapse of myelitis (4 patients) or developed ON (1
patient) within the first year of follow-up; an additional seropositive patient developed
ONin the second year of follow-up. In contrast, no seronegative patient had a further
neurological event. This finding raises the question of prophylactic or preventative
treatment, with the group at Mayo arguingforinitiation of immunosuppressive treatment
in those patients with an index event (ON or TM) andpositive NMO-IgG.
There is increasing evidence that NMO co-exists with a number of systemic connective
tissue disorders, particularly SLE and Sjogrens syndrome (SS)(31). Myelitis and optic
neuritis hitherto attributed to vasculitic complications of these disorders are most likely
due to co-existing NMO (16). In fact approximately half of such patients are seropositive
for NMO-IgG, whereas patients with SLE or SS who do not have optic neuritis or
myelitis are uniformly seronegative (16)
1.10 Aquaporin 4
The target antigen of NMO-IgG has been recently identified as the water channelprotein,
aquaporin-4 (AQP4). AQP4 is the dominant water channel within the central nervous
system(32). It is located within the CNS on the abluminal wall of small vessels in
astrocytic foot processes in close association with the cytoskeleton complex, which
includes a-syntrophin, B-dystroglycan, and dystrophin (Dp71). CNS Aquaporin’salso play
a role in osmoreception, K+ siphoning and CSF formation andare strongly implicated in
the pathogenesis of cerebral edema following water intoxication or focal cerebral
ischemia(33). Lennon et al have shown that NMO-IgG selectively bind AQP4. Precisely
how the AQP4 specific antibodies (NMO-IgG) cause NMO_ remains uncertain. The
antibodies may bind to AQP4 and activate complement initiating a cascade of
23
inflammation. Alternatively, they may have a functional effect on the water channel,
leading to disruption of water homeostasis. More recently glutamate mediated
excitotoxicity seems tobeplayer (34). The gene for AQP4is located on 18q11.2-q12.1.
Though no pathogenic mutations have been identified so far, it is conceivable that at least
in families with NMO that such a mutation may beinvolved in its pathogenesis.
1.11 Animal models ofNMO
Developing animal models that mirror human disease would be a major step forward in
understanding NMO pathogenesis. Development of such perfect model has been the holy
grail of researchers in MS . Several models that lead to opticospinal disease a variety of
myelin antigens particularly Myelin oligodendrocyte specific protein(35, 36) are known.
Two such mouse models (double-transgenic mouse strains [opticospinal EAE mouse]),
whichspontaneously develop an EAE-like neurological syndrome resembling NMO(37)
have been developed by crossing TCRmoc and IgHmocsingle-transgenic mice, both
onC57BL/6 background. At around 8 weeks of age these mice spontaneously developed
demyelinating lesions located in the optic nerve andspinal cord. Howeverthese lesion
were small (not longitudinally extensive) and there were no detectable AQP4specific
antibodies in the serum or IgG or complement deposition in the lesions. A more
definitive model that reflects human pathology more accurately is awaited(38).
1.12 Treatment ofNMO
Managing a patient with NMO involves treatment of relapses, strategies for relapse
prevention, management of symptoms andrehabilitation
1.12.1 Treatment of Relapses
Treatment recommendations in NMOare largely based on case series or expert opinion,
there is no class I evidence to guide long-term management. An acute relapse of NMO
(ON or LETM) should be treated as early as possible with intravenous corticosteroids,
typically 1 gram of methylprednisolonefor three to five consecutive days, after exclusion
or treatment of concurrent infection. Therapeutic plasma exchange (TPE) should be
considered when clinical symptoms and signs progress (or fail to improve) despite
corticosteroid treatment. TPE has been shown to be beneficial in acute CNS
demyelinating events unresponsive to steroids. In a randomized controlled, cross-over,
double-blind trial 6 of 10 (60%) patients with acute attacks of NMO recovered moderately
or markedly after TPE, a response rate greater than that seen in prototypic MS in the
samestudy (39, 40). Typically seven exchanges each of 1 plasma volume done on alternate
days are undertaken. I would consider exchange up to 3 months from relapse if significant
deficits persist.
1.12.2 Prevention of Relapses
Since the majority of patients with NMO follow a relapsing course, often acquiring
substantial disability within two or three relapses, and because immunosuppression
appears to reduce relapse rate treatments aiming at relapse prevention should beinitiated
as soon as the diagnosis of a relapsing NMO is made. Table 1.3 shows currently used
immunosuppressive drugs in NMO.It is important to note that no controlled trials
dedicated to preventionof relapses in this disorder have been conducted.
 
   
Drug Treatment Regimen and comments Serious side effects
Azathioprine (41) Azathioprine is the most widely used drug Bone marrow, liverin NMO.Aim for2.5 -3 mg/kgbody toxicity; Long term
weight. Usually begun along with potential for malignancies
prednisone 1 mg/kg body weight on ; potentially teratogenic.
alternate days. Steroids are gradually
tapered off after 6 months (Case series of  
 7 patients)
Rituximab (Monoclonal
antibody against CD20
bearing B cells)(42, 43)
Two 1000 mg infusions 2 weeks apart
followed by 6-9 monthlyinfusions.
Infections.
Reports of PML in
Rituximab treated patients
with SLE; Fetal effects
unknown
 
    
Mitoxantrone (44) Mitoxantrone monthlyintravenous Bone marrow, cumulative
infusions 12 mg/1e, for 6 months cardiac toxicity limits
followed by 3 additional treatments every 3 dose; teratogenic
months (Case series 5 patients)
Mycophenolate (45) 2g/day (Case report of 1 patient) Bone marrow
Intravenous Monthly intravenous infusions of Aseptic meningitis;
Immunoglobulin (46) immunoglobulin (400 mg/kg) (Case report caution in cardiac renal
of 2 patients impairment
Prednisone(47) Oral prednisone 1 mg/kg body weight on Weightgain, diabetes,
alternate days. Steroids can gradually taper infections, gastric bleeds,
after 6 months and the lowest dose that cataracts, poor wound
maintains remission can be continued. healing
Other Therapeutic regimens used in various Bone marrow,liver
immunosuppressants: connective tissue disorders have been used toxicity, Long term
Cyclophosphamide, in all majorseries of patients with NMO potential for malignancies;
Methotrexate potentially teratogenic
Table1.3 Drugs used to prevent relapses in NMO
 
Therapy for NMOspectrum disorders (with relapsing longitudinally extensive myelitis or
relapsing optic neuritis) is along the lines as NMO. Whetherpatients with a single attack
of LETM or ON with a positive NMO IgG should be treated remains uncertain. How
long treatment should be continued in those patients who have no further relapses with
immunosuppressants is uncertain. The long-term side effects of medications have to be
weighed against the potential risk of relapses, most of which are severe. Disease modifying
drugs (interferons) that are used in MS have not been shown to be helpful Whether
NMO-IeG titers could guide therapy is uncertain.
It is important to note that betainterferons used in MS worsens NMO.(48)
1.12.3 Symptom managementand rehabilitation
Pain, spasticity, bladder and bowel symptoms and sexual dysfunction need to be tackled.
Tonic spasms usually respond to low doses (100-200mg bd) of carbamazepine.
Rehabilitation, physiotherapy, mobility and visual aids may be needed. Some patients with
severe high cervical cordlesions will need long term home ventilatory support.
1.13. Prognosis ofNMO
Most attacks in NMO are moderate or severe; remissions are often incomplete and
neurologic disability accumulates in a step-wise fashion. A ‘secondary progressive’ course
is unusual though has been reported. In the Mayoclinic cohort more than half of patients
developed severe visual loss in at least one eye and/or inability to ambulate without
assistance within 5 years of disease onset. The 5 year-mortality rate in relapsing patients
was 32%. All patients died because of respiratory failure associated with attacks of
myelitis(11). However this group of patients was seen ata tertiary referral centre at a time
when immunosuppressive treatments in NMO were not aggressively pursued and may
therefore not reflect current outcomes. However it is beyond question that attacks of
NMOare generally more severe than those seen in MS and disability acquisition earlier
than seen in relapsing remitting MS.
1.14 Scope of the thesis
Much of what we know about NMOare extrapolated from the Japanese series and from
the retrospective Mayo clinic study over a 30 year period(11) Prospective studies in NMO
are rare. The exact epidemiology of NMOis also still uncertain in the western population.
Treatments are based on anecdotal or very small case series and often involve multiple
drugs. This study therefore aimed to
1. To establish the epidemiology of NMOin the Merseyside
2. To characterise a UK cohort of NMOandtheir long term outcomes
3. Toidentify new treatments for NMO
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Chapter2:
Materials and Method
2.1 Studies undertaken
As outlined in the scope ofthesis, four separate studies were done:
1. Epidemiology of NMO in Merseyside
This study was doneat the WCNN,and is restricted to Merseyside County.
2. Clinical, laboratory features and long term outcomes of NMOin the UK
This was a national study including patients from Merseyside.
3. Rituximab treatment of NVO
The retrospective evaluations on rituximab was an international study involving 7
centres from USA and UK and was done during a one-year fellowship at the
Mayo Clinic in Rochester, Minnesota, United States.
4. Mycophenolate treatment of NMO
This study was donesimilar to study 3 at the Mayo clinic hospitals, USA but
included patients only from the Mayo health care systems
2.2 Methods
Study 1 and 2 was registered in 2003 with the Regional Ethics Committee (MREC
()2/8/082) Manchester and the research governance committee of the Walton Centre for
Neurology and Neurosurgery (WCNN).
The methodsof study, study populations, statistical analysis of these are different and
therefore are best described separately within the individual chapters themselves.
Forstudies 1 and 2 after a formal consenting process,a clinical examination was done and
bloods were drawn. The MRIs where: possible, were analysed at the WCNN.Copies of
clinic letters were requested annually and telephone interviews were done(49). Relapses
before and after treatments, expanded disability status scores (EDSS) were monitored.
Epidemiological data for the denominators were obtained from the website of office of
national statistics
2.3 Laboratory testing
Blood samples were stored at the WCNN and were tested partly at the Mayo Clinic (for
NMO IgG )(3)and Oxford Radcliffe Infirmary (antiaquaporin-4) using established and
previously described methods(25, 50).
2.4 Statistical Analysis:
Summary statistics, paired t tests, Chi-squared tests, Wilcoxonsigned rank tests and
Kaplan -Meyersurvivalanalysis were done as appropriate usingJMP 6. (SAS Institute,
Cary, NC, 2005)
2.5. Criteria for NMO and NMOspectrum disorders
I will outline these, which are applicableto all chapters here.
Criteria for NMO (51
Optic neuritis and
Transverse myelitis
Andatleasttuo of three supportivecriteria
1. Contiguous spinal cord MRIlesion extending over 3 vertebral segments
2. Brain MRI not meeting diagnostic criteria for multiple sclerosis
3. NMO-IgG seropositive status
NMOspectrum disorder (51)
Optic neuritis or
Longitudinally extensive myelitis
And Presence of NMOlg G or Antiaquaporin-4 antibody
Othercriteria will be defined in the appropriate chapters
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Chapter 3:
Epidemiology of Neuromyelitis Optica in the
County of Merseyside
3.1 Introduction:
There are three population-based studies on NMOfrom which prevalencerates can be
derived. Thefirst study was the nationwide prevalence survey of MS in Japan, which
included 82 NMO and 509 MS cases, both with strict diagnostic criteria (52). With an
estimated nationwide prevalencerate of 2 per 100,000 population for Japan at hat
time this NMO/MS ratio would provide an NMO prevalence of 3.2 per 1000,000 (95%
Cl 0.26-0.40).
The second survey was in Martinique, French West Indies, where there were reported to
be French Afro-Caribbean patients with NMO(53). ‘Two of these were said to have
MRIs typical of MS; their exclusion would provide an estimated NMOprevalencerate of
3.1 per 100,000 (95% CI 1.5 - 5.5) with 11 cases.
A recent survey from 2003-2004 covered the white and non-white population from Cuba.
The prevalence was 5.1 per 1000,000 for the total Cuban population(4).The estimated
average annual incidence rate was 0.53 per 1000,000. Neither of these rates differed
significantly among whites, blacks, mixed, or non-whites. The number of cases however is
far too small to assert the presence or absenceof anyracial/ethnic predilection for NMO.
The prevalence rates by gender demonstrated a much higher rate in females (9.1) than in
males (1.2).
Thus although NMOis described worldwide, there have only been a limited numberof
epidemiological studies, and none in Europe. | therefore decided to examine the
epidemiology of NMOina well defined region ofthe UK.
3.2 Methods:
Setting:
The Walton Centre serves a population of three million in Merseyside, Cheshire,
Lancashire, North Wales, parts of Greater Manchester and the Isle of Man (54).
Neurological services are supplied with 26 Neurologists serving individual District
General Hospitals (DGH) and their catchment areas (54). It is conventional that any
transverse myelitis patient is referred to the visiting Neurologist in the DGH. These
patients are almost always transferred across to the Walton Centre for further evaluations.
There are of course border zones and patients could attend hospitals or accident
emergency departments of hospitals outside the region. To reduce possible over lap |
therefore restricted my epidemiological study to the county of Merseyside, which is
exclusively served by the centre. (Fig 3.1) To identify cases I searched the WCNN medical
records from 2003 to 1995 with the search terms “neuromyelitis optica” or “Devic’s
disease” or “optic neuritis and myelitis’ or “relapsing or recurring myelitis or optic
neuritis ”. All twenty-six neurology Consultants were contacted for any other possible old
or newly diagnosed cases. The Diagnostic criteria for the patients are as described in
chapter 2.Only adult patients were included
Thefollowing assumptions were made:
1. All cases of NMO would haveserious enough symptoms to attend a DGH. They
would have been referred to the visiting WCNN neurologists who would have
transferred them to the WCNN. The same would have been the case in the
unlikely event of slow onset of symptoms, when the primary care physician would
have referred to neurologist.
2. The diagnosis of NMO would have been made and recorded as such in the
Walton Centre medical records.
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3.3 Results:
31" Dec 2008 was considered the census day. The adult population of Merseyside (age
more than 16) is 1,145,322 (55). The United Kingdom has an adult population of
 
  
46,930,337(55).
Primary care Trusts in Merseyside Population
Bebington and West Wirral 98,292
Birkenhead and Wallasey 149,453
Central Liverpool 187,837
Ellesmere Port and Neston 64,584
Knowsley 115,942
North Liverpool 81,530
St Helens 140,246
South Liverpool 81,601
Southport and Formby 94,206
South Sefton 131,631
Total 1,145,322   
Table 3.1 Population within Primary care trusts of Merseyside(55)
Eight patients with NMO and four with NMO spectrum disorders (all with relapsing
transverse myelitis,) were identified during the study from 2003 till Dec 2008. Their
clinical details are given as part of the general description in chapter 3 .Three patients with
 
 
NMOdied.
NMO NMO SD Combined
All patients 2003-2008 8 4 12
Alive on 31s
December 2008 5 4 9
Incident cases 2003-
2008 3 4 7     
Table 3.2 NMO and NMOSpectrum Disorders from Merseyside
3.3.1 Prevalence
An estimated prevalence of
—
7.86/million for combined NMO and NMOSD was
calculated. The United Kingdom has an adult population of 46,930,337 and thus giving an
estimated 366 patients with NMO or NMOSDacross the UK.
3.3.2 Incidence
Seven patients were newly diagnosed (3 NMO and 4 NMOspectrum)over 5 years in the
region, since the prospective follow up was begun in 2003 (incident cases) giving an
incidence rate of 1.22/million. The United Kingdom has an adult population of
46,930,337 andtherefore and an annualincidence of 57 newpatients with NMO or NMO
spectrum disorders would be expected.
However these are combined figures for both NMO and NMOSD.Theindividual figures
for each of these are given below in table 3.3
 
     
NMO
spectrum
NMO Disorders Combined
Incidence in Merseyside: per
million/year 0.52 0.7 1.22
Projected new cases in UK / year 24.59 32.78 57.37
Prevalence in Merseyside/ million 4.37 3.49 7.86
Projected total cases in UK 204.88 163.9 368.78
3,3 Separate and combined figures of NMO and NMOSDin Merseyside.
3.3.3 Gender and ethnic differences:
Womenaccounted for 78%of patients. The majority of patients were white (88%, table
3.4) Only one patient was non white, a black woman,resident in the region since 2000,
with the onsetofillness while in Nigeria in 1996.
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Combined Population Population
NMO and| of of United
NMOSD %| Merseyside Kingdom(n) (/) (%)
Gender: Male 22(2) 48 48.7
Female 78(7) 52 52.3
Ethnicty:
White 88 (8) 97.6 91.31
Black 12 (1) 0.36 2.18
Asian 0 0.58 4.8
Mixed 0 0.8 1.27
Others 07 0.66 0.44  
Table 3.4.Gender and ethnic distribution (shown as percentages) of NMO_ patients
compared with the Merseyside population and the whole UK Population
3.4 Discussion:
A nationwide wide epidemiological study though desirable is not possible as there is a
referral bias in the patients seen across the United Kingdom — notall patients being
referred or seen as part ofthis study. However | attempted this in the selected catchment
area of the Walton Centre - a fairly well defined geo-political area.
I have estimated the crude prevalence and incidence of NMO and NMOSD in
Merseyside using hospital based statistics. Such data are rare in literature particularly in
regions with high number of Caucasian population. Wealso estimate the prevalence and
incidence of NMOSD which has not been documented before. The figures of NMO are
comparable to that of other reports, but when combined with those of NMOSDgive a
much higher numbers, increasing the burden of disease. As NMO and NMOSDfollow
the same morbidity and clinical course and as there are no treatment differences these
larger numbers have great significance when planning, specialist services.
These results also confirmed previously reported findings of a higher female frequency of
NMOin case series. In the population-based study in Martinique, all of the 13 prevalent
cases were French Afro-Caribbean women(53). In the nationwide prevalence study in
Japan, 52 (63.4%) of the NMO cases were women.
In the Cuban study prevalence rates by gender demonstrated a much higher rate in
females (9.1) than in males (1.2)(4). But there were no difference between whites, blacks,
mixed, or non-whites. The numbers in our study sample are too low to make
meaningful statistical comparisons.
However there are several important limitations to this estimate, which can beat best a
minimum value. The numberofcasesis far too small to assert the presence or absenceof
anyracial/ethnic predilection for NMO. The three presumptions made above maynot be
accurate. Though I am reasonably confidentthatall cases with an optico-spinal syndrome
or severe transverse myelitis would have been seen by the neurology services, the same
cannot be assumed for optic neuritis which may notbe referred on to the neurologist by
the ophthalmologist or brought into the centre for further tests. Though untreated NMO
has an average annual relapse rate of about 2 /year, it is possible that the secondrelapse,
the commonest reason for referral for further neurological evaluation may not have
occurred yet. Due these caveats I believe that my figures of incidence and prevalence are
the minimum. It is important to remember that children were notincluded in this study
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Chapter4.
Clinical, Laboratory Features and Long
Term Outcomes
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4.1 Introduction
Neuromyelits optica is an uncommon disorder. Though there are manycase reports
from the western countries, there are very few series of patients with substantial numbers
and none with prospective follow up. Thelargestseries to date is that from the Mayo
clinic reported in 1999, which reviewed 71 patients seen at the Mayo Clinic between 1950
and 1997. A French group retrospectively studied 13 patients (56) andlater (57)
presented data on 30 patients. A further French retrospective study looked at therapies
of 26 patients with NMOfollowed in five French neurological departments. An Italian
study of 46 patients from 15 centresalso retrospectively reviewed data and surmised
their experience (58). The only study form the United kingdom was a retrospective case
record based study in1996 that reviewed 12 patients attending The National Hospital of
Neurology and Neurosurgery, Queen Square and Moorfield's Eye Hospital between
1986 and 1994.(59)
Retrospective data have many well known innate inadequacies- selection andrecall bias,
lack of follow up, nonavailability of records andinvestigations. Prospective studies are
harder to organize, time consuming but may provide more accurate information of
long-term outcomes.
In 2003, at the outset of this study, NMO was still a ‘debated’ diagnosis. Diagnostic
criteria were not widely accepted and patients were often classified as optico - spinal
forms of MS. I therefore attempted tofirst identify a cohort of all forms of optico-
spinal demyelinating syndromes and then sub classify and follow them up prospectively.
4]
4.2 Materials and methods
4.2.1 Identification of Study population:
The UK Prospective Cohort study population was obtained by two methods:
1. British Neurological Surveillance Unit (BNSU)
The British Neurological Surveillance Unit was set up in January 1993 with the aim of co-
ordinating and improving the ascertainment of rare neurological disorders in the United
Kingdom by using a system of nation-wideactive surveillance. The unit provides a service
for individual investigators who mustfirst submit possible studies to a scientific advisory
committee. Once accepted the condition is listed on a report card which is sent to every
memberof the British neurological community every month. The cards are easy to use,
andall the reporting neurologist has to dois tick a box indicating whether a case has (or
has not been) seen. At the end of every month the individual investigators then initiate
further follow-up by contacting the reporting neurologists(60).
1 contacted all neurologists in UK through the British Neurological Surveillance Unit
(BNSU).Thenotification forms were then compiled by the BNSU andreturned to me. |
then contacted the individual Consultant. The Consultant would then request the
patient’s consent for recruitment into the Study. The primary investigator would then
visit the Hospital, review records, MRI scans, meet the patient at the Hospital or at their
home.
CRITERIA FOR REPORTING PATIENTS TO THE BNSU :
Adults (age > 16 years) with Optic Neuritis and transverse myelitis without a typical (61)
brain Magnetic resonance imaging (MRI) for multiple sclerosis
These patients were broadly called optico-spinal demyelinating diseases( OSD). These
criteria were necessarily broad to indude all possible optico-spinal dermelinatingases.
Adults with typical multiple sclerosis, single episode of optic neuritis or isolated transverse
myelitis or an obvious non-demyelinating cause for the spinal cord and optic nerve disease
were notto be referred.
2. Medical Record search at the Walton Centre
This was doneas outlined in Chapter 2
3. Additional patients included in the study
With the availability of antibody testing (NMO IgG /AQP4-Ab) the diagnosis of NMO
has been extended to patients who haveeither optic neuritis or myelitis if they have NMO
leG /aquaporin-4 antibody. Such patients - NMO spectrum disorders -behavelike NMO
clinically with a relapsing course and therefore have been included in the analysis of NMO
/NMOspectrumpatients, but notin the section on cases with optico-spinal presentation.
4.2.2 Analysis of data:
Patientclassification (Fig 4.1):
Based on clinical-radiological profiles, NMO antibody status and follow up, all OSD
patients were broadly divided into two categories:
1. Neuromyelitis optica.
2. Non-NMO optico spinal demyelination (NNOSD)
The additionalcriteria for NNOSDare:
Transverse myelitis shorter than 3 vertebral segments and
NMOantibodyis negative.
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The NNOSDcategory of patients was subdivided into two:
1. Patients with a pure optical and spinal presentation, who on follow up developed
typical relapsing-remitting, primary progressive or secondary progressive multiple
sclerosis. (62)
2. Patients who still remain as optical and spinal demyelination and did not develop
typical MS of any subtype with (ie associated with brain MRI changes satisfying
Barkhof’s criteria). These were called optico-spinal demyelination Unclassified
(OSD-U)
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4.3 Results
The classification of patients is summarised in Fig 4.1. 128 patients were evaluated for
inclusion into the study. 67 patients satisfied the inclusion criteria for OSD. 61 patients
were excluded, as they did notsatisfy criteria. These included patients who hadsingle
episodes of demyelination or relapsing myelitis or optic neuritis (antibody testing was
unavailable) or patients with alternative diagnosis.
Of the 67 patients with OSD 42(63%) were women and 25 (37%) men.
The median duration of follow up was 38 months (0-71 months). Based on clinical-
radiological profiles, NMO antibody status and follow up, all OSD patients were broadly
divided into two categories: 34 (51%) had NMO and 33(49%) had NNOSD.
NMOspectrum disorders
With the increasing understanding of NMO, and NMOSD,I included 8 patients with
NMOSD (which behavesimilar to NMOclinically) referred to WCNN in the NMO
group,raising the final number of patients with NMO or NMOSD to 42
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4.3.2 Neuromyelitis optica and NMOspectrum disorders
Forty-two patients had NVO/NMOSD. Thirty six of these patients had an optical and
spinal syndrome and were obtained from the national study. Eight patients were OSD
(Seven with relapsing myelitis and one with relapsing optic neuritis). Thirty-four (81%)
were antibody positive and 8 (19%) were negative. Thirty-one of the 42 patients (74%) are
women. Forty five percent of men were antibody positive compared to 94%women. The
epidemiological data of the patients are presented in table 4.4.
4.3.2.1 Gender:
 
         
Feature All NMOand NMOand
_|
Significance
|
Test of
NMO NMOSD NMOSD significance
and antibody Antibody
NMOSD| positive negative
(n=42)
|
(n=34) (n=8)
Gender Men 11 (26) 5 (45) 6(55) P=0.005 Fishers exact
(°%) Women| 31(74) 29(94) 1(6)
Race (%)
|
White 30 (71) 22(73) 8(27) NS Fishers exact
Non 12(29)
_
12(100) 0
white
Age at onset median
|
40.8 30 48 NS Mann-
(range) (11-76) (11-76) (16-61) Whitney U
L Table 4.1 Demographic data of 42 patients with NMO or NMOSD
4.3.2.2 Ethnic differences
Twelve of the 42 patients were non white. Fig 4.2 shows the ethnic distribution ofall the
patients comparing them to the UK distribution of ethnic minorities.
 
  
    
 
Count Ethnic
(%) distributio
nin UK71.4 a
Asian (A) 7(16.7) 48
Black (B) 49.5) 2.2
Mixed —ethnicity 1(2.4) 13
(M)
W White (W) 30(71.4) 913
Other 0.44
Total 100 100  
Fig4.2 Ethnic Distributions in NMOin the UK
White patients accounted for 71.4% of the cohort. However they account for 91.3%of
United Kingdom population. Onthe contrary Asian, black or mixed ethnicity patients
accounted for more than expected.
4.3.2.3 Index clinical event
The index (ie the first) clinical event was either optic neuritis in 32.5% and transverse
myelitis in 57.5% and a combination in the rest (10%). More specifically, unilateral optic
neuritis occurred in 20%,bilateral optic neuritis (12.5%) Fig 4.3.
4 5  
1. Optic neuritis -unilateral
2. Optic neuritis -bilateral
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3. Transverse myelits
4. Unilateral optic neuritis with myelitis
5. Bilateral optic neuritis with myelitis
Figure 4.3 The index event of NMO
4.3.2.4 Monophasic and relapsing subtypes.
All patients had a relapsing course. The number of relapses before and after
immunosuppressant treatmentis given in section on response to treatments
4.3.2.5 Time to second event:
I estimated the time between the first and second event in 40 patients (e.g.: If optic
neuritis was the first event, the time to next episode of either ON or TM). The median
time to the second event was 7.75 months (1.98 to 60). Date of the second episode was
 
     
uncertain in 2 patients.
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Fig 4.4. Kaplan-Meier survival curves for time to 2nd episode in 40 patients
Summary
Group Number failed Number censored Mean Std Error
Combined 40 0 12.8435 2.29055
Group Median Time Lower95% Upper95% 25% Failures 715%Failure
s
Combined 7.7536 3.9754 ld . 992 3.0226 13.996
Quantiles
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4.3.2.6 Treatments used in NMO
Azathioprine with or without steroids was the most favoured currenttreatment ( fig 4.4)
Two patients are not on treatment- one remains in remission and oneis deciding on the
drug that she wishesto start.
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AZT 17 42.5
AZT+PEX 1 2.5
AZT+PRED + 10.
COPAXONE 1 2.5
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MME 1 25
NONE 2 o
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Fig 4.5 Distributions of current treatments for NMO in 40 patients.
AZT (Azathioprine), PEX (Plasma exchange), Pred (Prednisone) cyclophosph
(cyclophsophamide), MMF (mycophenolate) and Ritux (rituximab)
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4.3.2.7 Responseto treatments
I calculated the duration of disease before and after starting any immunosuppressant
treatment and the numberofrelapses that occurred duringthese periods irrespective of
the type or numberof drugs they were on. However the precise numberand dates of
relapses were available only in 33 patients. The median annualised relapse rates before
treatment for these 33 patients was 1.6 (0.16-45) and post treatment was 0.19(0-5.5) at a
median follow up of2.7(0.04-5.9) years after entry into study (p= 0.0019, Wilcoxon signed
 
 
         
ranktest)
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Fig 4.6 Annualised relapse rates before any disease modifying treatment. The figure on
the left is the pre treatment and that on the right is post treatment. The horizontal axis
denotes the percentage of patients andthe vertical axis the relapse rate itself.
Nn Nw
The wide and high range of relapse rates is due to the short durations before andafter
starting treatment. To avoidthis bias patients who had a pre or post treatment duration of
less than one year was excluded; then,the Annualised relapse rates before treatment was
1.4(0.38-5.9) and post treatment was 0.19(0-2) at median follow up of 2.7( 0.04-5.9) years
(n=24; p< 0001, WilcoxonSigned ranktest).
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Fig 4.7 Annualised relapse rates before any disease modifying treatment. The figure on
the left is the pre treatment and that on the right is post treatment. The horizontal axis
denotes the percentage ofpatients and the vertical axis the relapse rate itself.
4.3.2.8 Disability
The median expanded disability status scale (EDSS) at the onset of the study was 6.5(2.5-
8.5) and at last follow up 6.75(1.5-1 0) (Fig 4.7) (p=0.15, Wilcoxon signed ranktest). This
Bo
change was over a median period 2.8years (0-5.9) and median duration of disease of 6.9
years (0.2-31)
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Fig 4.8 The EDSSofall 42 patients at the start of the study (upper figure) and at last
follow up (lower figure) the horizontal axis denotes the EDSS;the height and numbers
at the top of each barindicate the percentofpatients with that EDSS.
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4.3.2.9 Time to disability
I estimated the median time to development of permanentdisability (as defined by
residual disability before the next relapse or at 6 months if there are no furtherrelapses) as
0 months (0-89); i.e. the first eventitself. 75% patients would have developed a fixed
disability by 6 months.
I similarly estimated that episode that caused the permanentdisability would bethefirst
eventin 28 (67%), second in 6(14%) third in 7(17%) fifth in 1(2%)
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Fig 4. 9 Time to event: Time to fixed disability from first episode (months)
Summary
Group Number Number Mean Std Error
failed censored
Combined 42 0 7.22262 2.63047
Quantiles
Group Median Time Lower95% Upper95% 25% Failures 75'% Failure
Combined 0 0 1 0
Time to Survival Failure SurvStdErr Number Number At Risk
fixed failed censored
disability
from index
events
0.0000 1.0000 0.0000 0.0000 0 0 42
0.0000 0.4048 0.5952 0.0757 25 0 42
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1.0000 0.3333 0.6667 0.0727 3 0 17
3.0000 0.3095 0.6905 0.0713 1 0 14
6.0000 0.2381 0.7619 0.0657 3 0 13
8.0000 0.1905 0.8095 0.0606 iz 0 10
10.3500 0.1667 0.8333 0.0575 1 0 8
12.0000 0.1190 0.8810 0.0500 2 0 7
14.0000 0.0952 0.9048 0.0453 1 0 5
39.0000 0.0476 0.9524 0.0329 2 0 4
48.0000 0.0238 0.9762 0.0235 1 0 2
89.0000 0.0000 1.0000 0.0000 1 0 |
Combined
4.3.2.10: Mortality
Ten patients have died during the study period in the NMO group. Fig 4.5 All patients
were on some form of immunosuppression. The median time to death from onset of
illnessin these 10 patients were was 6.1 years (2 months to 16 years). Unfortunately details
of the circumstances of death are not available in all. No patients died in the NNOSD
group.
All NMO|NMO
—
and} NMO and
|
Signi Test of
and NMO- NMO-S NMO-S fican significance
S antibody Antibody ce
(n=42) positive negative(n=34) (n=8) |
No of Death
|
10(24) 7(70) 3 (30) 0.28 Fisher's exact
(%)
Men 2 (20) 2(20)
Women 5(50) 1(10)      Table4.2: No of deaths in NMOcohort stratified by antibody status.
CAUSE OF DEATH NUMBER OF
PATIENTS
Infection 3
Relapse 3
 
Accidental overuse of
opioids
1
Pulmonary embolism 1 Cause uncertain   in NMO
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Table 4.3: Cause of death
Using Kaplan- Meier survival statistics I estimated the expected median time to death as
16 years from onsetofthefirst episode even though 95%of patients were on treatment
(fig 4.5) 7 of 34 (20%) antibody positive and 3 of the seven (42%) antibody negative
patients died (p =0.28) Fig . Two of the NMO antibody negative patients died very
shortly after the onset of the disease (2.46 and 9 months) due severe brainstem relapse..
Antibody negative group had shorter median time to death (fig4.10)
 
   T] , I ' T ] T ; I5 10 15 20 25 30TIME TO EVENT-DEATH/CENSOR     p—  
Fig 4.10 Timeto death: Kaplan- Meier (Product-Limit) survival ofall patients
(interrupted grey) andstratified by NMOantibodystatus. The red lineis antibody
negative group and blue, antibody positive.
Summary
Group
n
PCombined
Number Number Mean
failed censored
3 5
7 27
10 32
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3.59788 Biased
13.7571 Biased
13.2454 Biased
Std Error
0.78226
0.94652
0:9219
Quantiles
Group Median Time
n .
p 16.257
Combined 16.257
Tests Between Groups
Test ChiSquare
Log-Rank 0.6848
Wilcoxon 4.9798
Combined
Lower95%
0.2053
10.081
10.081
DF
Upper95% 25%Failures 75%
Failur
es
4.6379
10.081
10.081
Prob>ChiSq
0.4079
0.0256
4.3.2.11 Co existing autoimmunediseases and autoantibodies
Co existing autoantibodies (AAB) were presentin 18/30 patients 60%. (Table 4.6 and 4.7)
10(24%) had a manifest autoimmuneillness and one had a thymoma.
 | Antibody
Rheumatoid factor
  ANA.—————
ds-DNA
SSA(Ro)SSB (La)
Scl 70
Jol
 c-ANCA
Smooth Muscle
Acetylcholine receptor antibody
Thyroglobulin
Anti cardiolipin antibodies IgG
 Anti cardiolipin antibodies IgM.
Celiac Screen
me|}
col
Col
BI]
Re
lR
]
RL
Ry
Rey
Rey
e
te
 |Antiganglioside antibody   
Table. 4.4: Co- existent autoantibodies in NMO. SSA and SSA-B: Sjogrens syndrome A,
and B, Jo-1: associated with inflammatory myopathy), Scl-70: scleroderma antibody
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against topoisomerase, dS-DNA: double stranded DNA, ANA: antinuclear antibody,
ANCA: anti neutrophil cytoplasmic antibody
 
Celiac disease
Psoriasis
Hypothyroidism
Systemic lupus erythematosis
Rheumatoidarthritis
Nonspecific possibly immunearthritis/arthralgia
Pernicious anemia
  elelolel
e)
Ni
Ni
w
Insulin depenedent diabetes mellitus  
Table 4.5 Co existent autoimmunedisease in patients with NMO
Three patients had celiac disease one of whom was antibody negative. (63). In two patients
gastrointestinal symptoms prompted testing for celiac disease, while in the third, the
diagnosis of NMO prompted testing for celiac antibodies as the patient was aymptomatic.
Diagnosis was confirmed by biopsy in all. All remain on azathioprine in remission of
both NMOandceliac disease.
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4.3.2.12 Oligoclonal bandsin the spinalfluid.
Oligoclonal bands (OCB) were absent in 28/33 (85%) where results were available. 78%
of patients positive for NMO antibodies had no OCB.
 All NMOand NMO Significance Test of
NMO NMO-S and significance
and antibody NMO-S
NMO-| positive Antibody
> (n=25) negative
(n=33) (n=8)
Oligoclonal Present 5 3(60) 2 (40) Fishers
bands in (15) P=0,35 exact
the
CSF(%) Absent |28 (85) 22 (78) 6(22)         
Table 4.6 Oligoclonal bands in NMO and NMO SDpatients
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4.3.3 Non NMO Optico-spinal demyelination
Thirty-three patients of the 67 were not NMO.Six of these developed MS. Twenty seven were
 
 
 
     
classed as OSD-U.
Feature (°%) No of Numberof Significance Test of
patients patients (o) significance
(%) with with Non
NMO NMO OSD
(n=34) (n=33)
Gender Men 8 (13) 17(51) p=0.0245 x?
- Women 26(77) 16(49)
Race White 23(67) 24(71) NS x?
Non 11(83) 9(19)
white
Age at onset median 39(16-69) 34(18-50 NS Mann-WhitneyU
_(tange)
Family history
|
Present 3(8) 1(3) NS x’
of
demyelinating |Absent 31(92) 31(97)
Illness
Coexistent Present 10(41) 5(16) NS x?
autoimmuneillwess Absent
|
24(69) 27 84)
NoofDeaths 10 (30) 0 (0) P<0.0069 Fishers exact  
Table 4.7 Differences between NMO/SD and NNOSD
Men and women were present almost equally in this group. The median EDSS at onset and at last
follow up was both 3 in NNOSD compared to 6.5 and 6.75 in the NMOgroup Nopatient in this
group died. Oligoclonal bands were absent in 67% patients. Since the scope of the thesis was the
study of patients with NMO,a detailed analysis of this subgroup is not presented here.
61
 
4. 4 Discussion:
4.4.1. Genderdifferences
Seventy four percent of the cohorts were women. This is similar to the Italian (80%), Mayo (83%)
studies. Eleven out of 12 patients in the previous UK study were women. Most autoimmune
diseases are more commonin females. Though there seems to besignificant difference between the
numbers of men in the antibody positive versus negative group, the low numbers make this
conclusion uncertain.
4.4.2. Ethnic differences
Our findings are consistent with widely held view that NMO is more commonin non-Whites. In
the previous UK study seven of the 12 patients were non-White. In the Mayo clinic study
6/71(8%) were non-White. Howeverthere is likely to be confounders in this observation. As the
belief that NMO is commonerin non-Whites is widely held, more patients with optico-spinal
presentation would have been diagnosed (and referred to the study) as NMO by neurologists than
whites who may have been diagnosed with MS.
It is interesting that in the hospital-based study of the Merseyside population (chapter 3) no over
representation was seen. Similiarly, the population based Cuban study did not find an ethnic
differences. Further study is needed to confirm this new view. Though MS maybeless common in
Asians and Blacks, NMO might not be more frequent than MS.
4.4.3 Monophasic and relapsing NMO
There were no monophasic cases in this study. All patients relapsed on longer follow up.
Wingerchuk etal classified NMO into monophasic (simultaneous or separate occurrence of ON or
TM and no further events) and relapsing type(11). The monophasic type occurred in about 32%
cases in their series. But they acknowledge that no monophasic case was diagnosed since 1988 i.e.
from 11 years before their study. In their retrospective study the mean follow up for monophasic
group was 16.9 years (minimum 3 years).
It is debatable whether monophasic NMOexists. It seems unlikely, though not impossible that an
antibody mediated disease with would confine itself to one or two events. It is likely that
simultaneous occurrence of optic neuritis and myelitis with no further events (30% of the in the
Wingerchuk series) may be a subtype of acute disseminated encephalomyelitis if they are antibody
negative. It is also interesting that the median time to second index eventin the monophasic group
in that study was 5 days only implying that both index events are manifestations of a single acute
event rather than two separate ones.
These arguments would mean that NMO is always a relapsing disorder. It could also imply that
there is no need toinitiate immunosuppressive treatmentin patients who have an antibody negative
monophasicillness.
4.4.4 Time to second attack in NMO
I estimated the time between the first and second event in 41 patients. The median time to the
second event was 7.8 months (1.98 to 60) [ 4.9 (1.9-50) in the antibody negative group and 9(2-59)
in antibodypositive group]. This has treatment implications. Though it is generally agreed thatall
patients with confirmed relapsing NMO should be treated with immunosuppressive medications
(based on anecdotal evidence) it is still uncertain whether patients with NMO-SD with a single
event should be treated in the same way. This is understandable. Both the physician and the
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patientare likely to be uncertain about the need for possibly life-long immunosuppression based on
the presence of a blood marker.
It has been shown that 55% ofisolated longitudinally extensive myelitis and 80% of those with
relapsing optic neuritis with NMO IgG will relapse by one and nine years respectively(30, 64). Our
findings would support the view that treatment should beinitiated, as a relapse seems highlylikely
in all untreated patients, where the antibody is positive(30, 64). This combined with very high
degree disability, acquired by 15 months or by the third episodeitself in 90%patients makes
preventative treatment importantin those patients where relapse can be predicted by presence of
the NMOantibody. Howeverit can be debated thata selection bias explains these results~ with
only patients whorelapsed being referred to the study - and the prediction of a relapse is self-
fulfilling,
4.4.5 Treatment response
Our results are consistent with the general view that disease modifying treatment ie.
immunosuppressants tend to lowerthe rate of relapses. The lack of controlled trials makes these
observations prone to errors. The median annualised relapse rates before treatment was 1.6 (0.16-
45). With any kind of disease modifying treatment the relapse rates improved to 0.19(0-5.5) at a
median follow up of 2.7(0.04-5.9) years for 33 patients (p< 0001, Wilcoxon signed rank test). These
improvements are comparable to those achieved with rituximab or mycophenolate (chapter 5 and
6). No treatment seems to have beeninstituted in one patient despite a longhistory ofillness. One
patient with
a
relatively new diagnosisisstill deciding on the treatment. In manypatients the initial
drug wasineffective or induced sideeffects leading to a change and this was needed several times in
some. Onepatient is now onglatiramer acetate. A single case report supports this attempt(65). She
had relapses and did not tolerate azathioprine, mitoxantrone, mycophenolate and rituximab.
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There are several majorlimitations to estimating relapse rates in retrospect:
1. Finding the exact stopping dates and start of new medications turned out to be extremely
difficult, making attempts to identify which treatment was more effective,fruitless.
2. Similarly the numberofrelapses that occurred pre and post treatment was often difficult to
ascertain. Recall bias was an important confounder.
3. Similarly the delays from the onset of symptom to be seen bythetertiary care, treatmentat the
primary care level itself with steroids for suspected symptoms of relapse (possibility pseudo-
relapses being unnecessarily treated) and patients perception of what a relapse is confounds
accurate relapse characterisation.
4. Manypatients with NMOare steroid dependent andtaper of steroids often leads to recurrences
of symptoms. Two patients who have hadfifteen to twenty relapses over a two to three year
period is an example.
5, Another problem in such analysis using annualised relapse rate is often the short time interval
between the onset of the disease to treatment. For example if an episode transverse myelitis was
immediately suspected to be an NMOspectrum disorder and proven correct with antibody testing
and the Physician initiated treatment with no relapses in the subsequentyear then the pre-treatment
anmunlised relapse rate would 12.5 [1 divided by 0.08 years (1 month)] and the post treatmentrelapse
rate would be0!
6. Some issues are indigenous to the NHS. The reasonably effective UK primary health care
system doesfilter out many patients with relatively minor relapses by providing treatment, before
they reach district hospitals where neurologists work This is unlike the US healthcare system
where primary healthcare Physicians are bypassed more often than not. Therefore documentation
ofclinical symptoms anddetails of relapsesin tertiary care hospitals seem to be much higher and
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extracting accurate data more easier as evidenced by the chapters on rituximab and mycophenolate
which were done while I was in the United States. Nevertheless I feel the values of pre and post
treatment annualised relapse rates are reasonable estimates.
4.4.6 Mortality and Disability
Disability in NMOis believed to be acquired byattacks as opposed to the gradual accumulation in
progressive MS. At a the median follow up of 2.8 years since the onset of the Study, the median
EDSSchanged from6.5 to 6.75. Evenif the 10 patients whoachieved an EDSS of 10(death) were
excluded the EDSSat onset and at last follow up remained 6.5.
The use of EDSS as an effective tool for assessing disability in spinal cord and optic nerve
predominantdisease can be contested. Specialised scoring systems like the ASIA (American Spinal
Injuries Association) score used for spinal cord injuries might be more appropriate. A similar
scoring system specific for visual loss could be used for the eye. However as EDSS is well
validated, commonly used andeasily interpreted by neurologists this was deemed more appropriate.
There are several limitations to my EDSS scores. Many of the EDSS scores have been estimated
from observation from hospital notes and subsequently by telephone, the latter method having
beenvalidated to be comparable to physical exam(49). Some were obtained while the patients were
in relapse and hence the improvement would have been ‘regression to the mean’. Nevertheless we
feel that our observations are valuable and provide some light into the progression ofthe disease in
this group ofpatients. Our Data compares well with the other documented series. The mayo clinic
series indicate that 50% of patients are wheel chair bound or havevision poorer than 20/200 at 5
years(11). The predicted median survival of patients in the Mayoseries is 17.6 years compared to
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ours of 16 years. Despite universal treatment with some form of immunosuppression, only modest
improvements in survival seem to have been achieved. This comparison could be skewed as the
Mayo series was retrospective with incomplete follow ups.
4.4.7 Anti Aquaporin- 4 antibodes:
We found that 81%of patients have anti AQP4 antibodies. The rigorous application of the
diagnostic criteria and use of newer methods to detect the antibodies might have improved the
sensitivity of the tests to detect the antibodies compared to other series. The patients who were
antibody negative could be so for many reasons. These include treatment with
immunosuppressants or intravenous steroids which reduce the levels(66), incorrect diagnosis or
true ‘antibody negative’ NMO. Thelatter brings into the possibility that there might be yet
unidentified antibodies involved in the pathogenesis. The antibody negative groups had a shorter
median time to death and treatmentof this group rigorously might be required. The small number
of patients in the antibody negative group makesresults difficult to interpret and the differences
between antibody positive and negative groups will be boreoutonlyin larger Studies.
4.4.8 Co existing autoantibodies and autoimmuneillness
Coexistence of autoimmuneillnesses is well known in NMO(67). In this series we identified several
autoimmuneillnesses and autoantibodies. Three patients had coeliac disease.
Treatments for managing both NMO and coexisting autoimmuneillnesses are similar ie
azathioprine, methotrexate, cyclophosphamide, mycophenolateetc. It is possible a proportion of
patients with a tendency to develop NMO but are not developing it because of ongoing
immunosuppressants for the primary non-NMO immunological condition. Whether it is
meaningful to screen patients with connectivetissue disorder for AQP4 antibodies as part of the
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screening strategy is debatable. The morbidity associated with NMOis so high this might be a
strategy that might be employed in the future.
Optic neuritis or transverse myelitis patients who are seropositive for NMO-IgG andalso having
Systemic sclerosis (SS)/Systemic lupus erythematosis or non-organ-specific autoantibodies is
thoughtto be an indication of coexisting NMO rather than a vasculopathic or other complication
of SS/SLE(16, 67). I found onepatient with SLE or SS.
4.4. 9. CSF oligoclonal bands:
CSF OCB wasabsentin 85%of patients with NMO inline with other studies. CSF often showed
acute changes of pleocytosis and raised protein often with eosinophilia but spinal fluids were not
done acutely in manypatients and even if done it were often difficult to obtain the dates of the
spinal fluid studies in relation to the clinical event. These markers are technique and technician
dependent which vary between thelaboratories. Iso-electric focusing which has a higher sensitivity
and specificity may not be used as standard in the detection of oligoclonal bands with many labs
still using gel electrophoresis.
4.4.10 Opticospinal demyelination- Unclassified:
At the median of 3.2 years (0-5.5)of follow up , 27 patients remained as unclassifiable opticospinal
demyelination. We were unable to categorise them into either typical relapsing remitting MS (ie.
with oligoclonal bands and MRI brain abnormalities) or NMO. This group has several
peculiarities. Their relapses are almost always confined to optic nerve and the spinal cord. The
spinal cord lesion length is always less than 3 cm. CSF oligoclonal bands were absent in 18/27
(67%) and MRI of the brain did not have the widespread lesions typical of multiple sclerosis.
Though “lumpers” might class them as multiple sclerosis, and others maycall it NMO with short
cord lesions and negative NMOantibodies, it is possible that this group toois a separate entity or
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subtype of MS. Thedistinctionis clinically important as treating NMO with beta-intererons as in
MS,can exacaerbate it(68). I believe that these groups need to be followed up for a longer term
with repeat MRI and reanalysis of sera to look for possible new markers.
4.4.11 Otherlimitations of the study
Radiological data was collected where possible but not analysed. There are several reasons forthis:
The number ofscans available for review was few. It was impossible to transferall scans across to
the Walton Centre to be reviewed by a neuroradiologist as these were largely hard copies. Many
patients were diagnosed in the pre-MRIera. Many centres had destroyed MRI scans due to storage
difficulties. Longitudinally extensive myelitis which is typical NMO or NMOSDis seen only in
scans which are done soonafter relapse and many scans were not doneacutely. The spinal cord in
resolved lesions can often be normal with the exception of atrophyor a syrinx. Gadolinium was
not given routinely. I therefore did not proceed to analyse this data or incorporate them into this
work as it would not have made any meaningful difference to whatis already known.
Using the BNSU as the central referral mechanism has advantages andlimitations. The advantages
include a centrally held database of all Neurologists and uninterrupted monthly reminders to
Consultants by a recognised and respected central organisation. However the referral process
depends on the Consultants being members of the Association of British Neurologists, and more
importantly the Consultant's willingness andability to identify and refer patients on to the BNSU.
Apart from this busy multiple sclerosis clinics (where NMO patients are usually followed up)
review appointments are usually only made oncein six months or a year and there is no certainty
that an individual consultant /registrar would recognise and re classify as NMO,a patient in
remission, who has long before been diagnosed as MS.
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Conusltants also hesitate to refer as this creates additional work like to filling in forms and making
arrangements for myvisit to the Hospital. There were occasional instances where neurologists
referred patients but did not proceed to the next level of organising notes and scans due to the
workinvolved to them ortheir secretaries.
Ideallyall of the neurologists in the Country would beenlisted to participate in such a study, would
search for the condition in their medical records of their respective hospitals and patients would be
seen at each hospital using standard diagnostic criteria and the data transferred to the chief
investigator. These patients could then be followed up. Betterstill would be a survey of all GP
Practices within the UK. such as the study as donein Cuba, that would capture mostpatients(4).
The time, effort and resources required for such a project were outside the scope ofthis study.
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Chapter5:
Treatment of Neuromyelitis Optica with
Rituximab
7]
5.1 Introduction:
There are no randomised trial recommendations to prevent relapses in NMO.Studies are based on
small case series. Immunosuppressant medications including azathioprine(41), cyclophosphamide,
mitoxantrone(44), mycophenolate mofetil(45) are used. Interferon beta is reported to be less
effective than immunosuppressive therapy(69) or deleterious(48). Open label use of rituximab
(Rituxan, Biogen-IDEC, Genentech, San Francisco, CA), a monoclonal antibody against CD20 B-
cells has been reported in NMO(42, 70). Given the lack of other treatments proven to be effective,
this report led to wide use of rituximab for NMO,even as a first line treatment. Howeverthere is a
clear need for further information about the role of Rituximab in NMO.I therefore conducted a
retrospective analysis of the use of rituximab in patients with NMO under the guidance of
Professor Weinshenker and Dr Cree
5.2 Methods:
Investigators from twenty centres in the USA and UK whoattended an exploratory meeting in San
Fransicso, USA about a potential clinical trial of a new humanized monoclonal antibody with
similar specificity for CD20 protein as rituximab were approached to participate in this study.
Seven centres responded to the request and contributed all the patients to whom rituximab was
administered for treatment of NMO by the recollection of the site investigators [UCSF, San
Francisco, CA, USA (n=7);Stony Brook Hospital , NY (n=6);Mayo Clinic Rochester, MN (n=5 );,
MayoClinic Scottsdale AZ (n=2); The Walton Center, Liverpool, United Kingdom (n=2);, Mellen
Center, Cleveland Clinic Cleveland, OH (n=2); Mount Sinai Hospital, NY (n=1) |. IRB approval
was obtained at each centre and consents were obtained from patients or next of kin. All patients
with relapsing NMO orlongitudinally extensive transverse myelitis (LETM)(30) who were treated
with at least one dose of rituximab and whohad atleast six months of follow up were included.
Patients who did not meet the abovecriteria were excluded. | analysed completed case report forms
whilst at the Mayo Clinic, Rochester, Minnesota. All patients reported to the analysis team by the
treating hospitals were found to beeligible and were included. Statistical analysis was performed
usingJMP 6.0 (SAS, Cary NC).
5.3 Results:
5.3.1 Patient characteristics
Twenty five patients were reported andall satisfied inclusion and exclusion criteria. There were
three men and twenty two women. The median (range) age of the patients was 38 (7-65). Two
children were included in whom rituximab was begun at age seven (patient 8, Table 1) and 14
(patient 11). Twenty three patients had NMO and two had relapsing LETM. The median (range)
interval from onset of NMO to treatment with rituximab was 4.5 (0.8 -17) years. The clinical and
demographic profile is outlined in table 1. NMO IgG waspositive in 14 of 20 patients. Seven of
eight patients from theinitial study are also included(42). Onepatient from the initial study was
lost to follow-up.
Rituximab was initiated in 23 patients due to failure of other medications (Table 1). In 19 patients
more than one drug was used (Table5.1). In two patients, rituximab was used as the first drug
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5.3.2 Treatment with rituximab
Two dosing regimens of rituximab were used as theinitial treatment. These were based on
use in rheumatology(71) haematology(72) and the previous reported series of 8
patients(42) and were guided by local practice. Regimen 1) 375mg/m¥ of rituximab was
infused four times with a one weekinterval between infusions (n=18)(72); 2) 1000mg
of rituximab was infused two times with a two week interval between the infusions
(n=4)(71). Information regarding dosing regimen was unavailable for three patients.
Seventeen patients received further rituximab treatments: Eight had further doses of 375
mg/m; seven had 1000mgrituximab two weeks apart; data regarding subsequent dosing
regimen were unavailable for two patients. Other immunotherapy was used in five
patients along with rituximab: azathioprine + prednisone (n=1), prednisone (n= 3),
interferon beta (n= 1).
The median (range; mean) interval between the last relapse and start of treatment was 1
month (0-7; 1.5). 20 of the 25 patients received treatment within 2 months of the last
relapse. The median (range) interval between rituximab treatment courses was 8 (4-26)
months. Subsequent treatments were either pre-planned at 6-12 month intervals or were
administered after relapse or when CD19 cells were again detectable. CD19 counts were
not routinely monitoredin all patients and no threshold value was utilized to determine
frequencyortiming of re-treatment.
5.3.4 Follow up
The follow up interval after initial rituximab treatment was 19 (6-40) months [median
(range)]. Eighteen patients planned to continue treatment with rituximab atlast follow-up
and 15 hadreceived rituximab in the last six months of follow-up.
Seven patients discontinued treatment. The reasons for discontinuation were death (n=2;
patients 5 and 10), relapses (n=2; patient 18 and 22), pregnancy (n= 1; patient 14) and
other (n=2; patient 13 and 20).Thedetails of these seven patients are given below.
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Three patients started other remission-inducing treatments (patients 18, 20, and 22).
Patient 18 was initiated on maintenance plasma exchange every six weeks, pulsed
intravenous steroids and mycophenolate mofetil. Patient 22 was placed on
cyclophosphamide after the third relapse. Patient 20 who was on azathioprine throughout,
was averse to parenteral administration of drugs, and wanted to retry azathioprine. So
after two minorrelapses the dose of azathioprine was increased and she remains relapse
free. One patient planned pregnancy (patient 14). One (patient 13) discontinued
rituximab and was not on any new treatment despite a minorrelapse (figure 1). However,
after completion of this analysis she was readmitted with a severe spinal cordrelapse at 2
years from last infusion ofrituximab (not shown in fig 1) and has now resumed rituximab;
this relapse was not included in the analysis of relapse rate.
5.3.5 Efficacy : Relapse rates.  Relapses before and after treatments are
represented in figure 5.1. Alll relapses after onset of rituximab were considered. However
if new treatments were introduced, only relapses until the start date of the new treatment
were included (patients 18, 20, 22). Relapses in patients who stopped rituximab but were
not on any other treatments were included. If all patients were included (n=25) the pre-
treatment annualized relapse rate was 1.7 (0.5-5; 2.7) and the post-treatment was 0) (0-3.2;
0.6) [Median (range; mean)(p < 0.0001, Wilcoxonsigned rank test) at a median follow up
of 19 months.
If the two patients who died (patients 5 and 10) were excluded from relapse analysis
(n=23) the pre-treatment annualized relapse rates was 1.7 (0.56-4.9; 2) and the post-
treatment was0 (0-3.2; 0.63) (p < 0.0001).
If the five patients who were on any additional immunological treatment(7, 11, 15, 19,
20) and the two whodied were excluded, the pre-treatmentrelapse rate was 1.7(0.7-4.9;
2.12) and the post treatmentrelapse rate 0(0-2.9; 0.5) at a median follow up of 18 months
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in the remaining 18 patients. If the patients who were followed less than one year were
also excluded (1,2,3,4) along with those on anyadditional immunological treatment (n=5)
or who died (n=2), the pre-treatment relapse rates were 1.5(0.7-4.9; 2.2) and the post
treatment relapse rates 0(0-2.9; 0.46) respectively at a median follow up of 22 months in
the remaining 14 patients.
 
     
Qe eens mee = oe S eS oe Pie Si Sie Fei Ses & wd= BSS (=~ ----+- 5-5 ee -5-4CI ad
+ Ce - » oe <p os o¢ o ~-
+ - - + ch Cc am qo +
- + “+ ca Ce je *| +
eo 7+ + G {J cI —-
20 > Oo -e % O10 - - -e- - + - - ~~~ ee o) eee er ee ee ee ee eee +} |were eee - -
- + Sod i ¢* @¢ Cf) +
« eo + oe + % ooeee veer «| +-
7 + os eof (I Co aa Cot
- « a - 4 ° . ad ° + oO co +
aee ee ee ee - ~~ - ~~~ ofl} ------- ee er eer rr rrr 7
- - * : C 3 * --
- - . a eo; +
+ od cm fe
* ° - > (> «© +
“+ Sa + J =
> “o =o
~~“? + - oo a4 7° * " tC) ofr
oe oe “7 oe fe2% 96 Se Ene~d a --- a nl o@-----
a - oo Cee
od > a oe © -+-
> * -
oa > oa + +e + 4
T
-40 -20 Oo 20 40
Time in Months   
Fig.1. Pre and postrituximab relapses. Each interrupted line on the y axis represents a
patient. The x axis indicates the 20 months pre and post rituximab treatment. The open
white boxes (a) indicate RTX treatment. The black diamonds (¢) indicate relapses. The
plus (+) signs indicate last follow up andthe blacksolid circles (@) indicate deaths. The
verticallines ( | ) indicate start of new treatments.
5.3.6 Efficacy: Disability. Two patients died (Patient 5 and 10). The median (range;
mean) EDSSat start of treatment with rituximab was 7(3-9.5; 6.8) and that at last follow
up at a median of 19 months was 5 (3-10; 5.5) n=25
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EDSSscores of 20 patients stabilized (n=9) or improved (n=11). In five patients (patient
3,5, 10 13, and 20) EDSSscores worsened.
The number of patients in the two treatment regimes was different (18 treated with
375mg/n¥ and four with 1000 mg); data was unavailable about the specific treatment
regimen for the remainder. Subsequent treatments were variable, making comparison
between dosing regimens difficult. Hence analysis was not attempted.
5. 3.7 Adverse events observed during treatment and follow up
Infusion-related transient side effects occurred in seven of 25 (28%) patients and were not
dose-limiting, New orreactivated infections developed in five of 25 (20%) patients and
included: herpes simplex (cold sore) and positive PPD (n=1) herpes zoster (n=1),
recurrent Clostridium diffiale colitis (n=1), cutaneous fungal infection (n=1), urinary tract-
related septicaemia and death (n=1).Worsening of pre-existing seborrheic dermatitis
occurred in one patient.
5.3. 8 Deaths: Patient five developed recurrent Clostridiumdiffiale colitis after her first
rituximab infusion followed by urinary tract infection. She died nine months after the last
dose following a severe brainstem relapse accompanied by a brainstem lesion extending
into the hypothalamus and thalamus detected on MRI. Clinical manifestations were
lethargy, obtundation, electrolyte imbalance and hypothermia. CD19 cells were not
detectable two months before death and seven months after last infusion.
Patient 10 died six months after the last dose of rituximab. She was obtunded and was
suspected of being septic. An autopsy restricted to brain and spinal cord showed
confluent demyelination in the cord from lumbarto cervical cord with focal necrosis and
cavitation, perivascular lymphoid infiltrate and macrophage infiltrates. Both optic nerves
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were atrophic and had lymphocyte and macrophage infiltrates. The brain did not show
any pathology. CD19 cells were undetectable five months after last infusion and one
month before death. Her total lymphocyte count was 0.9x10” just before death (normal
0.9-2.9 X10’/L) compared to 2.73x10” before starting rituximab; she had low IgA, IgG,
IgM levels one month prior to death. Priorto initiation of rituximab she was treated with
mitoxantrone.
5.4 Discussion
NMOis a relapsing disorder with rapid accrual of attack-related disability and a high early
mortality rate(11). Controlled trials of treatments to prevent relapses are unavailable and
treatment is based on case series and expert opinion. Though two cases were reported to
enter remission with use of glatiramer acetate(73, 74) immunomodulatory medications
(beta interferons or glatiramer acetate) do not appear to be beneficial in larger case
series(48, 69). Immunosuppressive drugs are the mainstay of treatment in NMO.
Azathioprine(41) is the most widely used medication. Cyclophosphamide,
mitoxantrone(44), cyclosporine, methotrexate (75),and mycophenolate mofetil (45) have
been used(76). However, patients commonly relapse on these treatments and relapses
with brainstem orcervical cord involvement are a frequent cause of death in NMO(11).
This retrospective, multicenter case series evaluated the use of rituximab in NMO largely
refractory to the other drugs. Relapse rates improved anddisability stabilized or improved
in 20/25 (80%) patients similar to the previous findings in a much smaller series (42).
Though the infections cannot be definitively classified as opportunistic, death of one
patient due to sepsis and the occurrence of infections in others are of concern. Patient 10
died following a presumed UTI and had reduced lymphocyte counts and immunoglobulin
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levels. It is possible that treatment with rituximab, and/or prior treatment with
mitoxantrone, contributed to the patient’s infections.
No attempts to identify factors predictive of response to rituximab was made. The small
size, retrospective acquisition of data and positive treatment response in 80% patients
precludes such an analysis.
It is unclear whetherrituximab should be thefirst line treatment for NMO. Comparative
studies between the immunosuppressive treatments used in NMO have not been
undertaken. The patients in this series are a selected population of treatment-refractory
NMO. Perhaps the majority of treatment naive patients may need less expensive and
widely available immunosuppressive drugs. Also even in this small group, there are
apparent rituximab treatment failures demonstrating that, it may not effective in all
patients. A recent case report on 2 patients with variable response to treatment with
rituximab highlights this(70)
Safety concems regarding rituximab persist. The relative risk of infections with rituximab
versus other immunosuppressive treatments in NMO is unknown. Recent reports of
progressive multifocal leukoencephalopathy (PML) in two patients with systemic lupus
erythematosus(SLE), one patient with systemic vasculitis and 23 patients with lymphoma
treated with rituximab are of concern(77). Howeverthese patients received treatment with
other immunosuppressive medications, either sequentially or in combination with
rituximab. Lymphomas and SLE are thought to predispose to PML, irrespective of
treatment. PMLhas also been associated with azathioprine(78, 79), cyclosporine(80, 81)
and cyclophosphamide(82).
Rituximab treatment is substantially much more expensive(83) than generic
immunosuppressive drugs such as azathioprine. However, this may be offset against the
cost of hospitalizations for relapses and plasma exchanges if rituximab is more efficacious.
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5. 5 Limitations:
This study is limited by the retrospective nature of this multicenter case series. The
treatment regimens differed although the total dose administered to each patient was
comparable. Theintervals between courses of treatment were variable. It is possible that
‘regression to the mean’ contributed to the decline in relapse rates. The wash-out period
between rituximab and previous drugs was often insufficient. A combination of drugs
was administered to five patients. CD19 B-lymphocyte counts were not measured to
assess efficacy of treatment andtiming of retreatment. The pretreatment EDSS may have
been determined immediately post-relapse, while the last available EDSS may have been
determined during a period of stability, thus showing improvementattributable to
recovery from an attack.
Despite these limitations I feel that this study is valuable. Much has been learned on
pathogenesis and course of NMOintherecent years. But data on treatment in NMOare
sparse, and there are no data from controlled trials. This is a large series of a single drug
treatment, particularly of the subgroup refractory to conventional treatment which has a
high mortality. Controlled trials are difficult to organize due a variety of reasons due to the
rarity of the disease, need for early treatment, high morbidity from relapses but it should
becomea priority to physicians caring for people with NMO.Until then studies such as
this provide ‘some evidence’ to guide the choice of treatment for this potentially life
threatening disease.
8]
Chapter 6
Treatment of Neuromyelitis Optica with
Mycophenolate Mofetil
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6.1 Introduction
No randomised controlled trials have been conducted in NMO andtreatmentis empiric,
based on small case series. The mainstay of treatment for a majority of patients is
prednisone alone or in combination with Azathioprine.Its use is largely based on series
of seven NMO patients who were treated with long-term prednisone and azathioprine
and were followed every 2 months for at least 18 months. Their EDSS score improved
significantly and no relapses occurred for more than 18 months(41). A similar small case
series on 5 patients on mitoxantrone over 2 years also showed improvement (44). 2
patients each had a relapse once within the initial 5 months of treatment. 1 patient had a
reversible decrease in cardiac ejection fraction.
Rituximab a monoclonal antibody against CD20" B cells(43)has been used in NMO.
Following an initial report on 8 patients, | conducted a retrospective multicentre
experience on twenty five patients showed that the drug seemed effective in reducing
relapse rates and improvingorstabilising disability in 80% of treated patients(42, 84).
However 28 per cent of patients had infusion related adverse events and 20 percent had
infections that could possibly be reactivated due to immunosuppression. ‘T'wo patients
died, onelikely due to septicaemia. Rituximab, therefore, was potentially beneficial but
seemed associated with the risk of infections. But even in this small series there were
treatmentrefractory patients. It also requires intravenous infusion, which may necessitate
admission. These factors and the risks of significant infections from immunosuppression
may limit its use, especially as a first-line agent in the treatment of NMO spectrum
disorders.
Mycophenolate Mofetil (MMF)(Cellcept®, F.Hoffmann-La Roche, Basel, Switzerland)is
2- morpholinoethyl ester of mycophenolic acid and a reversible inhibitor of inosine
monophosphate dehydrogenase involved in the de novo (but not salvage) pathway for
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guanosine nucleotide synthesis, on which the T and B Lymphocytes are exclusively
dependentfor proliferation(85). It also exerts an inhibitory effect on antibody synthesis.It
is routinely used in cardiac and renal transplants and is being increasingly used as a
treatment option in a variety of other immunological conditions including lupus induced
and other immune nephropathies, autoimmune hepatitis, psoriasis, blistering
dermopathies, and vasculitides. Neurologists are familiar with the drug due to its use in
myasthenia gravis(86-89).There are reports ofits use in multifocal motor neuropathy(90),
inflammatory myopathies(91), CIDP(92), autonomic ganglionopathy(93) vascullitic
neuropathies (94)and multiple sclerosis(95-97). It is considered to have fewer side effects
than other immunomodulators andis given orally. All of these factors may have favoured
its off label use in NMO,insufficient published evidence exists forits benefit in NMO.
Only one case of NMOtreated with MMF has been reported(45). A 9 year old girl with
NMOhad 5 relapses over 2 year period despite azathioprine. Steroids caused a vertebral
fracture. MMF introduced 16 months after onset of NMO was able to sustain a remission
at 2 years(45). The dose, duration, and efficacy of the drug for NMO remain uncertain.
I therefore did another study under the guidance of Dr Sean Pittock to assess the efficacy
of MMF.
6. 2 Methods
A retrospective chart review of a// Mayo Clinic patients with NMO (as per 2006
diagnostic criteria) or a NMO spectrum disorder (NMO-IgG seropositive patients with
optic neuritis or longitudinally extensive transverse myelitis) treated with MMF from
Junel999 until June 2006 was performed. Patients were identified by searching the
centralised medical records of all the 3 Mayo Clinics sites [Rochester (MN), Scottsdale
(AZ) and Jacksonville (FL)] using the search terms “Neuromyelitis optica” or “Devic’s
disease” or “optic neuritis” or “myelitis” and “mycophenolate” or “cellcept.”
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Local institutional review board approval was obtained and informed consent was
obtained from patients or the next of kin. Telephone follow up was performed in June
2007 and more recently in August 2008(49). Data was analysed using JMP, Version 6.0
(SAS, Cary, North Carolina). Wilcoxon signed-rank test was used to compare pre and post
treatmentrelapse rates and EDSS. Relapses and disability were assessed by chart review
and telephone interview. A relapse was defined as objective worsening of neurologic
function lasting for more than 24 hours. Pseuco-exacerbations (temporary increase in
symptoms) brought on byheat, exertion or fever were not consideredattacks.
6.3 Results
6.3.1 Patient Characteristics
Twenty-four patients were identified. There were 19 women and 5 men. The median age
of the patients at onset of treatment with MMF was 56(range 34-77) years. The median
duration of NMOto onset of treatment with MMF was 4.2 years (range 0.1-39). The
diagnosis was NMO in 15 [(63%); 13 of 14 were NMO-IgG seropositive, and all fulfilled
2006 NMO diagnostic criteria]; relapsing LETM in 7(29%); relapsing optic neuritis in
1(4%) and a single episode of LETM in 1 (4%). The patients with LETM and optic
neuritis were all NMO IgG seropositive.
6.3.2 Treatment with Mycophenolate
Seven (29%) patients were treatmentnaive. The remaining 17 (71%) were tried on other
immunosuppressive (n= 6), immunomodulatory (n=2) or a combination (n=9) therapy,
Twelve (50%) received Azathioprine (Table 1). Reasons for switching to MMF were
identified in all and included medication side effects in 7(29%), continued relapses in 8
(33%), contraindication to azathioprine due to low thiopurine methyltransferase (TPMT)
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levels in 2 (8%). |The median dose of MMF used was 2000 mg/day (range 750-3000).
Theclinical and demographic profiles of the patients are summarized in thetable.
6.3.3 Follow Up
After identification of the initial cohort in June 2007, telephone follow up and chart
review was again obtained, for 20 patients in late 2008, at a median of 27 months after
starting treatment (18-89). For 4 patients who were not contactable (one died) by
telephone recently, chart review provided data up to a median 46 months (21-54). The
median follow up ofall patients (irrespective of whether they stayed on treatment) was 28
months (range18-89).
The median duration of treatment on MMF was also 27.4 months (range 1-89). At last
review 19 (79%) patients continued on treatment with MMF with a median duration of
29.4 months (range 20-89). Five (21%) patients discontinued the drug after a median
duration of 16 months (1-54). The reasons for discontinuation were death in one (patient
21) , relapses in two (patient 3 switched to rituximab at 3 months and patient 14 to
azathioprine at 25 months) and side effects in one (patient 2, low WBC counts, who
switched to azathioprine at 1 month). Patient 1 had neither relapses norside effects but
chose rituximab at 1 month.
6.3.4 Treatment Efficacy : Relapse Rates
Figure 6.1 shows the relapses before andafter treatment. All relapses after initiation of
MME until its discontinuation or until the last date of follow up was included in the
analysis. Nine patients were on additional treatments [steroids (n= 8) and IV
immunoglobulins (n=1)] for variable periods after starting MMF (table1).
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Fig.6.1. Pre and post mycophenolate relapses. Each interrupted line on the y axis represents
a patient. The x axis indicates the 100 months pre andpostrituximab treatment, 0 being the
start date of treatment. The plus (+) signs indicate last follow upor date of discontinuation of
treatment ;(e) indicate deaths. Therelapsesof patient 21 are distributed evenly over his MMF
treatment duration due to incomplete data.
Entire Cohort:. The median treatmentduration forall 24 patients was 27.4 months (range
1-89), the median annualised post treatment relapse rate was 0.09 (range 0-1.56) and the
pre treatment rate was 1.28 (range 0.23-11.78, P< 0.0001, Wilcoxon signed-rank test).
Nineteen of the 24 patients (79%) had an improvementin relapse rates. As analyses of the
total group were confounded by concomitant treatments, short duration of treatments
and death, | performed subgroup analyses.
Subgroup analysis 1: Duration of therapy
Twoofthe 24 patients were on MMF for a very short duration (patients 1 and 2 for one
month each) and discontinued the drug early due to side effects. If these patients were
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excluded from the analysis, the remaining 22 patients had median treatment duration of
28 months (16-89). The median post treatment annualised relapse rate on treatment for
these 22 patients was 0.19 (range 0-1.56) versus the pre treatmentrate of 1.37 (range, 0.23-
11.78, P <0.0001). 17/22 (77%) patients had an improvementin relapse rates.
Subgroup analysis 2: Death and Duration of therapy
If I exclude the patient who died (patient 21) along with those with short follow ups
(patient 1 and 2) the median duration on treatment for the 21 patients was 27.4 months
(range, 16-89). The median post treatment annualised relapse rate on treatmentfor this
subset was 0.18 (range, 0-1.5) and the pre treatment rate was 1.15 (range, 0.23-11.78, P
<().0001).
Subgroup analysis 3: Death, Duration of Therapy and Concomitant therapies
If patients who were on any additional treatment (3,5,6,9,12,13,15,21 and 22) and those
on treatment for less than a month (patients 1 and 2 ) and the patient 21 who died were
excluded, the median duration of treatment in months was 31 (range, 21-89) for the
remaining 12 patients. The median post treatment annualised relapse rate on treatment for
this subset was 0.24 (range 0-1.22) and the pre treatment rate was 1.15(range 0.23-7.6, P
<0.001).
6.3.5 Treatment Efficacy: Disability
The median Expanded Disability Status Scale (EDSS) score at the start of treatment with
MME (n=24) was 6 (range, 0-8) andat last follow-up at a median of 28 months was 5.5
(range, 0-10) (P=0.17). Excluding the 2 patients who were on very short period of
treatment (n= 22), did notalter the median scores.
The EDSS scores were unchanged in 15 and improved in 7 (22/24, 91%). The median
reduction in EDSS was 1 point (0-5 - 2.5). Four of these patients stopped using their cane.
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EDSSworsenedin 2 patients (patient 3 who worsened from EDSS6 to 8 and patient 21
whodied after being bed bound for 54 months).
6.3.6 Adverse Events Observed During Treatment And Follow-Up
Onepatient (21) died. This was a 45 year old Hispanic man whopresented with optic
neuritis and myelitis in 1999 and had a further3 relapses in the same year. He was initiated
on MMFand prednisone in 2000, after developing liver dysfunction with azathioprine.
Noside effects were noted in theinitial year. He was lost to follow up. Recent telephone
discussions with family indicate that he continued to relapse once every six months while
on MME (exact details not available) and died 54 months after onset of treatment with
MMF. The death certificate documents the cause of death as ‘cardiopulmonary failure;
respiratory drive failure and Devic's disease’. The relapses indicated in the figure 1 are
evenly distributed over the period of follow up.
Six patients (25%) reported side effects: headache (n=1), constipation (n=1), easy
bruisability (n=1), anxiety (n=1) hair loss (n=1), diarrhea and abdominal pain (n=1, dose
limiting,) and low WBCcounts (n= 1, needing change of drug)
6.4 Discussion
NMOis considered to be a rapidly disabling disorder with attack related early
accumulation ofdisability. Preventing attacks by immunosuppressive drugs is the
mainstay of preventing disability(98). Azathioprine(41), corticosteroids(99),
mitoxantrone(44) and more recently rituximab(42, 43) have been found to be useful in
small case series. Rituximab seemed to be potentin reducingrelapse rates in these
retrospectiveseries. In oneseries, 23 of 25 patients were refractory to other treatments
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(compared to 17 of the 24 in this cohort) including 1 patient who was on MMF.Only 2
patients were treatment naive (compared to 7 in the present study). However, even in the
25 patients treated with ritiximab, there were treatmentrefractory patients (2 ; one each
switched to azathioprine and MMB), side effects and 2 deaths. No patient was tried on
rituximab prior to MMFin thepresent study.
The wide use of MMFin rheumatology and transplant medicine and myasthenia gravis
has prompted its use in NMOandthis retrospective study is intended to summarise the
treatment experience at the Mayo Clinic. I found that the relapse rates were improved in
19/24 (79%) patients and disability stabilised or improved in 22/24 patients (91%).
Identifying reliable predictors of response was not attempted as the good response to
treatment in majority; varying doses and additional treatment in 9 patients are strong
confounders. The side effects observed in this study were dose limiting in one patient and
necessitated change to azathioprine in another.
Despite the apparent benefit, serious safety concems exist with mycophenolate.
Progressive multifocal leukoencephalopathy (PML) has been reported in Kidney, heart and
lung, transplant patients and in systemic lupus erythematosis (SLE)when MMF was used
in conjunction or after the use of other immunosuppressants (100). A retrospective
cohort study of 32,757 renal transplant recipients using the United States Renal Data
Systemkidney transplantfiles identified 9 cases. Based on this the incidence density of
PML in MMF users was 14.4 cases/100,000 person-years at risk versus 0 for non-MMF
users. Howeveras 75% ofpatients in the cohort were on MMF rostatistically significant
association was found. Nocases were seen in patients on MMF monotherapy(101).
Though an increased risk of lymphoma was initially reported in patients who underwent
transplants and occasionally in autoimmune disorders (102-105), an international
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prospective registry of 6751 patients receiving MMF and an equal number of matched
controls receiving non mycophenolate-based immunosuppression, did not find this
association, at least in renal transplant patients with lupus nephritis(106).
There are also concernsregarding efficacy of mycophenolate. Though the drug had ample
anecdotal evidence supporting its use(89), the two large recently concluded randomised
controlled trials in myasthenia gravis showed no benefit (87, 88, 107). There are also
reports on the lack of advantage over azathioprine in recipients of cadaver kidney-
transplants in preventing acute rejections (108). MMF is also much more expensive than
azathioprine, but cheaper than rituximab. I used an online drug store to compare drug
prices (109). This I felt might be a better option than prices from hospital pharmacies,
where discounts might apply and costs may vary across the country. The estimated drug
cost for azathioprine, MMF andrituximab for one year were $846.8 (150 mg /day),
$11373.4 (2000mg/day) and $23,287.6 ( four 1000 mg infusions/year) respectively.
Additional expenses related to drug infusions (eg; day admission) for rituximab and
regular laboratory based monitoring(liver function tests and complete blood counts) for
azathioprine and MMF would also factorin the overall cost.
6.5 Limitations of the study.
The predominantly retrospective (and 14 month prospective) nature of the evaluation, the
small cohort of patients and use of additional treatments make definitive statements on
the effectiveness of the drug perilous. The reduction in the relapse rates could be a
regression to the mean phenomenon(110). The pre-treatment EDSS could be at a time of
relapse while the post treatment scores could be during a period ofstability. It is also
possible that the observed efficacy of MMF could be the continued benefit from the drug
a1
precedingit. The loss of follow up and subsequent death of one patient due to unknown
causes also adds to some uncertainty.
There is no consensus amongst neurologists on the drug of first choice for relapse
prevention in NMO.Therehave been no controlled trials in NMO(let alone comparative
trials) and azathioprine with or without oral prednisone, rituximab, MMF and other
immunosuppressants all seem effective; therefore, side-effects and cost along with the
urgencyin rendering the patient immunosuppressed influencethis decision. It is uncertain
if the benefits seen in this study will be bome out in controlled clinical trials. But this
case series might provide some justification to the use of the drug in patients experiencing
life-threatening relapses and for organising a multicentre trial comparing the currently
used drugs.
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Chapter7.
Discussion and Conclusions
Since this study began major advances have occurred in NMO byvarious groups
across the world. These were spurred on by the discovery of the antibody marker
and its antigen- aquaporin-4(32, 111).We now have a better understanding of the
partners and mechanisms of antiaquaporin-4 antibody
AQP-4 antibodies are produced by B Cells in peripheral circulation and access its
antigenic target the water channel AQP4on astrocyte membranes. Regions with high
expression of AQP-4,like the foot processes of astrocytes abutting the capillary walls
in the blood brain barrier, optic nerve head, spinal cord and those regions where no
blood brain barrier exists -circumventricular organs — seem more susceptible to such
damage. After crossing the blood brain barrier, binding occurs only to
macromolecular aggregates of AQP4 (orthogonal array particles, OAP). Only the
M23isoform of AQP4 (and not M1) form such OAPS (112). AQP4 and the sodium
dependentexcitatory aminoacid transporter 2 (EAAT2) co-exist as a complex on the
plasma membrane. EAAT2is crucial to the re uptake of glutamate(34). The binding
of AQP4-Ab to AQP-4 onastrocytes leads to the AQP4 being internalised bythecell
[into early endosome antigen 1 (EEA1) containing early endosomal vesicles with
probable subsequent degradation (113-115)] along with EAAT2resulting in impaired
glutamate uptake leading to excessive glutamate outside the cell. The resulting over
stimulation of glutamate receptors in neurons and oligodendrocytes could
contribute indirectly to the pathobiology of NMO.This in turn leads to injury to
neurones and oligodendrocytes in the vicinity(34). EAAT2 accounts for > 90% of
glutamate uptake in the CNSandis critical for clearing glutamate from excitatory
synapses, and is expressed selectively in astrocytes. AQP4 and EAAT?2exist in
astrocytic membranes as a macromolecular complex. Because astrocytes are
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relatively tolerant of increased glutamate concentrations disruption of glutamate
homeostasis by NMO-IgG has particular excitotoxic potential for neurons and
oligodendrocytes. A focal increase of extracellular glutamate levels secondary to
NMO-IgG — induced down-regulation of AQP4 may suffice to injure or kill
oligodendrocytes that express calcium permeable glutamate receptors.
Oligodendrocytes in the spinal cord and optic nerve, whichare principal sites of
demyelination in NMO, are particularly sensitive to changes in glutamate
concentration.. Granulocytes attracted by complement, Null Killer cells and antibody
dependentcellular cytotoxicity all adds to furthertissue injury(115).It is plausible that
upregulation of EAAT-2 or prevention of OAP formation couldlimit injury in NMO
(34, 116).
Tissue injury in NMO IgG negative patients may be due to a yet unidentified
antibody(117) or mediated by mechanisms other than autoantibodies e.g, cell
mediated cytotoxicity(118). Similarities can be drawn to myasthenia gravis where a
subset of Acetylcholine receptor antibody negative myasthenia was found to have
another antibody- -MusK. Perhaps the same is possible for NMO.It could also be
that the current techniques are unableto detect the low levels of antibody that maybe
pathogenic in uniquely vulnerable patients , explaining the higher morbidity in that
group.
Depletion of AQP4 water channels in the plasma membrane would disrupt water
homeostasis and promote edema. So far therapies targeting glutamate receptors
have not been useful (in degenerative disorders) but it might be feasible to
ameliorate tissue damage in both gray and white matter if therapeutic up regulation
of EAAT2 can be achieved.
oF
Another exciting prospect is the possibility of aquaporinopathies as a new disease
category. There are a variety of aquaporins distributed widely in the body both within
and out of the CNS. It is uncertain why disease manifestations of NMO are
restricted only to the CNS.
Since its discovery in 2005, aquaporin- 4 antibodies have been demonstrated by
several groups to have a high specificity and sensitivity for the diagnosis of NMO. Of
the three methods used in the detection of the antibody, indirect immunofluroscence
(NMOIgG),cell based assays and immuno-precipitation; the cell based assays have
the highestsensitivity in (90%). This is closely followed by the immunofluroscence
(86%) and immunoprecipitation(83%). Both cell based and immunoprecipitation
assays had 100% specificity while indirect immunofluroscence have specificity of
91%(29). Wider availability of the tests will no doubt increase the amount of newly
diagnosed cases. However whoto teststill remains a thomyissue. Ideally all patients
with optic neuritis and transverse myelitis should be tested. In an increasingly cost
constrained healthcare such broad guidelines may not be acceptable. It therefore
seems reasonable that tests at the present time, be restricted to patients who have
very severe optic neuritis, longitudinally extensive transverse myelitis, recurrent optic
neuritis or myelitis. Another category of patients who might benefit from such tests
are patients with atypical brain stem or hypothalamic changes. The need for testing
in typical NMOis uncertain. Though a positive test would validate the diagnosis, a
negative test does notinvalidate it and treatmentstrategies will not be change.
It is uncertain if additional antibodies are present in currently sero-negative NMO
patients. Newer techniques using samples from treatment naive patients may reveal
additional antibodies
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Yet another important prospectis the utility of the antibody in monitoring the course
of the disease. Preliminary results suggest that the AQP4antibody levels rise before
relapses and are reduced almost immediately with the use of intravenous steroids (66)
Immunosuppressants particularly azathioprine seem to maintain the lowlevels in the
few patients tested. Rituximab also drops thelevels quickly but levels reappear within
afew months. There seems to be no threshold value which will lead to a relapse. In
fact in a few patients high levels of antibody do not seem to inducea relapse. This
might mean that there might be other mechanisms that need to co-exist with high
antibodylevels to induce or trigger a relapse(66). These findings have important
implications. If borne out by formal studies, one could envisage routine monitoring
of NMO antibodies on a monthly basis looking for the reappearance following
therapy andinstituting pre-emptive therapy before relapses actually occur.
I have conducted 4 different studies looked at 3 aspects of NMO that were not well
known before: epidemiology, long-term outcomes, and new treatments. Of the 128
patients 67 patientssatisfied criteria for an optico spinal demyelinating syndrome. At
a median follow up of 38 months 34 of these OSD patients satisfied current criteria
for NMO. These combined with another 8 patients with NMO spectrum disorder
formed the cohort of the prospective study of 42 patients, the largest prospective
study to date.
81% of these patients were positive for the aquaporin-4 antibody. Treatments
improved relapse rates, but did not improve disability. Ten (24%) patients died and
all patients had some disability.
The current emphasis and interest in NMO_ treatment seems largely to be in
preventing relapses which is a reasonable and laudable goal as relapses leave behind
serious sequelae and the disability is acquired during attacks and not due to disease
99
progressionas is typical of multiple sclerosis. However an equal emphasis has to be
placed on improving the disability during an attack or terminating the attack The
presentcare of patients duringa relapse need to be optimised. The rationale of using
a short term intravenous course of steroids is derived from its use in multiple
sclerosis where the disease is primarily demyelinating and recovery usually occurs
irrespective ofsteroid treatment. However NMO relapses are serious and severe and
are not just demyelination but involve tissue necrosis and loss. Therefore aggressive
steroid therapy foratleast five days with oral maintenance of prednisoneis required
in all cases in
a
relapse. Plasma exchange whichis sparingly used has to be made
widely available. The efficacy of plasma exchange in a variety of idiopathic
inflammatory demyelinating disorders have been demonstrated by a controlled trial
(39, 40). A subset of patients enrolled in this study with NMO had excellent
outcomes. Much delay occurs from admission to being seen by a Neurologist and a
decision for plasma exchange is taken, to the start of therapy. All patients diagnosed
with NMO need to have a standardised treatment plan andalgorithm that should
automatically come into play when they are admitted.
Targeted blockadeofinterleukins, tumour necrosis factor - alpha and
B
cell activating
factor (BAF) that mediate inflammationin the spinal cord might have potential future
applications. Therapy to reduce glutamate mediated excitotoxicity can be combined
with acute treatments with steroids and mightlimit the intensity of the inflammatory
damage.
Preventative treatments for NMO unfortunately remain sparse. It remains
conventional and makes economic sense that patients are initially tried on
Azathioprine with or without steroids at an optimal dose.  Thiopurine
methyltransferase levels needs to be checked before initiation of Azathioprine as 10
% of patients do not metabolise the drug which cause serious liver toxicity. Both
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rituximab and mycophenolate seems to be beneficial with quick suppression of CD20
positive B cells. However there is still a proportion of cases who remain refractory
to these. Newer preventative therapies will hopefully emerge with time. No
randomised trial has yet been conducted and though head to head controlled trials
between, azathioprine, mycophenolate and rituximab are required to decide thefirst
line agent. Therarity of the disease andtheearly disability make placebo controlled
studies unethical. Till such time cost, availability, logistics, side effect profiles have
to be considered in deciding the drug offirst choice. Several of the drugs that are in
use in rheumatological and other immunological disorders and MS could potentially
be applied to NMO:these includetacrolimus, olmecruzimab and alemtuzumab.
Perhaps in the future the burden of disease will diminish be limited bytheintensity of
thefirst attack. Ideally all patients presenting with the index event of optic neuritis or
myelitis with anti AQP4 antibodies would be instituted on effective
immunosuppression. Serial antibody levels would help predict relapses which could
be avoided by pre-emptive treatment. Therefore the only patients with serious
disability due to NMO might be those thatare left behind with serious sequelae after
the very first event which we will be unable to predict. Large scale screening of the
community for AQP4 antibodies is nota feasible option even in the future as the vast
majority cases are sporadic and no genetic marker has yet been identified .
The prevalence of NMO, NMOSDand the combined group was estimated to be
4.37 and 3.49 and 7.86/million. The incidence was estimated to be 0.52, 0.7 and 1.22
/million/year respectively. These data suggest that there are at least 369 patients with
NMO or NMOSDand 57 new patients/year in the UK. The various shortfalls of a
hospital based study limit the epidemiological validity of the Merseyside data’ A
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population based study geographically defined area with adequate representation of
all ethnic groups will be needed to truly answer the question if NMOis indeed less
frequent in Caucasians.
Another outstandingclinical question is the existence of monophasic NMO. Long
term follow up of such patients or a review of the published series of cases of
monophasic NMO will help answerthis. Thedifferences between NMOantibody
positive and negative groups, particularly the poorer outcomes in thelatter, need to
bevalidated in larger cohorts.
The exciting developments in NMO may havespin offs to multiple sclerosis whose
pathogenesis which despite two centuries of research has remained still ambiguous
and elusive. Several fundamental changes in scientific mindset need to occur if we
are to make inroadsinto the understanding of multiple sclerosis. One of them is to
delineate subpopulationsoftheillness. We should move away from the conventional
view that multiple sclerosis is one disease —an all encompassing one - an explanation
to all unexplained disease phenomena that have white matter lesions and an
inflammatory CSF. Such an approach has long delayed the understanding of NMO
and still continues to hinder varieties and subsets of opticospinal demyelination.
Whetherall OSD- U patients in my cohort will tum out into MS over time or remain
a separate subgroup needs to be seen. The lumping of multiple sclerosis hadits
purpose at a time when therapies were ineffective or unavailable. In this new era of
treatment of demyelinating disorders our goals should necessarily include clinical
characterisation and immunogenetic classification of subtypes of demyelinating
disease. Such an approach should bring to light several other lesser known or
unknown demyelinating disorders which have been left in the shadows of an often
irrevocable diagnosis of “a slightly atypical multiple sclerosis.”
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9.1 Kurtzke Expanded Disability Status Scale (EDSS)
[0.0 - Normal neurological exam (all grade 0 in all Functional System (FS) scores”).
(41.0 - No disability, minimal signs in one FS* (i.e., grade 1).
(11.5 - No disability, minimal signs in more than one FS* (more than 1 FS grade 1).
(2.0 - Minimal disability in one FS (one FS grade 2, others 0 or 1).
(42.5 - Minimal disability in two FS (two FS grade 2, others 0 or 1).
(13.0 - Moderate disability in one FS (one FS grade3, others 0 or 1) or mild disability in
three or
four FS (three or four FS grade 2, others 0 or 1) though fully ambulatory.
[43.5 - Fully ambulatory but with moderate disability in one FS (one grade 3) and one or
two FS
grade 2; or two FS grade 3 (others 0 or1) orfive grade 2 (others 0 or 1).
(34.0 - Fully ambulatory without aid, self-sufficient, up and about some 12 hours a day
despite
relatively severe disability consisting of one FS grade 4 (others 0 or 1), or combination
of
lesser grades exceeding limits of previous steps; able to walk without aid or rest some
500
meters.
04.5 - Fully ambulatory without aid, up and about much of the day, able to worka full
day, may
otherwise have some limitation of full activity or require minimal assistance;
characterized
by relatively severe disability usually consisting of one FS grade 4 (othersor 1) or
combinations of lesser grades exceedinglimits of previous steps; able to walk without
aid
or rest some 300 meters.
120
(5.0 - Ambulatory without aid or rest for about 200 meters; disability severe enough to
impair
full daily activities (e.g., to work a full day without special provisions); (Usual FS
equivalents are one grade 5 alone,others 0 or 1; or combinations of lesser grades
usually
exceeding specifications for step 4.0).
@ 5.5 - Ambulatory without aid for about 100 meters; disability severe enough to
preclude full
daily activities; (Usual FS equivalents are one grade 5 alone, others 0 or 1; or
combination
of lesser grades usually exceeding those for step 4.0).
Q 6.0 - Intermittent or unilateral constant assistance (cane, crutch, brace) required to
walk about
100 meters with or without resting; (Usual FS equivalents are combinations with more
than
two FS grade 3+).
Q 6.5 - Constantbilateral assistance (canes, crutches, braces) required to walk about
20 meters
without resting; (Usual FS equivalents are combinations with more than two FS grade
3+).
Q 7.0 - Unable to walk beyond approximately 5 meters even with aid, essentially
restricted to
wheelchair: wheels self in standard wheelchair and transfers alone; up and aboutin
wheelchair some 12 hours a day; (Usual FS equivalents are combinations with more
than
one FS grade 4+: very rarely pyramidal grade 5 alone).
Q 7.5 - Unable to take more than a few steps: restricted to wheelchair; may need aid in
transfer;
wheels self but cannot carry on in standard wheelchaira full day; May require motorized
wheelchair; (Usual FS equivalents are combinations with more than one FS grade 4+).
Q 8.0 - Essentially restricted to bed or chair or perambulated in wheelchair, but may be
out of
12]
bed itself much of the day; retains manyself-care functions; generally has effective use
of
arms; (Usual FS equivalents are combinations, generally grade 4+ in several systems).
Q 8.5 - Essentially restricted to bed much of day; has someeffective use of arm(s);
retains some
self-care functions; (Usual FS equivalents are combinations, generally 4+ in several
systems).
Q 9.0 - Helpless bed patient; can communicate and eat; (Usual FS equivalents are
combinations, mostly grade 4+).
Q 9.5 - Totally helpless bed patient; unable to communicate effectively or eat/swallow,
(Usual FS
equivalents are combinations, almostall grade 4+).
(3110.0 - Death due to MS.
*Excludes cerebral function grade 1.
Note 1: EDSSsteps 1.0 to 4.5 refer to patients who arefully ambulatory and the precise
step
numberis defined by the Functional System score(s). EDSS steps 5.0 to 9.5 are
defined by
the impairment to ambulation and usual equivalents in Functional Systems scores are
provided.
Note 2: EDSS should not change by 1.0 step unless there is a change in the same
direction of at
least one step in at least one FS.
Sources: Kurtzke JF. Rating neurologic impairmentin multiple sclerosis: an expanded
disability status scale (EDSS).
Neurology. 1983 Nov;33(11):1444-52.
Haber A, LaRocca NG. eds. Minimal Record of Disability for multiple sclerosis. New
York: National Multiple Sclerosis Society; 1985.
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euromyelitis optica also known as
Devic's disease is an uncommon,
immune mediated demyelinating
condition of the central nervous
system affecting predominantly the spinal
cord and optic nerves. Since 1894 when
Eugene Devic summarised 17 known cases of
optic neuritis and myelitis the relation between
neuromyelitis optica and multiple sclerosis (MS)
has been controversial, The overlappingclinical
features and the propensity for patients with
neuromyelitis optica to express a range of auto-
antibodies can result in misdiagnosis, of both
MSand other autoimmunedisorders. However,
clinical, radiological, and immunopathological
studies suggest neuromyelitis optica is distinct
from MS. The recent identification of an
apparent disease specific antibody—termed
NMO-IgG against the aquaporin-4 water
channel) implicates humoral immunity.” ? This
further differentiates the disorder from MS and
suggests that treatment to prevent relapses
should be aimed primarily at humoral B cell
mediated immunity if a pathogenic role for
NMO-IgG is confirmed.
EPIDEMIOLOGY
Neuromyelitis optica is an uncommondisorder
in Western populations; based on observed
cases among a population of 3 million over 10
years in North West England weestimated a
minimum incidence of 0.4/million/year and a
prevalence of 4/million, representing only one
in 200 patients with demyelinating disease in
this population.* This contrasts with a much
higher incidence in populations of Asian,
Afro-Caribbean, and South American descent
implying underlying genetic mechanisms
in the expression of demyelinating disease.
In all populations there is a strong female
predominance,of >3:1 compared with males.*®
The mean age of onset is around 40,although
cases have been reported in childhood.
CLINICAL FEATURES
The cardinal clinical features of the disorder are
transverse myelitis, which is often longitudinally
extensive, and optic neuritis. These two index
events can occur simultaneously, in rapid
succession, or they can be separated by many
years. The optic neuritis can be unilateral or
bilateral. Some patients have repeated episodes
of optic neuritis before myelitis occurs and vice
versa (the nomenclature of the disease at this
stage is relapsing myelitis or relapsing optic
neuritis). Most of those affected (>80%) go
on to have repeated relapses(relapsing NMO)
though a minority may have only the index
events (monophasic disease). Relapses are
generally moredisabling than those in patients
with typical MS. Whereas in MS disability
develops largely in the progressive phase of
the disease, in neuromyelitis optica disability
is acquired as a consequence of relapses;
progressive disability without relapses is rare
in our experience.
In white populations most patients presenting
with optic neuritis and myelitis are likely to have
MSrather than neuromyelitis optica. Features
which may help distinguish the disorder from
MSclinically are the more severe myelitis, optic
neuritis with poor recovery, and no involvement
of other parts of the neuraxis. However the
disease spectrum may be wider than currently
accepted (see discussion below).
A variety of diagnostic criteria for the disorder
have been formulated and are summarised
elsewhere.® Noneis perfectandit is likely that they
will be revised in the light of emergingclinical and
laboratory data. In general we would consider the
diagnosis in the presenceof:
Clinical, radiological, and
immunopathological
studies suggest
neuromyelitis optica Is
distinct from MS
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    EugéneDevic (1858-1930). Imagecourtesy of Professor ChristianC ,H6pital Neurologique Pierre Wertheimer,Lyon,France.Eugéne Devic was born in 1850 in La Cavalerie, a small village in Aveyron,insouthern France. He trained at the medical college of Lyon and later workedon a variety of subjects, and was especially interested in typhoid fever andcardiovasculardiseases. In the field of neurology, he wrote aboutinfantile chorea,"polyneuritic psychosis”, mental disorders in typhoid fever, cerebral glioma, corpuscallosum tumours, meningeal angiosarcoma, and post-hemiplegic contracture.In December 1892 he saw a 45 year old French womanforintractable headacheand depression with “generalweakness" at the Hétel-Dieu Hospital ofLyon.On 27 January urinary retention appeared, followed by complete paraplegiaandbilateral blindness. She diedfrom bedsores on 4 March 1893. The caseand pathological examination, which confirmed lesions in the spinal cord andoptic nerves,was presented asa clinicopathological study atthe First CongressofInternal Medicine inLyon in 1894. Here Devic mentioned16 other similarcases reportediin Europeand the USA. These 17 cases were studied in detailin the doctoral thesisof FernandGault —"Dela neuromyélite optiqueaigué’—in the sameyear. Neuromyelitisoptica was called "Devic's disease” after Acchioteproposed this eponymin 1907. In his paper Devicnamedthedisorder “neuro-myéliteoptique" or “neuroptico-myélite’‘The two cardinal questions he raisedmorethan a century ago "Why such a peculiarlocalisation?” and “Whatis theintimate nature ofthe process?" still remainlargely unanswered.t
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Figure 1
Sagittal T2 MRI appearancesof
longitudinally extensive cervical myelitis
(arrow), usually centrally located within
the cord.
 
e longitudinally extensive myelitis (usually
more than three vertebral segments)
© optic neuritis
© normal brain MRI, or if abnormal, atypical
for MS—see below.
The prognosis also differs from MS. Early
reports suggested a five year survival of 68%,
death often resulting from severe spinal
cord disease and respiratory compromise.
More recent series suggest a better outcome,
possibly reflecting better case ascertainment
or treatment. However there is no doubt that
disability is acquired earlier in neuromyelitis
optica than MS; this and a mean relapse rate
of around two per year make early diagnosis
and therapy imperative.
RADIOLOGY
The most characteristic radiological featureis a
longitudinally extensive cord lesion, extending
often over three or more spinal segments
and expanding the cord (fig 1). This is usually
hypointense on T1 and hyperintense on 12 MRI.
Lesions are centrally situated within the cord
and patchy contrast enhancementis often seen.
Occasionally lesions can be identified in the
optic nerves. Though classically NMO has been
defined by lack of brain lesions or symptoms,
it has increasingly been noted that up 60%
of patients with otherwise typical relapsing
NMO (many with positive NMO-IgG)can
The most characteristic radiological feature is a
longitudinally extensive cord lesion, extending
often over three or more spinal segments and
expanding the cord
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havelesions on brain MRI. These range from
extension of high cervical cord lesions into the
brain stem, diencephalic, brainstem or cerebral
lesions “atypical” for MS and in minority MS-
like lesions. Howeverall these patients have
long cord lesions which seemsto be a specific
feature, distinguishing these cases from MS.°
LABORATORYINVESTIGATIONS
Cerebrospinal fluid acutely may reveal a
prominentpleocytosis of either lymphocytes or
neutrophils and raised protein. In contrast to
MS,there are usually no oligoclonal bands(in
over 80%). Lennon and co-workers at the Mayo
clinic recently reported the discovery of NMO-
IgG, which maybethefirst “disease specific"
antibody in CNS demyelinating disease? The
antibody, identified initially from Western blots
in patients screenedfor possible paraneoplastic
antibodies, is reported to have a sensitivity of
73% and a specificity 91% for neuromyelitis
optica and wasalso positive in a significant
proportion of patients deemed to be at high
risk of neuromyelitis optica (that is, patients
with recurrent optic neuritis or myelitis).
Despite the apparent association of NMO-
IgG with neuromyelitis optica, independent
confirmation of this finding and indeed
evidence of pathogenesisis still awaited. The
Mayo group has also recently reported that
the target antigen for NMO-IgG appears to
be the aquaporin-4 water channel, located in
astrocytic foot processes at the blood-brain
barrierTo date, testing for NMO-IgG is only
available through the Mayoclinic (Rochester,
USA; at a cost of $500/sample). If the role
of the antibody is confirmed and the assay
becomesreadily available, the hope is clearly
that the relation between neuromyelitis optica
and “neuromyelitis optica spectrum”disorders
(see below) will be clarified, and predictive
testing for neuromyelitis optica in patients with
isolated myelitis or severe optic neuritis may
be possible.
A range of positive auto-antibodies
(including ds-DNA) have been reported in
up to 40% of patients.* This can give rise to
diagnostic difficulties. We would consider these
to be epiphenomena occurringin the context of
disordered humoral immunity. However there
are reports of patients with unambiguous
systemic lupus erythematosus, Sjégren’s
syndrome, and mixed connective tissue
disease who have developed neuromyelitis
optica. Whether they have two separate
autoimmunediseases, or neuromyelitis optica
is a consequence of the primary disorder, is
impossible to determineclinically. Testing for
NMO-lgG and pathological examination in
such cases maybeable to clarify this.
PATHOLOGY
Extensive necrosis, demyelination, and
often cavitation across multiple spinal cord
segments, involving grey and white matter with
perivascular infiltrates, prominent macrophages,
eosinophils, and vascular hyalinisation is
typical. Deposition of complement in a ring
pattern on the outer surface of blood vessels
and in a rosette perivascular pattern has been
elegantly demonstrated. Prominentperivascular
IgG reactivity and IgM deposition in a rosette
pattern implicate these as sites of immune
mediated damage.
TREATMENT
Therarity of the condition inevitably limits the
evidence for therapeutic interventions. As in
most immune mediated disorders management
consists of treatment of relapses, therapy for
the underlying disease, symptom control, and
rehabilitation. For the general neurologist
managing a patient with neuromyelitis optica
the approachto relapses and indeed underlying
disease therapy is perhaps most comparable to
that of the more commonantibody mediated
disorder myasthenia gravis.
MANAGEMENTOF RELAPSES
High dose corticosteroids and supportive
care remain the mainstays of management
of relapse. In view of the severity of relapses
and likely need for maintenance treatment
our policyis to follow a course of intravenous
methylprednisolone (1 gram daily for 3-5 days)
with a gradual taperof oral prednisolone over
several months, from an initial dose of 1 mg/kg/
day. An alternate day maintenance dose of the
order of 10-20 mg prednisoloneis generally
our target in patients with relapsing disease.
A minority of patients fail to respond to
adequate steroid therapy or relapse rapidly
and in such casesthereis a role for therapeutic
plasma exchange. We consider it early—within
weeks of symptom onset. In the North
American randomised trial of plasma exchange
in severe demyelinating events, patients with
neuromyelitis optica were overrepresented
among the responders, with a 60% response
rate (versus 6% overall for sham exchange).In
this study plasma exchange was undertaken
within three monthsof onset ofrelapse.
PREVENTION OF RELAPSES
Most patients follow a relapsing course, often
acquiring substantial disability within two or
three relapses. Immunosuppression appears
to reduce the relapse rate. The first report of
successful treatment was a series of seven
patients treated with prednisolone(tailing dose
as above) and azathioprine (at 2.5-3 mg/kg). In
our initial case series of 42 patients, relapse rates
PRACTICE POINTS
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e Although neuromyelitis optica is uncommonitis a rapidly disabling yet
treatable disorder.
e Early recognition and diagnosis followed by prompt, carefully supervised
immunosuppressive treatmentin relapsing patients is paramount.A blind,
quadriparetic, ventilator dependent person, from a treatable disorder, is a
tragedy that one should strive to avoid atall costs.
e Managementappears distinct from that of MS and should probably be in
the handsofclinicians with an interest in demyelinating disease.
were reduced by over 80%in patients established
on immunosuppressive therapy (most frequently
azathioprine). This has therefore remained our
initial therapy option in patients with relapsing, but
reasonably stable, disease. For patients intolerant
of azathioprine, mycophenylate mofetil is a
reasonable alternative (but without any evidence
base), with the possible advantage of more rapid
onsetofaction.
In patients who have "breakthrough"
disease on azathioprine, or who present with
frequent severe relapses, more aggressive
immunosuppression may be necessary. Recent
small case series have reported on the successful
use ofrituximab (a B cell depleting monoclonal
antibody) and mitoxantrone. We have used both
of these agents in small numbers of patients
without complications. Interferon beta, the
mainstay of treatment in relapsing MS, does
not appear to beeffective.
SYMPTOM CONTROL AND
REHABILIATION
Pain, stiffness, bladder, and bowel symptoms
need to be tackled. Tonic spasms seem to
be much commoner than in MS and in our
experience usually respond to carbamazepine.
Rehabilitation, physiotherapy, mobility, and
visual aids are often needed. Some patients
with high cervical cord lesions will need long
term home ventilatory support. There is a UK
based self-help group (telephone +44 (0)151
529 6100) and a patient friendly website
(http://www.thewaltoncentre.co.uk/patients/
Neuromyelitis_Optica.html)
THE WIDENING SPECTRUM OF
NEUROMYELITIS OPTICA
There may be a numberofrelated disorders, a full
discussion of which is beyond the scope of this
review.Patients with idiopathic relapsing myelitis,
Asian “optico-spinal" MS, and chronic relapsing
www.oractical-neuraloav.com
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inflammatory optic neuropathy may form part
of the "neuromyelitis optica spectrum” We have
seen several patients presenting with severe
myelitis without visual symptoms but delayed
visual evoked responses, some of whom have
subsequently developed optic neuritis. It seems
likely that such patients have neuromyelitis optica
although they fall outside current criteria for
the disorder. Traditionally patients with clinical
or radiological findings outside the optic nerves
and spinal cord have also been excluded from
the diagnosis of neuromyelitis optica. There are
howeverrecent reports of patients with clinically
typical neuromyelitis optica who have developed
brain lesions on MRI. Interestingly these patients
have been shown to have positive NMO-IgG,
and histopathology (of the brain lesions) similar
to classical neuromyelitis optica, widening
the spectrum still further. More studies with
a validated disease marker in the near future
should clarify these relationships. Genetic links
between neuromyelitis optica and MS have been
hypothesised andwill perhaps open a window to
the better understanding of both conditions?
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Abstract
Neuromyelitis optica (NMO; Devic’s disease) and the NMOspectrum disorders are idiopathic inflammatory demyelinating disorders that
affect the central nervous system and havea predilection for optic nerves andspinal cord. The identification of NMO-IgGasa disease-specific
marker and aquaporin 4 as the target antigen has renewed interest in NMO. Based on current data, we suspect that autoantibodies arising from
peripheral B cells bind to aquaporin 4 expressed on astrocyte foot processes on the abluminal surface of microvessels, activate complement and
initiate inflammatory demyelination and necrosis. The development of animal models and further analysis of the association of NMO-IgG with
disease severity and treatment response will elucidate the pathobiology of NMO.
© 2007 Elsevier B.V. All rights reserved.
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1. Introduction
Neuromyelitis optica (NMO)is an inflammatory demyelin-
ating disease of the central nervous system (CNS) that most
commonly targets the optic nerves and spinal cord selectively.
Its historical roots begin with Allbutt who in 1870 reported a
patient with a “sympathetic disorder of the eye” after an acute
myelitis (Allbutt, 1870). Twenty four years later, Devic and his
student Gault summarized 16 cases from the literature in
addition to one of their own and the syndrome came to be
eponymously called Devic’s disease (Devic, 1894). For much
of the 20th century, NMO was considered to be a severe
monophasic syndromecharacterized by bilateral optic neuritis
(ON) and myelitis occurring in rapid succession. Subsequent
studies included patients with less severe clinical attacks,
unilateral ON and symptomsseparated by monthsoryears.It
became a matter of debate whether NMO wasa distinct
disease or a peculiar variant of multiple sclerosis (MS) and
whetherit included patients with recurring disease. Based on
emerging conventions of MSas being a disease “disseminat-
ed in time and space” NMO too was soon entrenched as a
form of MS.
In recent years, medical opinion has shifted because of a
number of developments. Firstly, unlike MS, NMOis not
associated with brain lesions at disease onset in most patients;
nonetheless, brain lesions do occurovertime in the majority of
patients, and their recent characterization has proven informa-
tive as to the pathogenesis of the disease. Secondly, large
clinical series published over the past decade have revealed that
most patients with NMO have longitudinally extensive
transverse myelitis (LETM) defined by an MRI lesion
extending contiguously over three or more vertebral segments,
whichis hardly ever occurs in MS (Cabreet al., 2001; de Seze
et al., 2003; Ghezzi et al., 2004; Nakashimaet al., 2006; Papais-
Alvarengaet al., 2002; Wingerchuket al., 1999, 2006). Thirdly,
neuropathologic studies demonstrate that although demyelination
is present, NMOis characterized by distinctive ““vasculocentric”
pathology with prominent perivascular immunoglobulin deposi-
tion and evidence ofactivation of complement lytic pathway,
invoking B cell participation in the disease process (Lucchinetti
et al., 2002; Wingerchuk, 2006). Lastly, a highly specific serum
antibody (NMO-IgG) (Lennonet al., 2004) has been found in
patients with NMObutnotin patients with “prototypic” MSorin
other conditions characterized by optic neuropathy and myelop-
athy. Theseclinical, radiological, pathological and immunolog-
ical data provide convincing evidence that NMO spectrum
disorders are distinct from MS. Nonetheless, while apparently
distinct, the boundaries that delimit NMO from MSare notyet
well defined. Whetherall relapsing “optic-spinal” forms ofMS,as
have been commonlyrecognized in Asia, are the sameentity as
NMOdescribed in Western countries is a continuing source of
debate.
The recent discovery that NMO-IgG reacts specifically with
aquaporin 4 (AQP4) (Lennonet al., 2005) has opened new avenues
for the understanding of the pathogenesis of idiopathic inflamma-
tory demyelinating disease;it is the first instance in whicha specific
target for an immunereaction resulting in an inflammatory demye-
linating disease in humanshas beenidentified.
Wereview the evolving epidemiological, clinical, imaging
and immunological research that suggests that the clinical
spectrum of the disease is broader than previously recognized,
emphasizing the NMO-IgG biomarker. NMO-IgG is now
utilized as a clinical test for this disease and promises to
provide substantial insight into the pathogenesis of NMO.
Finally, we discuss the preferred therapeutic options for this
condition, which differ substantially from those for MS.
2. Epidemiology
Relapsing NMOhas a female to maleratio of5:1. Monophasic
NMO,bycontrast, affects both sexes equally. The median age of
onset in Caucasiansis late in the fourth decade(Wingerchuketal.,
1999), which is considerably older than that of MS. Pediatric
cases have been reported and may be either monophasic or
relapsing (Arabshahiet al., 2006; Domingueset al., 2004;Jeffery
and Buncic, 1996; Jouhadiet al., 2004; Milaniet al., 2004). Non-
Caucasians (African, Hispanic and Asian) are over-represented
among NMOpatients when compared to MSpatients; however,
Caucasians comprise the majority in series from Western
countries. In Japan, 15-40% of cases of demyelinating disease
are “opticospinal” (Kira, 2003). Nevertheless the terms ‘optico
spinal’ MS (OSMS) and NMO,maydefine overlapping, but not
identical groups of patients. Many Asian investigators apply the
term OSMSto patients with ON and myelitis who do not have
long spinal cord lesions whereas we wouldclassify such patients
as having prototypic MS;ourcurrentview is that NMOis a subset
of optico-spinal MS in Asia. This is a common source of
confusion in comparing data from Western and Asian series.
The incidence and prevalence of NMOhasbeendifficult to
estimate because it is still an under-recognized illness and
diagnostic techniques such as spinal MRI and availability of
NMO-IgGtesting are not readily available in all geographic
regions.
3. Genetics
It is uncertain whether genomic variation accounts for
differences in susceptibility to NMO. Instances of familial
NMO have been reported: identical twin sisters, one who
developed the illness at age 24 and the other at age 26
128 A. Jacobet al. / Journal of Neuroimmunology 187 (2007) 126-138
(McAlpine, 1938); two sisters with bilateral ON followed by
myelitis at 2 and 3 years (Ch’ien et al., 1982); two Japanese
sisters aged 62 and 67 (Yamakawaet al., 2000); and twosisters
ofSpanish—American ancestry, who developed NMOat ages 26
and 28 (Keegan and Weinshenker, 2000) are amongthese cases.
HLAassociation studies in NMOare few and haveprimarily
been conducted in Japan. Among Japanese patients, HLA
DRB1* 1501, theallele that is most strongly associated with MS
in western countries, is not associated with OSMS,althoughit is
associated with Japanese “classical” MS (Kira, 2003). HLA
DP*0501 has been reported to be over-represented in Japanese
patients with OSMS(Yamasakiet al., 1999); however, the high
frequency of this allele in the general Japanese population
complicates the analysis of the putative association in this
population. Recently, over-representation of the DPB/*0301
allele among non-OSMSpopulation has been reported as a
confounding factor in the interpretation of the DP*050/
reported primary association (Fukazawaet al., 2006).
4. Clinical features
The sine qua non ofNMOis the simultaneousor consecutive
occurrence of ON (unilateral or bilateral) and acute LETM. ON
in NMOtendsto be moresevere and leaves a greater impairment
compared to attacks of ON in the context of MS. Clinical
features such as ocular pain, visual field deficits and positive
phenomenadonotdiffer substantially (Wingerchuket al., 2006).
Spinal cord relapses, unlike those ofMS,typically presentas a
complete transverse myelitis with bilateral motor weakness, a
sensory level and sphincter dysfunction; prominent dysesthetic
and even radicular pain are common.Brain stem involvement can
occur, usually as an extension of a severe cervical myelitis, and
may cause hiccoughs, intractable nausea, or respiratory failure
(Misu et al., 2005). Paroxysmal tonic spasms are more commonin
NMO compared with prototypic MS. This pathognomonic
symptom of demyelination, believed to represent ephaptic
transmission across demyelinated axons, clearly place NMO in
the category ofa demyelinating disease (Wingerchuket al., 1999).
After the initial index events of ON and myelitis that define
NMO,either no further events take place (monophasic course)
or, as occurs in greater than 80% ofthe patients, relapses of ON
and myelitis occur, interspersed by intervals of monthsor years.
Among patients with NMO,a relapsing course is associated
with female sex, older age at onset, longer time interval between
index events, and the presence of systemic autoimmunity.
(Wingerchuket al., 1999; Wingerchuk and Weinshenker, 2003)
Many NMOpatients have other auto-immunediseases, the
most frequent of which are thyroid disease, systemic lupus
erythematosus (SLE) and Sjégren’s syndrome (SS). Even more
frequently, non-organ specific antibodies, such as antinuclear
antibodies or SSA antibodies, are detected in the absence of
clinical symptoms and signs of their associated systemic
illnesses. Patients with SLE or SS who have never experienced
ON or myelitis are uniformly NMO-IgG seronegative, whereas
those with ON or myelitis are usually seropositive. This has led
us to conclude that NMO-IgGis a specific marker for the ON
and myelitis (NMO spectrum disorders) occurring in this
conditions, rather than a nonspecific coexisting serological
finding associated with SS or SLE.(Pittock et al., 2006b)
The prognosis is often poor for patients with relapsing disease.
Unlike MS, most attacks are moderate or severe; remissions are
often incomplete and neurologic disability accumulates in a step-
wise fashion. More than half of patients will develop severe visual
loss in at least one eye and or inability to ambulate without
assistance within 5 years of disease onset. In the original Mayo
Clinic cohort, the 5 year-mortality rate in relapsing patients was
32%. All patients died becauseofrespiratory failure associated with
attacks of myelitis. (Wingerchuk etal., 1999). Patients seen at the
Mayo Clinic may have a more severe course than average, and
ascertainment bias may have influenced this conclusion, although
 
Fig. 1A T2 weighted cervical spinal cord MRIin a patient with NMO showinga longitudinally extensive (>3 vertebral segments) lesion (arrow). 1B: Coronal T1-
Weighted brain MRI of NMOpatient showing enlargement and gadolinium enhancementofthe right side of the optic chiasm (arrow).
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mostseries are consistent that attacks ofNMOare generally more
severe than of MS.
5. Neuroimaging
Almostinvariably, if a spinal cord MRIscan is performed at
an appropriate interval after an acute attack (within days to
weeks), it reveals a central cord lesion extending overthree or
morevertebral segments (Fig. 1A). Spinal cord MRIis the most
specific diagnostic test for NMO aside from NMO-IgG
serological testing. Acute imaging commonly reveals cord
edema and gadolinium enhancement, the latter of which may
persist for several months. On follow-up MRI studies, cord
atrophy and a cavity resembling a syrinx may bepresent; lesions
mayresolveentirely, or may leave only atrophy in their wake.
Brain MRIoften reveals gadolinium enhancementofthe optic
nerve during an acute ON episode, of variable extent and
occasionally extending into the chiasm from the globe. (Fig. 1B)
Atdisease onset, the brain parenchymais usually normal or may
demonstrate few nonspecific subcortical white matter changes
that usually do not fulfill Barkhof radiological criteria for MS.
Pittock et al. reviewed 60 NMOpatients and found brain MRI
lesionsin 36 patients (60%). Most were nonspecific, but 6 patients
(10%) had MS-like lesions, usually asymptomatic. Another 5
patients (8%), mostly children, had diencephalic, brainstem or
cerebral lesions, atypical for MS. In a subsequent study of 120
patients, 8 patients were identified who haddistinctive magnetic
resonance imaging abnormalities in the hypothalamic and
periventricular areas that corresponded to brain regions of high
AQP4expression,the target antigen for NMO-IgG (Pittocketal.,
2006a,c). In somecases, brain abnormalities were associated with
transient encephalopathy or with endocrinopathies when the
hypothalamic—pituitary axis was involved. (Poppeet al., 2005;
Vernant et al., 1997). Symptomatic brain lesions, originally
believed to exclude the diagnosis, are no longer an exclusionary
criterion in the most recently proposed diagnostic criteria for
NMO(Table 1) (Wingerchuket al., 2006).
Analysis of normal-appearing brain tissue (NABT) using
diffusion tensor imaging has shown abnormaldiffusion in patients
with NMO.It is postulated that this could be secondary
degeneration causedbylesions in the spinal cord and optic nerve
(Yuet al., 2006).
6. Cerebrospinalfluid
CSF examination obtained during a relapse often reveals
elevated total protein and on someoccasions (perhaps 10% of
attacks) reveals a prominent pleocytosis up to 50-1000 x 10°
Table 1
 
Proposed diagnostic criteria for neuromyelitis optica (Wingerchuketal., 2006)
Optic neuritis
Acute myelitis
Andat least two of three supportive criteria
1. Contiguous spinal cord MRIlesion extending over 3 vertebral segments
2. Brain MRInot meeting diagnostic criteria for multiple sclerosis
3. NMO-IgG seropositive status
WBCIL, which may occasionally include or be dominated by
neutrophils. Whenpresent, this is a useful distinguishing feature
from MS(Wingerchuket al., 1999). CSF pleocytosis in relapses
of MS rarely exceeds 50x 10° WBC/L (Zaffaroni, 2004;
Wingerchuket al., 1999). Oligoclonal bands which are present
in approximately 90% of patients with an established diagnosis
of MSare present in fewer than 20% of patients with NMO
(Wingerchuket al., 1999). Eosinophils mayalso be foundin the
CSF in NMO(Correale and Fiol, 2004).
Other differences have been noted between MS and NMO.
Matrix metalloproteinase-9 in CSF is higher in MS compared to
NMO (Mandler et al., 2001). Although the total IgG
concentrations were elevated in the CSF of patients with
NMOand MS,IgG1levels and index were elevated only in
patients with MSandnotin patients with NMO.The lower CSF
IgG1 level in NMO wasinterpreted to indicate a lesser Thl
autoimmuneresponse than in MS (Nakashimaetal., 2004).
Ishizu et al. evaluated sixteen cytokines/chemokines simul-
taneously in CSF supernatants from 20 OSMSand 20typical
MS(at relapse) patients and compared the findings with those
from 19 controls with spinocerebellar degeneration. The OSMS
MSpatients hadelevatedlevels of interleukin (IL)-17 and IL-8,
which might explain the increased neutrophil presence in the
central nervous system in NMO. Moreover, both the length of
the spinal cord lesions on MRIand the CSF/serum albuminratio
correlated with the cytokinelevels (Ishizu et al., 2005). Correale
et al. have reported increased numbers of IL-5, IL-6, IgG, and
IgM secretingcells in the CSF that are MOG-specific in patients
with NMO compared to patients with RRMS, SPMS and
healthy subjects (Correale and Fiol, 2004).
Chemokine levels (CXCL10/IP-10, CCL17/TARC, CCL2/
MCP-1, and CCL11/Eotaxin) in the cerebrospinalfluid did not
differ between NMOand MS.Similarly there was no difference
in cerebrospinalfluid levels of CD26(a dipeptidyl peptidase-IV
highly expressed on Th1 cells), and CD30 (a memberof the
tumornecrosis factor/nerve growth factor receptor superfamily
preferentially expressed on Th2 cells) between NMO and MS
(Narikawa et al., 2005). However in another study CSF
Eotaxins (selective eosinophil chemoattractants and activators)
Eo-2, Eo-3 and ECP(eosinophil cationic protein) levels were
significantly higher in NMO patients compared to RRMS,
SPMSandhealthy controls (Correale and Fiol, 2004).
7. Pathology
The hallmark of NMOpathologyis the presence of necrotic
spinal cordlesions involving both gray and white matter, often
resulting in cavitation, as well as the presence of vascular
hyalinization (Cloys and Netsky, 1970; Mandler et al., 1993;
Prineas and McDonald, 1997). Lucchinetti et al. examined the
spinal cord of nine autopsied cases of NMO and found a
prominent eosinophil infiltration in active NMO lesions in
addition to demyelination and necrosis with cavitation. A single
autopsied case from a cohort of Canadian aboriginals, 5 of 7 of
whom shared a NMOphenotype,also had extensiveinfiltration
of eosinophilsin the spinal cord lesions (Mirsattari et al., 2001).
Lucchinetti et al. also described perivascular immune complex
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deposition in a characteristic “rim” and “rosette” pattern
(Lucchinetti et al., 2002) (Fig. 2). Based on these findings,
the investigators proposed that NMO was a humoral disorder
targeting the perivascular region. A similar pattern of immuno-
globulin deposition and complement activation was recently
described in patients with Japanese OSMS (Misuet al., 2005).
Furthermore,the pathology ofcavitary cerebral lesions from two
NMOpatients was similar to that observed in optic nerve and
spinal cord NMO lesions, strongly suggesting a common
pathogenesis (Jacobset al., 2006; Nakamuraet al., 2005).
8. Immunology
8.1. Discovery ofNMO-IgG
In 1998, the observation that patients with NMO frequently
had multiple autoimmunedisorders and a variety of non-organ-
specific autoantibodies prompted a search for a specific
autoantibody marker ofNMO.Sera ofestablished NMOpatients
or those whowereat a high risk of developing it (e.g. recurrent
LETM or recurrent ON) were screened for IgG that binds
selectively to CNS tissues using an indirect immunofluores-
cence assay optimized in Mayo Clinic’s Neuroimmunology
Laboratory in 1994 (Lennon, 1994; Lennonet al., 2004).
After testing the first few NMOpatients’ sera, a recurring
pattern ofimmunostaining ofmousecerebellum and midbrain was
detected that was named “NMO-IgG”. This pattern was identical
to that ofan unclassified IgG ofunknown clinical significance that
the Laboratory had documented photographically in the preceding
2 years. Review of the clinical information for seropositive
patients, whose undiagnosed neurological disorder had prompted
submission of their serum for paraneoplastic autoantibody
evaluation from across the USA,surprisingly revealed that 12 of
14 patients hada clinical presentation consistent with NMOor a
limited version thereof(recurrent myelitis or recurrent ON).
Anindependent pathologic study from the Mayo Clinic had
meanwhile recognized immunohistochemical pattern of immu-
noglobulin and complement deposition detected around small
vessels ofautopsied spinal cord tissues ofpatients with NMO-IgG
(Lucchinetti et al., 2002). This pattern was reminiscent of the
pattern of immunostaining of serum from NMOpatients to the
abluminalsurface ofpenetrating microvessels in the mouse brain
substrate.
A larger prospective survey of sera from patients with
clinically definite NMOor a syndrome deemed to be at high risk
for progression to NMO wasundertaken (Lennonet al., 2004).
Patients with classical MSthatinitially involved spinal cord and
optic nerves, and patients with paraneoplastic autoimmune
 
Fig. 2. Immunopathology ofNMO. A. Complementactivation products are deposited in a vasculocentric rim and rosette pattern (Immunocytochemistry for C9neo
antigen (red). B/C. Higher magnification demonstrates colocalization of immunoglobulin (B, Immunocytochemistry for IgG) and complement (C,
immunocytochemistry for C9neo antigen) on sequential sections.
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disorders, myelopathies and miscellaneous disorders were
evaluated as controls. Two independent readers blinded to
diagnoses were 100% concordantin their interpretation. In the
cerebellum and midbrain, NMO-IgG boundin a linear pattern
along pial membranes, extending into the Virchow—Robin
spaces, the abluminal surface of cerebral microvessels, and the
subpial region with a mesh pattern (Fig. 3). Thirty three (73%)
of 45 patients with clinically defined NMO wereseropositive.
Only 2 of 19 patients with classical MS and none of 56
individuals with other neurological or systemic autoimmune
diseases were positive. Thus, NMO-IgG was 73% sensitive and
91% specific in distinguishing NMO from MS.Patients with
“typical” Asian OSMS, Japanese classical MS and control
patients with cerebral infarction, independently diagnosed by
investigators at Tohoku University Medical Center in Sendai,
Japan were tested at Mayo Clinic blinded to the diagnoses.
Seven of 12 patients with OSMSwereseropositive. None ofthe
five patients with classical “Western” MS and noneof the five
control individuals with cerebral infarcts were seropositive. The
sensitivity (58%) and specificity (100%) of NMO-IgG were
comparable to the results in North American patients with
NMO.This study suggested, as previously suspected on clinical
grounds, that typical Asian optic-spinal patients had the same
disease as NMOin western countries (Lennonetal., 2004).
The specificity of NMO-IgG has been validated at several
international centers. Various studies presented at the 2006
European Committee for Treatment and Research in Multiple
Sclerosis (ECTRIMS)address the sensitivity and specificity of
autoantibodies to AQP4 that were tested with a variety of
different assays (Table 2).
Whether NMO-IgG titer correlates with disease severity,
attack severity or favorable response to therapy is unknown.
Typically, NMO-IgGis detected at the first attack of myelitis or
ON,suggesting that the antibody is more likely an integral part
of the pathogenesisofthe disease rather than an epiphenomenon
of the tissue injury, but longitudinal data are limited and
preliminary.
8.2. Spectrum of neurological disorders in which NMO-IgG
has been identified
NMO-IgG is not restricted to typical NMO.It has been
identified in “NMO-related diseases” whichat present consist of
four groups:
8.2.1. Limitedforms of the disease
These include recurrent myelitis without evidence ofON and
recurrent ON without evidence of myelitis.
The NMO-IgG seropositivity rate in recurrent LETM
approachesthat of definite NMO.In a prospective study of 29
consecutive patients evaluated at Mayo Clinic with a single
event of longitudinally extensive “idiopathic” transverse
myelitis, 40% were seropositive (Weinshenkeret al., 2006a).
Of 9 seropositive cases followed for 1 year or longer, 55% (5
patients) had a relapse of myelitis (4 patients) or developed ON
(1 patient) within | year of follow-up; an additional seropositive
patient developed ON in the second year of follow-up. In
contrast, no seronegative patient had a subsequent neurological
event. Scott et al. have studied the incidence ofNMO-IgGin acute
partial transverse myelitis with lesions less than 3 segments. They
 
Fig. 3. Immunofluorescencepattern ofbound NMO-IgG in mouse CNSandkidney. A (100X): Cerebellar cortex (molecular layer — ML,granular layer — GL,white
matter — WM), prominent microvessel and pia (P) staining. B (400X): Detailed picture showingthestained pia outlining a Virchow—Robin space (V—R). C (200*):
Midbrain and kidney. D (400x): Kidney,collecting tubules of medulla. (Image Courtesy: Sean J Pittock MD and Vanda A Lennon MD,Departments of Neurology,
Laboratory Medicine and Pathology, Neuroimmunology Laboratory, Mayo Clinic, Rochester MN,USA).
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Table 2
Aquaporin-4 antibody validation studies
Investigator Country NMO/OSMS LETM MS
n Positive % n Positive % n Positive %
Zuliani (Zuliani et al., 2006) Spain 10 50 2 100 8 0
Littleton (Littleton et al., 2006) UK 10 50 2 100 10 0
Kim (Kim, 2006) Korea 27 19 39 3 25 8
Marignier (Marignieretal., 2006) France 20 55 11 45 52 9
Jarius (Jarius et al., 2007) Europe 35 54 5 80 140 3
Akman-Demir (Akman-Demiret al., 2006) Turkey 14 57 - - 14 0
Results summarized in the table were presented at ECTRIMS 2006, Madrid. (n = numberofpatients tested; OSMS= optic spinal multiple sclerosis; LETM =
longitudinally extensive transverse myelitis; MS = multiple sclerosis; NMO = Neuromyelitis optica).
found only 1 out of22 patients to be positive and that seropositive
patient subsequently developed recurrent LETM (Scott et al.,
2006). The ability to predict recurrences of ON or myelitis in
patients whopresent with a single LETM indicates thatNMO-IgG
serological testing may influence decisions on whom and whento
initiate prophylactic immunosuppressive therapy (see treatment
section).
A survival analysis of follow-up of 72 patients who
presented with two or more sequential events of ON without
other clinical manifestations that would support a diagnosis of
MS or NMOafter the second episode revealed that 12%
developed clinically definite NMO and 14% developed MS
five years from their first episode of ON (Pirko et al., 2004).
While the risk of converting to MS continued to increase
beyond five years, conversion to NMO seemed to reach an
early plateau. Approximately half the patients at the final
follow-up were still classified as having “idiopathic recurrent
ON”. Of8 individuals with recurrent ON tested for NMO-IgG
prior to 2004, 2 (25%) were seropositive for NMO-IgG (Pirko
et al., 2004). This frequency is consistent with our clinical
observations that less than 25% of patients with recurrent ON
develop NMO.
8.2.2. Atypical cases
Patients with clinically manifest or subclinical (MRD) brain
lesions, for whom reliable diagnosis ofNMO wasindetermi-
nate or impossible based on the diagnostic criteria proposed in
1999(Wingerchuket al., 1999) are now suspected to have a
NMOspectrum disorder whenotherclinical characteristics are
typical of NMO and whenseropositive for NMO-IgG. The
absence of symptoms,signs and radiological evidence ofbrain
involvementhastraditionally served as a clinical criterion for
making the diagnosis of NMO. However, up to 60% patients
with longstanding NMOdeveloplesions, largely nonspecific,
and morerarely symptomsreferable to brainstem orbrain lesions
(Nakamura et al., 2005; Pittock et al., 2006a). Among these
patients, some with otherwise typical NMO developed brain
MRI lesions judged as typical of MS. Approximately 10% of
individuals with NMOdevelop MRIlesions atypical for MS in
the brainstem, hypothalamusor large tumefactive lesionsin the
cerebral hemispheres (Pittock et al., 2006a). NMO-IgG is
particularly valuable for assigning the correct diagnosis in such
cases.
8.2.3. Patients with significant comorbidities
LETM, ON or both are well reported complications of
systemic lupus erythematosus (SLE) or Sjégren’s syndrome(SS)
(Arabshahietal., 2006; de Sezeetal., 2001; Inslichtet al., 1998;
Margaux et al., 1999), although patients described may lack
sufficient clinical manifestations to make a formal diagnosis of
SLE or SS. We addressed the relationship of myelitis and ON
occurring in the context ofconcomitant connective tissue disease
by serological testing for NMO-IgG. Approximately half of such
patients are seropositive for NMO-IgG, whereas patients with
SLEor SS whodo not have manifestations ofNMOare uniformly
seronegative (Weinshenkeret al., 2006b).It is likely that these
patients have two coexisting autoimmunedisorders rather than a
vasculitic complication ofa systemic autoimmunedisease such as
SLEorSS(Pittock et al., 2006b; Weinshenkeret al., 2006b), in
the same way that NMO maycoexist with myasthenia gravis or
other systemic autoimmunediseases (Gotkineet al., 2006; Kister
et al., 2006).
8.2.4. Asian OSMS
Although clinically similar to NMO, Asian OSMS has
traditionally been considered to be separate entity, mainly
because of a perceived milder course and the frequent presence
ofbrain lesions. Japanese investigators have attempted to define
a “pure form” of OSMSwithout brain involvement and with
long lesionsin the cord (Misuetal., 2002). However,the results
of the blinded analysis of coded serum samples from Japan
strongly supports the identity of Japanese OSMS and NMOto
be the same (Lennonet al., 2004). The 58% seropositivity rate
in Japanese patients with OSMS (OSMS) did not differ
significantly from the 73% seropositivity rate of North
American patients with NMO. As mentioned earlier the terms
OSMS and NMO donotdefine exactly the same group of
patients (see epidemiologysection). Thereforeit is possible that
some of patients with OSMS had ‘western MS’, which may
explain somewhat lower rates of seropositivity in some
Japanese and Asian studies.
8.3. Aquaporin 4
The target antigen ofNMO-IgG has beenrecently identified
as the mercurial-insensitive water channel protein, aquaporin-4
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(AQP4) which is the dominant water channel within the central
nervous system (Lennonet al., 2005).
Aquaporins (AQPs) are a family of widely distributed
membrane-inserted water channel proteins providing a pathway
for osmotically-driven water transport through cell membranes.
CNS AQPsalsoplay role in osmoreception, K+ siphoning and
CSF formation andare strongly implicated in the pathogenesis of
cerebral edema following water intoxication or focal cerebral
ischemia (Manleyet al., 2000; Saadoun et al., 2002; Vajdaetal.,
2002; Amiry-Moghaddam and Ottersen, 2003; Lehmann et al.,
2004).
To determine whether the NMOantigenis restricted to the
CNS, NMO-IgG-positive patients’ sera was tested by indirect
immunofluorescence on sections ofnormal mouseliver, kidney,
and stomachtissues. In contrast to the characteristic intense
staining ofpial and microvascular elements in the brain (Fig. 3A
and B), NMO-IgG did not bind to any vascular or visceral
autonomic neural elements in stomach, kidney or liver.
However, NMO-IgG bound prominently to distal urine-
collecting tubules in the renal medulla (Fig. 3C and D) and to
parietal cells in the gastric mucosa. The distribution of NMO-
immunoreactivity in CNS, kidney, and gastric mucosa sug-
gested the water channelprotein, AQP4,as a candidate antigen.
By use of dual immunostaining with AQP4-specific rabbit IgG,
confocal microscopy demonstrated that the antigen to which the
IgG binds colocalized with AQP4 inall of these tissues.
Astrocyte
Foot Process 
Using sera from NMO-IgGpositive patients and matched
controls, in a blinded fashion, on frozen sections of brain tissue
obtained from transgenic AQP4 null mice, Lennonet al. showed
that IgG from NMOpatients’ sera bound to microvessels,pia,
and subpia in the wild-type brain tissue in a pattern that was
identical to that obtained by immunostaining with rabbit anti-
AQP4-IgG. However, neither human serum IgG from NMO
patients nor the rabbit anti-AQP4-IgG bound detectably to
AQP4-null mousebrain tissue (Lennonet al., 2005).
To demonstrate selective binding to membranes of AQP4-
transfected cells, stably transfected human embryonic kidney
cell line (HEK-293) expressing a transgene encodingfull-length
AQP4 and plasmid encoded GFP (green fluorescent protein)
were created; cells transfected only with the vector served as
controls. Codedsera, tested in blinded conditions, showed that
neither patient nor controls’ [IgG bound to the HEK-293 cells
that were not transfected with the AQP4-containing vector.
However, IgG in the sera of NMOpatients stained the plasma
membrane of AQP4-transfected cells, consistent with the
known expression pattern of AQP4in cells.
In astrocytic end-feet, AQP4 is closely associated with the
cytoskeleton complex, which includes a-syntrophin, B-dystro-
glycan, and dystrophin (Dp71) (Fig. 4). To exclude a primary
effect on one ofthese cytoskeletal proteins as targets, lysates of
the AQP4 andcontroltransfected cell lines were immunopreci-
pitated with antibodies specific for a-syntrophin, B-dystroglycan,
Sixes
of Score) (ny flay
Fig. 4. Proposed pathogenesis ofNMO.An unknownantigenic stimulusleads to productionofcirculating immunoglobulin (NMO-IgG). Thougha presumedbreach or
deficiency in the blood-brain barrier,the antibodies access the extracellular domain of AQP4attheglia limitans. AQP4is held in the plasma membraneby a complex
ofcytoskeletal elements,including a syntrophin (a syn), dystrophin (DP-71), ® and a dystroglycan (8 DG and aDG). Where a critical density ofAQP4 expression is
present, complement becomesactivated,initiating the inflammatory response. Chemotactic complement fragments and possibly cytokines and chemokines(pinkdots)
recruit neutrophils and eosinophils. These mechanisms mightlead to disruption of the cellular water transport mechanisms and cause demyelination, necrosis and
axonalloss, although the mechanisms underlying axonal injury and demyelination remain undefined.
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and dystrophin (Dp71) as well as antibodies specific to AQP4.
Only NMO-IgG or anti-AQP4 antibodies but not antibodies to
other cytoskeletal elements were able to immunoprecipitate the
GFP-AQP4fusion protein.
The mechanism underlying the presumed pathogenicity of
AQP4specific antibodies remains unclear. The antibodies may
simply cause disease by binding to their target antigen and
activating complementleading to a cascade of inflammation by
cytotoxicity, chemotaxis of neutrophils and eosinophils and
other complement-mediated mechanisms. Alternatively, they
may have a functional effect on the water channel, perhaps
disrupting water homeostasis that may lead to direct effects
separate from complementactivation (Lennonet al., 2005).
8.4. AOP4 immunoreactivity in NMO lesions
Recently, widespread absence of stainable AQP4 in spinal
cord tissue of NMOlesions has been demonstrated by several
groups(Misuet al., 2006a,b; Roemeret al., 2007; Sinclair et al.,
2006). Misu et al. compared aquaporin staining in spinal cord
lesions of optico-spinal MS,classical MSand control subjects.
In MS plaques, AQP4 staining was increased, presumably
reflecting a glial reaction, whereas in NMOlesions, AQP4 was
markedly lost. There were some NMOlesions where the
myelin basic protein (MBP) stained myelinated fibers were
relatively preserved despite the loss of AQP4 staining,
suggesting that the loss of AQP4 did not reflect necrosis and
cell loss. These findings suggested that AQP4 loss may be the
initial event in NMO lesions. The areas surrounding the
AQP4-absent NMO lesions had expression of AQP4 and
GFAPstaining comparable with that in control spinal cords
(Misuet al., 2006a,b).
Sinclair et al. have confirmed a lack of expression of AQP4
in optic andspinal cordlesions in a single case ofNMO which
contrasted sharply with the increased levels ofAQP4 expression
seen in MSlesions. They also reported immunohistochemical
and semi-quantitative analysis of the expression pattern of
AQP4ontissue microarray samples of MSandcontrol white
matter. AQP4 was morehighly expressed in all categories of
MStissue compared to normal control tissues with the most
abundantexpression in active lesions(Sinclair et al., 2006).
Lucchinneti et al. (Roemeret al., 2007) have independently
demonstrated selective loss of AQP4 immunoreactivity in
NMOlesions and performed detailed comparative study with
MS. They used carefully matched MS controls, rigorously
matching for stage of lesions, and revealed that AQP4
immunoreactivity in MS lesions was variable and dependent
on the stage of demyelination. AQP4 immunoreactivity in the
periplaque white matter and within reactive astrocytes ofactive
MSlesionswasincreased, as described by others(Aoki-Yoshino
et al., 2005; Misu etal., 2006a; Sinclair et al., 2006). However,
AQP4 immunoreactivity was also markedly reduced in inactive
MSlesions sampled from both the acute and chronic phases of
the disease. Furthermore, these investigators rigorously estab-
lished that loss of AQP4 immunoreactivity wasnotattributable
to necrosis and cavitation that are common in NMOand are
potential confounders.
Lucchinneti et al. also described two pathologic patterns in
NMO,both of which were associated with loss of AQP4
immunoreactivity. The first and most prevalent lesion type
involved thespinal cord and optic nerves, where AQP4 loss was
in the context of vasculocentric immune complex deposition,
active demyelination and vascular hyperplasia with hyaliniza-
tion. These lesions were often cavitary, and involved both gray
and white matter in the spinal cord. The second, less frequent
lesion type was foundin the spinal cord and medulla extending
into the area postrema. AQP4 loss was associated with
vasculocentric IgG and IgM deposits and complementactiva-
tion, and tissue rarefaction, but there was no evidence of
demyelination (Roemeret al., 2007).
In summary, these findings from 3 different groups all
indicate loss ofAQP4 in NMO,compared to MS.Theintriguing
report by Roemeretal. describing loss of AQP4in the absence
of demyelination or necrosis suggests that binding of antibody
to AQP4 maybetheinitial pathogenic event in NMOlesions
(Roemeretal., 2007).
9. Pathogenesis
Thoughthe pathogenesis ofNMOis incompletely understood,
a model may beproposed from recently accumulated observa-
tions (Fig. 4). In a susceptible individual, an unknown antigenic
stimulus leads to production of circulating immunoglobulin
(NMO-IgG). Through a presumed breach or deficiency in the
blood-brainbarrier, the antibody is able to accessthe extracellular
domain of AQP4atthe glia limitans. Wherea critical density of
AQP4 expression is present, complement becomes activated,
initiating the inflammatory response that ensues. Chemotactic
complement fragments mayrecruit neutrophils and eosinophils,
as might cytokines such as [L-17 and IL-8, which have been
demonstrated in excess in OSMS(Ishizu et al., 2005). Cross-
linking of AQP4 molecules by NMO-IgG may lead to
endocytosis and downregulation of the channels, which may
limit the inflammatory cascade. These mechanisms might lead to
disruption of the cellular water transport mechanisms, which
might contribute to some of the lesions that occur in NMO
patients. The peripheral synthesis ofNMOIgG isconsistent with
the relative lack ofCSF oligoclonal bands in the NMO, as NMO-
IgG is not generated primarily by intrathecal synthesis (this in
contrast to MS,whichis characterized by synthesis of oligoclonal
immunoglobulin within the CNS by B cells recruited from
periphery). The peripheral source ofNMO-IgG mayalso explain
the excellent response to plasma exchange in patients with NMO
(Keeganetal., 2002).
The basis of individual susceptibility to NMO remains
unexplained, as doesthe role ofcellular limbs of the immune
system. Also lacking are definitive proof for the pathogenicity
of AQP4 antibodies and details of how tolerance to AQP4is
initially abrogated, assuming that it is the principal antigenic
stimulus to the immune system in NMO. The demonstration of
AQP4loss in spinal cord NMOlesions and suggestion that this
event occurs even prior to demyelination may pointto these as
the initial inciting events in the genesis of NMOlesions (Misu
et al., 2006a,b; Roemeret al., 2007).
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10. Animal models
Lewisrats immunized with medium dosesofaggregate myelin
oligodendrocyte glycoprotein (MOG) without pertussis toxin
develop inflammatory disease confined to the optic nerve and
spinal cord characterized by prominenthistiocytosis but minimal
T cell infiltration (Sakumaet al., 2004). Experimental autoim-
mune encephalomyelitis (EAE) induced in the Brown Norway
(BN)strain of rat by immunization with MOG in Freund’s
adjuvantalso induces an EAEthathas a predilection for the optic
nerves and spinal cord; active demyelination is associated with
prominent deposition of antibody and evidence of complement
activation; furthermore, the inflammatory infiltrate contains large
numbers of eosinophils, reminiscent of the findings in NMO
(Gold and Linington, 2002; Storch et al., 1998).
Recently, two research groups have reported a double-
transgenic mousestrain (optic-spinal EAE [OSE] mouse), that
spontaneously develops an EAE-like neurological syndrome
resembling NMO (Krishnamoorthy et al., 2006; Bettelli et al.,
2006; Ransohoff, 2006) by crossing TCR™°S and IgH“°S
single-transgenic mice, both on a CS7BL/6 background. IgHM°S
mice were generated with knock-in technology, inserting the
recombined heavy chain of a demyelinating anti-myelin oligo-
dendrocyte glycoprotein (anti-MOG)antibodyin the IgJ region.
The TCR™°% mice recognized an immunodominant part of
MOG.Thecrossing of these two strains yielded mice in which
20-30% ofcirculating B cells produced anti-MOGantibodies and
expressed a cell receptor (BCR) that recognized MOGprotein.
The spontaneously-occurring, inflammatory, demyelinating
lesions that developed at about 8 weeks of age in these mice
werelocatedin the optic nerve and spinal cord, sparing brain and
cerebellum. Single-transgenic litter mates remained healthy. B
cells may have presented the antigen (MOG) with MHCclassII to
the T cells activating them. Activated T cells expressing the
proinflammatory cytokines IFN-y and IL-17 may havefacilitated
the differentiation of B cells to plasma cells and antibody
production. While the authors suggested that this is an
experimental model for NMO, the resemblance to NMO in
humans maybe superficial (Ransohoff, 2006). The spinal cord
lesions in this modelare notlongitudinally extensive and typically
extend only a single vertebral segment. There is also insufficient
evidence for humoral contribution to pathology in the lesions;
there is no IgG or complement deposition in the tissues. Anti-
AQP4antibodies were also not detected.
Future research into the pathogenesis of NMO would be
facilitated by animal models that develop the characteristic
vasculocentric lesions in the spinal cord and optic nerves either
spontaneouslyor by passive transfer of AQP4IgG,or byactive
immunization with AQP4.
11. Treatment
Noclinical trials dedicated to treatment of acute relapses or
prevention of relapses have been conducted. Treatment recom-
mendations are largely based on case series or expert opinion
(Wingerchuk and Weinshenker, 2005). Thefirst-line therapy for
acute attacks is intravenous corticosteroids, typically 1 g of
methylprednisolone for five consecutive days, initiated as soon as
possibleafter relapse onset and exclusion ortreatmentofbacterial
infections(e.g. respiratory orurinary tract). Plasmapheresis should
be considered when clinical symptoms and signs progress (or
severe symptoms fail to improve) despite the corticosteroid
infusion. Removaloflarge molecular weightparticles from plasma
including autoantibodies, immune complexes and inflammatory
mediators is the likely mechanism of action (Lehmannet al.,
2006). The favorable effects of plasma exchange in acute CNS
demyelinating diseases, including NMO and myelitis ofuncertain
etiology was demonstrated in a randomized, controlled, crossed-
over and double-blindtrial. In this study there was improvementin
8 of 19 (42.1%) patients receiving active treatment and only in | of
17 (5.9%) receiving sham exchange (Weinshenkeret al., 1999). An
extended review of the Mayo Clinic experience with plasma
exchange for acute CNS demyelinating disease showedthat, 6 of
10 (60%) patients with acute attacks of NMO recovered
moderately or markedly after the plasma exchange treatment
(Keegan et al., 2002). The efficacy of plasma exchange wasalso
retrospectively studied in MSpatients who had a fulminant attack
and were submitted to a diagnostic brain biopsy. When considering
the four different immunopathological patterns of demyelination
seen in early MSlesions, only the patients classified as pattern II
with antibody/complement-associated process had a neurological
improvement (Keeganetal., 2005). By analogy, this may explain
the apparently superior responsiveness of attacks of NMO,
because of the prominent IgG deposition and evidence of
complementactivation.
Treatments aimingat relapse prevention should beinitiated as
soon as the diagnosis of a relapsing NMOis made.It is also
reasonable to start therapy after a first episode of LETM in
patients seropositive for NMO-IgG, since NMO-IgG has proven
to be a potent predictor of future relapse in this context
(Weinshenker et al., 2006a). Immunosuppression, rather than
interferon betaor glatirameracetate, which are used for prototypic
MS,is the preferred treatment (Papeixet al., 2005). Azathioprine
(2.5—3 mg/kg daily) has been the mostfrequently used drug, often
in combination with prednisone (1 mg/kg daily or every other
day), either temporarily until azathioprine has taken full effect, or
indefinitely in patients who relapse following gradual withdrawal
of steroids. Mandler etal. studied 7 patients with NMOtreated
with azathioprine (75-100 mg) and prednisone 10 mg over
18 months. These patients remained relapse free for 18 months
and had improved disability(Mandleret al., 1998).
Mycophenolate mofetil (1-3 g/day), which has a cytostatic
effect on T and B lymphocytes and suppresses antibody
formation, may achieve faster immunosuppression. A case of
sustained remission for 2 years with mycophenolate 2 g/day has
been reported (Falcini et al., 2006).
Monthly intravenous infusions of mitoxantrone hydrochlo-
ride in 5 patients over 2 years, (12 mg/m’, for 6 months
followed by 3 additional treatments every 3 months) appeared
to reduce relapse rates in four out of the five patients with
relapsing NMO (Weinstock-Guttman et al., 2006).
Monthly intravenous infusions of immunoglobulin were
effective in 2 patients. The first patient was followed up for 5
and half years and the second for one year without relapses
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(Bakker and Metz, 2004; Weinstock-Guttman et al., 2006;
Minagar, 2002).
Althoughinterferon beta was reported to reduce attacks in
Japanese OSMS,the study did not showstatistically significant
differences between low and high dose interferon beta-1b-
treated patients, possibly due to lack ofpower; the MRI analysis
wasnoninformative in this subgroup of patients who generally
have no or few MRIlesionsin the brain and accordingly, we do
not considertheseresults as definitive(Saida, 2006; Saidaetal.,
2005). In fact, one Japaneseseries has suggested that interferon
beta may worsen NMO(Warabiet al., 2007).
Cree et al. conducted an open-label study of rituximab
(a murine/human chimeric monoclonal antibody that targets
CD20+ B cells) in eight NMO patients who had failed other
therapeutic regimens with a mean follow up of | year. Each patient
received four infusions of IV rituximab dosed at 375 mg/m’,
administered once per week. B cell counts were followed
bimonthly by FACSusing the CD19 marker. WhenB cell counts
becamedetectable, patients were given the option to be retreated
with rituximab. Rituximab retreatment consisted of two IV
infusions of 1000 mg administered 2 weeks apart. The drug was
well tolerated. Six patients were relapse free over 12 months and
seven had a neurological improvement(Cree et al., 2005). Re-
treatments seem feasible without major cumulative toxicity
Becauseofits selective action against cells, rituximab treatment
may be an effective therapeutic option in NMO. However, the
potential risks of opportunistic infections and malignancies must
be considered and, perhaps,are not yet fully appreciated.
The optimal duration of treatmentin patients without further
relapses with immunosuppressants is uncertain. The long term
side effects of medications have to be weighed against the
potential risk of relapses. Whether NMO-IgGtiters could guide
therapy is uncertain and appropriate studies are being pursued.
12. Conclusion
Although NMO wasdescribed more than a century ago,
there were few advances in understanding of the disease until
recently. Over the past decade, there has been a resurgence of
interest in this frequently disabling, occasionally life-threaten-
ing, but treatable disease. Elucidating the pathogenesis ofNYO
may offer important insights into the pathobiology of MS and
other demyelinating disorders. Passive or active transfer of the
disease, development of animal models, identification of
potential genetic and environmental susceptibility factors are
ongoing arenas of research. Discovery of a potential specific
antigenic target, AQP4, may facilitate the development of
effective antigen-specific therapy.
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Background: Neuromyelitis optica (NMO)is an
uncommon, life-threatening inflammatory demyelinat-
ing disorder. Recently, much has become known
about its immunopathogenesis. However, optimal
treatments, with expected outcomes, have not been
established.
Objective: To evaluate the use and efficacy of ritux-
imabfor treating NMO.
Design: Retrospective multicentercase series of NMO
patients treated with rituximab.
Setting: Seven tertiary medical centers in the United
States and England.
Patients: Twenty-five patients (including 2 children),
23 of whomexperiencedrelapses despite use of other
drugs beforerituximab. Extended follow-up of7 previ-
ously reported patients is included.  
Interventions: Infusions of rituximabat medianinter-
vals of 8 months.
Main Outcome Measures: Annualized relapserate and
disability (expressed as ExpandedDisability StatusScale
score).
Results: At a median follow-up of 19 months, the me-
dian annualized posttreatmentrelapse rate was lower than
the pretreatmentrate(0 [range 0-3.2] vs 1.7 [range, 0.5-5]
relapses, P<.001). Disability improved orstabilized in
20 of 25 patients (80%, P=.02). Twopatients died dur-
ing the follow-upperiod, 1 owing toa brainstemrelapse
and 1 owingto suspectedsepticemia. Infections were re-
ported in 20%of patients.
Conclusions: In NMO, treatment with rituximab ap-
pears to reduce the frequencyof attacks, with subse-
quent stabilization or improvementin disability.
Arch Neurol. 2008:65 (1 1): (doi: 10.100 I/archneur.65.1 1.noc80069)
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EUROMYELITIS OPTICA
(NMO)is an inflamma-
tory demyelinating dis-
order, usually relapsing,
that targets the optic
nerves and spinal cord, resulting in
attack-related accrual of disability. It is
probably the same disorder as Asian opt-
cospinal multiple sclerosis in those
whose spinal cord lesions extend 3 or
more segments during acute attacks.
Comparedwith typical multiple sclerosis,
NMOis more rapidlydisabling; 50%of
patients must use a wheelchair and 62%
become functionally blind (visual acuity
of 20/200 or worse) at 5 years.’ Treat-
ment of NMO with interferon beta
appears to be substantiallyless effective
than immunosuppressive therapy” and
possibly even deleterious,’ which further
underscoresthe difference between NMO
and typical multiple sclerosis. Random-
ized controlled trials have not been con-
ducted on NMO,andtreatment options
are based on small case series that used
immunosuppressant medications, includ-
ing azathioprine,’ mitoxantrone,’ and
mycophenolate mofetil.° Despite use of
these drugs, patients with NMOoften
experience ongoing disease activity.
Open label use of rituximab (Rituxan;
Biogen Idec, Cambridge Massachusetts/
Genentech, San Francisco, California), a
monoclonal antibody against CD20" B
cells, was reported to be potentially ben-
eficial in patients whoarerefractory to a
variety of immunotherapies.”* Given the
lack of provenefficacious treatments, this
case series led us to use rituximab in
patients with NMO, even as a first-line
treatment. We describe our multicenter,
longitudinal experience ofthe effective-
ness and adverse effects of rituximab in
25 cases of NMO.
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This is a retrospectivecaseseries ofthe use ofrituximab in NMO.
Investigators from 20 centers whoattendedanexploratory meet-
ing about apotentialclinical trial of a new humanized monoclo-
nal antibodythat, like rituximab, recognizes the CD20protein
were approachedto participate in this study. Seven centers re-
spondedto the request. Investigators recalled and contributedin-
formation on all the patients to whomrituximab was adminis-
tered for NMO (University of California-San Francisco, San
Francisco [n=7]; Stony Brook Hospital, Stony Brook, New York
[n=6]: Mayo Clinic, Rochester, Minnesota [n=5]; Mayo Clinic,
Seousdale, Arizona [n=2]; The Walton Center, Liverpool, En-
gland [n= 2]; Mellen Center, Cleveland Clinic, Cleveland, Ohio
[n= 2]; and Mount Sinai Hospital, New York, New York [n=1}).
University of California-San Francisco provided extended fol-
low-upon 7 previouslyreportedpatients.’ Newpatients from Uni-
versityof California-San Franciscowere notincludedbecause of
contemporaneousrecruitmentof patients with NMOinto a clini-
cal trial. Local institutional review boardapproval was obtained
at each center and informed consent was obtained frompatients
or their nextof kin. All patients with relapsing NMOorlongitu-
dinally extensive transverse myelitis? who were treated with at
least 1 dose of rituximab and whohadat least 6 monthsoffol-
low-up were included. Patients whodid not meet these criteria
were excluded. Given the small numberof patients treated at each
center, we are reasonably confident, but not absolutely certain,
that othereligible patients were not excluded. Completed case
report forms were analyzedat the MayoClinic in Rochester. All
patients who were reported to the analysis team bythe treating
hospitals were foundtobeeligible and were included. Statistical
analysis was performedusing JMP, version 6.0 (SAS, Cary, North
Carolina).
eT
E——
PATIENT CHARACTERISTICS
All 25 patients qualified for inclusion in the study, ac-
cording totheinclusionandexclusioncriteria, There were
3 men, 20 women, and
2
girls. The medianage ol the pa-
tients was 38 years (range, 7-05 years). Two children re-
ceivedtheirinitial rituximabtreatment at age 7 years (pa-
tient 8) and14 years (patient 11). Twenty-three patients
had NMOand 2 had NMO-lgG—seropositive recurrent
longitudinally extensive transverse myelitis. The me-
dian interval from onset of NMO totreatment with ri-
tuximab was 4.5 years (range, 0.8-17 years). Theclini-
cal and demographicprofiles of the patients are outlined
in the Table. Seventy percent ofpatients assessed were
positive for NMO-IgG(14 of20 patients). Seven of8 pa-
tients from the previously reported case series were in-
cluded.’ One patient from the initial study waslost to
follow-up despite multiple attempts to contact her. Ri-
tuximab was usedin 23 patients owing tofailure ofother
medications. In 19 patients, more than | treatment was
usedbefore treatment with rituximab. Rituximab was used
as a first-line therapyin 2 patients.
TREATMENT WITH RITUXIMAB
Tworituximab regimens were used: (1) 375 mg/m? in-
fused once per week for 4 weeks (n= 18)" and (2) 1000
mg infused twice, with a 2-weekinterval betweenthe in-
fusions (n=4).'! These regimens were based on ritux-
imab’s usein rheumatology,'' hematology,'® andthe pre-
viously reported series of patients with NMO.’ Local
practice determinedselection of the regimen. The spe-
cific treatment regimen for the remaining 3 patients was
not available.
Seventeenpatients were retreated with rituximab: 8
had 4 additional doses of 375 mg/m’ and7 had 2 1000- mg
doses 2 weeks apart. Data regarding the subsequent dos-
ing regimen were unavailable for 2 patients. Other im-
munotherapies with rituximab were usedin 5 patients:
azathioprine with prednisone (n= 1), prednisone (n=3),
andinterferon beta (n=1).
The median interval between the last relapse and
start of treatment was 1 month (range, 0-7 months;
mean, 1.5 months). Twentyof the 25 patients received
treatment within 2 months of their last relapse. The
median interval between rituximab treatments was 8
months (range, 4-26 months). Subsequent treatments
were either planned at 6- to 12-monthintervals or
were administeredafter relapse or when CD19"
B
cells
became detectable. Counts of CD19 cell markers were
not routinely monitoredin all patients, and a thresh-
old value was not used to determine the timing of
retreatment.
FOLLOW-UP
The medianfollow-upintervalafterinitial rituximabtreat-
ment was 19 months(range, 6-40 months). Eighteenpa-
tients plannedto continue treatment with rituximabat
their last follow-up and15 received rituximab during the
preceding 6 monthsoffollow-up.
Seven patients discontinued treatment. The reasons
for discontinuationwere death (n=2 [patients 5 and 10]),
relapses (n=2 [patients 18 and22}), pregnancy (n=
1
[pa-
tient 14]), and other (n=2 [patients 13 and 20]).
After experiencing relapses after treatment with
rituximab, 2 patients started other treatments(patients
18 and 22). Patient 18 required plasmapheresis every
6 weeks in conjunction with pulsed intravenous corti-
costeroids twice per month and mycophenolate
mofetil to maintain remission from additional relapses.
Patient 22 started treatment with cyclophosphamide
after her third relapse.
Patient 20, who took azathioprine throughout the
study, was averse to parenteral administration of drugs
and wishedto restart treatment with azathioprine.
After 2 minorrelapses, the dose of azathioprine was
increased; the patient was relapse-free when this
manuscript was written. One patient had a planned
pregnancy(patient 14) and discontinuedtreatment.
Patient 13 discontinuedtreatment withrituximab and
did not receive other immunosuppressive treatment
despite having a minor relapse (Figure). However,
after completion of this analysis, she was readmitted
with a severe spinal cord relapse 2 years after her last
infusion ofrituximab (not shownin the Figure) and
has now resumed taking rituximab; this relapse was
not includedin the analysis of the relapse rate.
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 Table. Clinical Profile of Patients Treated With Rituximab
Patient No./Sex/Age Disease Duration Drugs Used
at First Rituximab at First Rituximab NMO0-1gG LETM Before Rituximab Concomitant
Treatment, y Diagnosis Treatment, mo Status on MRI (Duration of Treatment, mo) Immunotherapy
1/F/49 NMO 4.84 - t Glatiramer acetate (7)
2/M/28 NMO 5.25 + + Interferon beta (24)
Azathioprine (28)
Intravenous immunoglobulins (23)
3/F/19 NMO 4.62 + + Azathioprine (9)
Interferon beta (7)
4/F/43 NMO 2.09 - + None
5/F/43 NMO 17.22 Test not done + Azathioprine (U)Prednisone (U)
Mitoxantrone(2)
Cyclophosphamide (U)
Mycophenolate mofetil (U)
6/M/22 NMO 15.79 + + Azathioprine(U)Prednisone (U)
Methotrexate (U)
7/F/40 NMO 6.77 Test not done + Glatiramer acetate (9) AzathioprineAzathioprine (13)
Interferon beta (3)
Mitoxantrone(2)
Azathioprine (20)
Prednisone(20)
8/F/7 NMO 4.17 + - Prednisone (3)
Q/F/21 NMO 7.92 + + Interferon beta (6)Azathioprine (27)
Cyclophosphamide(1)
Mitoxantrone (2)
1O/F/53 NMO 3.68 + + Mitoxantrone(5)Azathioprine (6)
V/FIV4A NMO 128 - U Prednisone (7) Prednisone, azathioprineIntravenous immunoglobulins (U)
12/F/50 NMO 0.83 Test not done + U
13/F/33 NMO 2.89 i + Interferon beta (U)Intravenous immunoglobulins (U)
14/F/28 NMO 6.08 Test not done + Interferon beta (60)Azathioprine (72)
Prednisone (24)
Intravenous immunoglobulins (15)
15/F/18 NMO 8.17 + + Interferon beta (102) Interferon betaMitoxantrone (3)
Intravenous immunoglobulins (4)
46/F/19 NMO 6.32 + + Interferon beta (12)
Glatiramer acetate (3)
Interferon beta (45)
Intravenous immunoglobulins (7)
Mitoxantrone (3)
17/F/22 NMO 7 + + Interferon beta (12)Azathioprine (14)
Mitoxantrone (22)
Azathioprine (4)
18/F/52 NMO 4.25 - + Interferon beta (26)
19/F/54 NMO 1.17 + + Azathioprine (5) PrednisonePrednisone (5)
20/F/43 Relapsing myelitis 4.13 + * Hydroxychloroquine (1) PrednisoneAzathioprine (53)
Prednisone (12)
21/F/43 Relapsing myelitis 2.62 + + Cyclophosphamide(22)
22/F/35 NMO 3.63 - + Glatiramer acetate (24)
23/F/47 NMO 3.1 + + Prednisone (3)Azathioprine (6)
24/M/62 NMO 2.88 Test not done + Interferon beta (4)Azathioprine (2)
25/F/24 NMO 4.93 - + Azathioprine (12)Prednisone (12)
Interferon beta (33)
intravenous immunoglobulins (1) 
Ue
Abbreviations: LETM, longitudinally extensive transverse myelitis MRI, magnetic resonance imaging; NMO, neuromyelitis optica; U, unknown; + , positive: -, negat
ive.
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Figure. Relapses in patients with neuromyelitis optica before and after
treatment with rituximab
TREATMENT EFFICACY
Relapse Rates
Relapses before andafter treatmentare representedin the
Figure. All relapsesafter onsetofrituximab treatment were
considered. However,if newtreatments werestarted, only
relapses until the start date of the newtreatment were
included (patients 18, 20, and 22). Relapses in patients
whostoppedtaking rituximab but who were not under-
going anyother treatments were included. For all 25 pa-
tients, the median annualized pretreatment relapserate
was1.7 relapses (range, 0.5-5 relapses) and the median
annualizedposttreatmentrate was0 relapses (range, 0-3.2
relapses, P<.001, Wilcoxon signed-rank test) at a me-
dian follow-up of 19 months. The following sensitivity
analyses were performedto address whether these re-
sults were biased by including patients whodied, were
followed upfor less than 1 year after treatment with ri-
tuximab, or received concomitant treatment with other
immunotherapies.If the 2 patients whodied (patients 5
and 10) were excluded (n= 23), the median pretreat-
ment annualizedrelapse rate was 1.7 relapses (range, 0.6-
4.9 relapses) andthe posttreatment was0 relapses (range,
0-3.2 relapses) (P<.001). If the 5 patients who were un-
dergoing additional immunotherapies (patients 7, 11, 15,
19. and 20) andthe 2 whodied were excluded (n=18),
the medianpretreatment relapse rate was 1.7 (range, 0.7-
4.9) and the median posttreatment relapse rate was 0
(range, 0-2.9) ata median follow-up of 18 months. If the
patients who were followed up [orless than | year were
also excluded (patients 1, 2, 3, and 4) along with those
taking additional immunotherapies (n=5) and those who
died (n=2), the median pretreatment andposttreat-
ment relapserates were 1.5 (range, 0.7-4.9) and0 (range,
0-2.9), respectively, ata median follow-upof 22 months
in the remaining 14 patients.
Disability
Twopatients died (patients 5 and 10). The median Ex-
pandedDisability Status Scale (EDSS) scoreat the start
of treatmentwithrituximab(n= 25) was7 (range, 3-9.5)
andat last follow-up at a median of 19 months was 5
(range, 3-10) (P=.02). The EDSS scoresstabilized in 9
patients andimprovedin 11. In 5 patients (patients 3, 5,
10, 13, and 20), EDSS scores worsened.
ADVERSE EVENTS OBSERVED DURING
TREATMENT AND FOLLOW-UP
Transient infusion-related adverse effects occurredin 7
of 25 patients (28%) and were not dose-limiting. New
or reactivated infections developed in 5 of 25 patients
(20%) and includedherpes simplex (cold sore) andposi-
tive tuberculin skintest (n=1), herpes zoster (n= 1), re-
current Clostridium difficile colitis (n= 1),a cutaneous fun-
gal infection (n=1), and fatal urinary tract-related
septicemia (n= 1). Worseningofpreexisting seborrheic
dermatitis occurredin | patient.
DEATHS
Patient 5 developedrecurrentCdifficile colitis after her
first rituximab infusion followed by a urinarytract in-
fection. She died 9 monthsafter the last dose following
a severe relapse; she had a brainstemlesion that ex-
tendedinto the hypothalamus and thalamus on mag-
netic resonance imaging. Clinical manifestations were
lethargy, obtundation, electrolyte imbalance, and hypo-
thermia, CD19* B cells were not detectable 2 months be-
fore her death (7 monthsafter last infusion).
Patient 10 died 6 monthsafter the last dose ofritux-
imab. She was obtundedandsuspectedofbeing septic. An
autopsyof the brain andspinalcord showedconfluent de-
myelinationfromthe lumbarspinal cordto the cervical cord
with necrosis and cavitation, perivascular lymphoid infil-
trate, and macrophageinfiltrates. Both optic nerves were
atrophic and hadlymphocyte and macrophage infiltrates.
Thebrain did not showanypathology. CD19" B cells were
undetectable 5 monthsafter herlast infusion (1 month be-
fore death). Hertotal lymphocyte count was 900/pL (to con-
vert to X 10° per liter, multiply by 0.001) before death (nor-
mal, 900-2900/yL.) compared with 2730/aLbefore starting
rituximab.Shealso hadlowIgA, IgG, and 1gM concentra-
tions | month before her death. She was treated with mi-
toxantronebeforeinitiation ofrituximab.
Neuromyelitis opticais a relapsing disorder withrapid ac-
crual ofattack-related disability and a high, early mortal-
ity rate.' Controlled trials of treatments to prevent re-
lapses are unavailable, and treatmentis based oncaseseries
andexpert opinion. Although 2 cases were reported to en-
ter remission with the use of glatiramer acetate,'?'> im-
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munomodulatory medications (interferon beta or glat-
iramer acetate) do not appearto be beneficial in larger case
series.*’ Immunosuppressive drugs are the mainstayof treat-
ment of NMO.Azathioprine' is the most widely used medi-
cation. Cyclophosphamide, mitoxantrone,’ cyclosporine,
methotrexate, and mycophenolate mofetil’ have also been
used.'' However, patients commonlyrelapse onthesetreat-
ments; relapses with brainstemor cervical cord involve-
ment are a frequent cause of death in NMO.'
In this retrospective, multicenter case series, we evalu-
ated the use ofrituximabin patients with NMOwhowere
largely refractoryto other treatments. Relapse rates im-
provedand disability stabilized or improvedin 20 of25
patients (80%), a rate that is similar to previouslyre-
ported observations.’
Althoughthe infections cannot be definitivelyclassi-
fied as opportunistic, the death of 1 patient owingto sep-
sis and the occurrence of infections in others raise im-
portant concerns about rituximab’ssafetyin this specific
disease setting. Patient 10 diedfollowing a presumeduri-
narytract infection and had reduced lymphocyte counts
and immunoglobulin concentrations. It is possible that
treatment with rituximaband/orprior eatment with mi-
toxantrone contributed to this patient’s sepsis.
Wedid not attempttoidentify predictive factors of a
beneficial responseto rituximab treatment. The small size
of the study, retrospective acquisition ofdata, andposi-
tive treatment responsein 80%ofpatients precludes such
an analysis. We did not compare the 2 regimens owing
to the differing number ofpatients in the 2 groups and
the switching betweenthe 2 regimensfor subsequent treat-
ments in somepatients.
It is unclear whetherrituximab shouldbe the first treat-
ment for NMO. Comparative studies of the immunosup-
pressive treatments usedfor NMOhavenot been under-
taken. Most patients in this series are fromaselected
population with treatment-refractory NMO.It is pos-
sible that patients who have never undergone treatment
maybenefit from morewidelyavailable and less expen-
sive immunosuppressive medications. Furthermore, even
in this small group, there are apparent rituximabtreat-
ment failures, demonstrating that it is not effective inall
patients. A recent case report of 2 patients with variable
responses to rituximabhighlights this point”
Safety concernsregarding rituximab persist. Therela-
tive risk of infections with rituximab vs other immuno-
suppressive treatments of NMOis unknown. Recent re-
ports of progressive multifocal leukoencephalopathyin 2
patients with systemic lupus erythematosus, | patient with
systemic vasculitis, and 23 patients with lymphoma treated
with rituximabare concerning.” However, these patients
received treatment with other immunosuppressive medi-
cations, either sequentially or combined with rituximab.
Lymphomasandsystemiclupus erythematosusare thought
to predispose individuals to progressive multifocal leuko-
encephalopathy, irrespectiveoftreatment. Progressive mul-
tifocal leukoencephalopathyhasalso beenassociated with
azathioprine,'*"’ cyclosporine,"*” cyclophosphamide,“ and
mycophenolate mofetil”
Rituximab treatment is more expensivethan ge-
neric immunosuppressive drugs, such as azathioprine.
However, the higher cost mayoffset the cost of hospi-
talizations for relapses and plasma exchanges if ritux-
imabis more effective.
Ourstudyis limitedby the retrospective nature of the
caseseries, whichis based on theclinical experience with
rituximab at 7 centers, and several important caveats
should be mentioned. First, 2 treatment regimens were
used, though the total dose administered to each pa-
tient was similar. Second, the intervals between courses
of treatmentvaried. Third, itis possible that regression
to the mean contributedto the declinein relapse rates.
However, webelieve that this is unlikely because there
was no specific relapse requirement preceding ritux-
imab treatmentfor inclusion in this case series and be-
cause the pretreatmentrelapse rates were determined from
disease onset rather than froma fixed period immedi-
ately preceding rituximab therapy. Fourth, the interval
between rituximab andprevious drugs was often short,
andit is possible that some of the effects that were at-
tributed to rituximab could be due to residual benefits
from other medications. Fifth, rituximab was used with
other drugs in 5 patients. Sixth, CD19~ B-lymphocyte
counts were not measuredtoassessefficacy oftreat-
ment and timing of retreatment. Lastly, the pretreat-
ment EDSS score may have been determined immedi-
ately postrelapse, while the last available EDSS score may
have been determined during a periodof stability, thus
showing improvement attributable to recoveryfrom an
attack.
Despite theselimitations,wefeel that the data are cred-
ible, particularly considering the robust suppression of
disease activity in patients with NMOfollowing ritux-
imab treatment. Recently, much has been learned about
the pathogenesis of NMO.” However, data on treat-
ment of NMOaresparse, and randomized,controlled trials
onthis disease have never been performed. This is the
largest case series of a single drug treatment, particu-
larly in the subgroupofpatients with NMOwhoarere-
fractory to conventional treatment in whom the risk of
mortality is high. Controlled trials are difficult to orga-
nize owingto a variety of reasons, including the rarity
of the disease, need for early treatment, and high mor-
bidity from relapses. Given the absence of such con-
trolled trials, studies such as this provideat least anec-
dotal evidence to help guide clinicians in selecting
treatments for this potentiallylife-threatening disease.
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Treatment of Neuromyelitis Optica
With Mycophenolate Mofetil
Retrospective Analysis of 24 Patients
Anu Jacob, MD; Marcelo Matiello,MD; Brian G. Weinshenker, MD; Dean M. Wingerchuk, MD;
Claudia Lucchinetti, MD; Elizabeth Shuster, MD; Jonathan Carter, MD;
B. Mark Keegan, MD; OrhunH. Kantarci, MD, SeanJ. Pittock, MD
Background: Neuromyelitis optica (NMO)is the first
inflammatoryautoimmune demyelinating disease of the
central nervous systemfor whicha specific antigenic tar-
get has beenidentified: the marker autoantibody NMO-
IgG specifically recognizes the astrocytic water channel
aquaporin 4. Current evidence strongly suggests that
NMO-IgG maybe pathogenic. Since disability accrues in-
crementally related to attacks, attack prevention with im-
munosuppressivetherapyis the mainstay of preventing
disability.
Objective: To evaluate the efficacy and safety of
mycophenolate mofetil therapyin NMOspectrumdis-
orders.
Design: Retrospective case series with prospectivetele-
phonefollow-up.
Setting: MayoClinic Health System.
Patients: Twenty-fourpatients with NMOspectrum dis-
orders (7 treatment-naive).  
Intervention: Mycophenolate mofetil (median dose of
2000 mg per day).
Main Outcome Measures: Annualized relapse rates
anddisability (ExpandedDisability Status Scale).
Results: At a median follow-up of 28 months(range,
18-89 months), 19 patients (79%) were continuingtreat-
ment. The median duration oftreatment was 27 months
(range, 1-89 months). The median annualizedposttreat-
ment relapse rate was lower thanthe pretreatmentrate
(0.09; range, 0-1.5; and 1.3; range, 0.23-11.8, respec-
tively; P< .001). Disability stabilized or decreased in 22
of 24 patients (91%). One patient died of disease com-
plications during follow-up.Six patients (25%) noted ad-
verse effects during treatment with mycophenolate.
Conclusion: Mycophenolateis associated with reduc-
tion in relapse frequencyandstable or reduced disabil-
ity in patients with NMOspectrum disorders.
Arch Neurol. 2009;66(9):1 128-1133
 
EUROMYELITIS OPTICA
(NMOQ)is an idiopathic
autoimmune inflamma-
tory demyelinating disor-
der that affects the cen-
NMO-IgGin these disorders is predictive
of further relapses.*”
Disability in NMO accrues incremen-
tally in relationship to attacks.°” Fifty per-
cent of patients are dependent ona wheel-
chair and 62%are functionally blindat 5
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tral nervous systemwitha predilection for
the optic nerve and spinal cord. Itis thefirst
inflammatory autoimmune demyelinat-
ing disease ofthe central nervous system
for whicha specific antigenic target, the as-
trocytic water channel aquaporin 4, has
been identified.'? Neuromyelitis optica—
IgGis an autoantibodyspecific for this wa-
ter channelandis
a
clinicallyvalidatedse-
rum biomarkerthatdistinguishes relapsing
NMOfrom multiplesclerosis, whichhas no
distinguishing biomarker.’ Patients sero-
positive for NMO-IgG with either optic neu-
ritis or longitudinally extensive transverse
myelitis are considered to have limited
forms of NMO, whichwehavecalled NMO
spectrum disorders. Seropositivity for
years.°” In contrast, patients with mul-
tiple sclerosis have a more favorable out-
come, anddisability usually occurs dur-
ing the progressive rather than the
relapsing phase oftheir disease.*'® Be-
cause disability in NMOis attack-related,
attack preventionis anticipated to be an
effective strategy in prevention of cumu-
lative disability. Immunosuppressive
therapyis the mainstayof preventing at-
tacks and thus disability.'’ Azathio-
prine,”? corticosteroids,'? mitoxan-
trone.'* and more recently rituximab!*'®
have been reportedtobeeffective in small
case series. No randomized controlledtrials
have been conductedin this disorder.
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Recently, mycophenolate mofetil has been increas-
ingly used in NMO,thoughto date only | case of NNO
treated with mycophenolate mofetil has been re-
ported.!’ Mycophenolate mofetil (Cellcept, F. Hoff-
mann-La Roche, Basel, Switzerland) is a 2-morpho-
linoethyl ester of mycophenolic acid and areversible
inhibitor of inosine monophosphate dehydrogenasethat
is involvedin guanosine nucleotide synthesis, on which
the T and B lymphocytes are exclusively dependent for
proliferation.'* It also exerts an inhibitoryeffect on an-
tibody synthesis. It is routinely used in cardiac andre-
nal transplant settings andis being increasingly used as
a treatmentoptionina variety of other autoimmunecon-
ditions, including systemic lupus erythematosus—
induced and other immune nephropathies, autoim-
munehepatitis, psoriasis, blistering dermopathies, and
vasculitides. It is also used to treat myastheniagravis,"”
multifocal motor neuropathy,” inflammatory myopa-
thies,' chronicinflammatory demyelinating polyradicu-
loneuropathy,”? autonomic ganglionopathy,”’ vasculitic
neuropathies,”' and multiple sclerosis.°°*" It is consid-
ered to have fewer adverse effects than other immuno-
suppressive agents andis administeredorally. The opti-
mal dose and duration and the effect size of
mycophenolate mofetil for prevention of NMO attacks
remain uncertain. Herein we report on our experience
with mycophenolate mofetil in a cohort of adult pa-
tients with NMO.
EE———t
Weperformeda retrospective medical record review of all Mayo
Clinic patients with NMO(per 2006 diagnostic criteria) or an
NMOspectrumdisorder (NMO-IgG-seropositive patients with
optic neuritis or longitudinally extensive transverse myelitis)
whowere treated with mycophenolate mofetil anytime from
June 1999 until June 2006. Patients were identified by search-
ing the centralized medical recordsof all the 3 Mayo Clinicsites
(Rochester, Minnesota; Scottsdale, Arizona, andJacksonville,
Florida) using the search terms neuromyelitis optica, Devic’s dis-
ease, optic neuritis, or myelitis and mycophenolate or Cellcept.
Local institutional review board approval was secured and
informed consent obtainedfrompatients or next of kin, Tele-
phone follow-up was performed by one of us (AJ., M.M., or
5.J.P.) in 2008. Data analysis was performed at the Mayo Clinic,
Rochester, using JMP, version 6.0 (SAS Institute Inc, Cary, North
Carolina), Wilcoxonsigned-ranktest was used to compare pre-
treatment andposttreatment relapse rates and ExpandedDis-
ability Status Scale (EDSS) scores. Relapses and disability were
assessed by medical record reviewandtelephoneinterview, A
relapse was definedas objective worsening of neurologicfunc-
tion lasting more than 24 hours.
US
PATIENT CHARACTERISTICS
Twenty-four patients (19 women) wereidentified. The
medianage of the patients at onset of treatment with my-
cophenolate mofetil was 56 years (range, 34-77 years).
The medianduration of NMOtoonsetoftreatment with
mycophenolate mofetil was 4.2 years (range, 0.1 -39years).
The diagnosis was NMOin 15 patients (63%, 13 of 14 tested
were NMO-IgG-seropositive andallfulfilled 2006 NMO
diagnostic criteria); relapsing longitudinally extensive trans-
verse myelitis in 7 patients (29%); relapsing optic neuri-
tis in 1 patient (4%); anda single episodeof longitudi-
nally extensive transverse myelitis in | patient (4%). The
patients with relapsing or single episodes of longitudi-
nally extensive transverse myelitis or relapsing optic
neuritis were all NMO-lgG—seropositive.
TREATMENTWITH
MYCOPHENOLATE MOFETIL
Sevenpatients (29%) were treatment-naive. The remain-
ing 17 patients (71%) hadpreviously used other immu-
nosuppressive (n=6), immunomodulatory (n=2), or com-
bination (n=9) therapy. Twelve (50%) received
azathioprine (Table). Reasons for switching to myco-
phenolate mofetil included medication adverse effects
(n=7 [29%]). continued relapses (n=8 [33%]), and con-
traindication to azathioprine owing to low thiopurine
methyltransferase levels (n=2 [8%]). The median dose
of mycophenolate mofetil used was 2000 mg per day
(range. 750-3000 mg per day). Theclinical and demo-
graphic profiles of the patients are summarizedin the
Table.
FOLLOW-UP
Afteridentification of theinitial cohort in June 2007, tele-
phonefollow-up and medical record review were again
performedin 20 patients in late 2008 ata median of 27
monthsafterstarting treatment(range, 18-89 months).
Telephone contact wasnotpossiblefor 4 patients (1 died);
medical record reviewin these patients provided post-
treatment follow-up data for a median of 46 months
(range, 21-54 months). The medianfollow-up of all pa-
tients (irrespective of whether they continuedtreat-
ment) was 28 months(range, 18-89 months).
The median duration of treatment with mycopheno-
late mofetil was also 27.4 months(range, 1-89 months).
Atlast review, 19 patients (79%) continuedtreatment with
mycophenolate mofetil, with a medianduration of 29.4
months(range, 20-89 months). Five patients (21%)dis-
continuedtaking the drug after a median interval of16
months (range, 1-54 months). The reasons for discon-
tinuation were death in | (patient 21), relapses in 2 (pa-
tient 3 switched to rituximab at 3 months, patient 1+ to
azathioprine at 25 months), andadverseeffects in 1 (pa-
tient 24 had low white bloodcell counts and switched
to azathioprine at 1 month). Patient 1 hadneither re-
lapses nor adverse effects but chose to switch to ritux-
imab after | month of mycophenolate mofetil.
TREATMENTEFFICACY
Relapse Rates
The Figure depicts the timingof relapses before andaf-
ter treatment. All relapses after initiation of mycophe-
nolate mofetil until its discontinuation or until the last
date of follow-up wereincludedin the analysis. Nine pa-
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Table. Clinical Characteristics of Patients Treated With Mycophenolate Mofetil
Disease Duration at
Patient No./ First Mycophenolate NMO-lgG  LETMon Drugs Used Prior to Concomitant
Sex Diagnosis Mofetil Treatment, y Status Mri Mycophenolate Mofetil Immunotherapy
1/M Relapsing myelitis 3 t ,
2/M NMO 4.08 + + Azathioprine
iF NMO 6.83 + + Interferons Oral prednisone
4/F NMO 5.89 + + Azathioprine, interferons,
prednisone
5/F Relapsing myelitis 0.83 + + Azathioprine Prednisone on alternate days
6/F NMO 1.17 + + Glatiramer acetate Pulsed intravenousmethylprednisone monthly
7/F NMO 1 U +
8/M Relapsing myelitis 2.75 t 4
O/F NMO 12.5 + + Azathioprine, prednisone, Intravenous immunoglobulinintravenous monthly
immunoglobulins
10/F Relapsing myelitis 1.25 + +
11/F Relapsing myelitis 6.25 + + Interferon, prednisone
12/F Relapsing optic neuritis 10.83 + - Oral prednisone
13/F NMO 26.33 + + Azathioprine, interferon, 1g of oral methylprednisoneglatirameracetate, monthly
methotrexate
14/F NMO 18.16 a * Prednisone, glatiramer acetate,mitoxantrone,
cyclophosphamide,
interferon
15/F Single episode of 0.08 ; + 5 mg of oral prednisone daily
myelitis
16/F NMO 13.01 + + Azathioprine, intravenousmethylprednisone,
interferon, mitoxantrone,
methotrexate
17/F NMO 25.83 + + Glatiramer acetate,azathioprine, interferons,
prednisone
18/F NMO 38.75 + + Azathioprine, interferon,intravenous
immunoglobulins
19/F NMO 0.66 ” =
20/F Relapsing myelitis 18 + + Cyclophosphamide
21/M NMO 1.42 + + Azathioprine, prednisone Prednisone, intravenousmethylprednisone
22/F Relapsing myelitis 0.25 + + Azathioprine Pulsed intravenousmethylprednisone
23/F NMO 4.33 + - Azathioprine, prednisone,cyclophosphamide
24/M NMO 6.5 t t Azathioprine, interferon  
Abbreviations: LETM, longitudinally extensive transverse myelitis, MRI, magnetic resonance imaging; NMO, neuromyelitis optica, U, unknown; +, present: -, absent.
tients were undergoing additional treatments (oral [n=8]
and intravenous [n=1] corticosteroids) for variable pe-
riodsafterstarting treatment with mycophenolate mofetil
(Table).
The median annualized posttreatment relapserate was
0.09 (range, 0-1.56), and the pretreatmentrate was 1.28
(range, 0.23-11.78; P<.001, Wilcoxonsigned-ranktest).
Nineteenofthe 24 patients (79%) had an improvement
in annualizedrelapse rate. Because analysesofthe total
group were confoundedbyshort duration oftreatment,
death, and concomitant treatments, we performedthefol-
lowing 3 subgroupanalyses.
Analysis Excluding Patients With Less Than 6 Months
of Mycophenolate Mofetil Therapy. Two of the 24 pa-
tients took mycophenolate mofetil for a very short du-
ration (patients | and 2 for | month each) and discon-
tinuedtaking the drug early owing to adverseeffects. With
these patients excluded from the analysis, the median
treatment duration was 28 months(range, 16-89 months).
The median posttreatment annualized relapse rate on
treatment for the remaining 22 patients was 0.2 (range,
0-1.5), a significant reduction compared with the pre-
treatmentrate of 1.37 (range, 0.23-11.78; P< .OOL). Sev-
enteen of 22 patients (77%) had an improvementin re-
lapse rate.
Analysis Excluding Thosein First Analysis and| Patient
Death. After exclusion ofthe patient whodied (patient
21) and thoseexcluded in thefirst subgroupanalysis, the
median duration of treatmentfor the 21 patients was 27.4
months (range, 16-89 months). The median posttreat-
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ment annualized relapse rate with treatment forthis sub-
set was 0.18 (range, 0-1.5), and the pretreatmentrate was
1.15 (range, 0.23-11.78; P<.001).
Analysis Excluding Those in Second Analysis and
Patients Receiving Concomitant Therapies. After ex-
clusion ofpatients whoreceived concomitant immuno-
suppressive treatment (patients 3,5,6,9, 12,13, 15,21,
and 22) and thosein the second subgroupanalysis, the
median durationof treatment in months was 31 (range,
21-89 months) for the remaining 12 patients. The me-
dian posttreatment annualized relapse rate on treat-
ment for this subset was 0.24 (range, 0-1.22), and the
pretreatment rate was 1.15 (range, 0.23-7.6; P<.001).
Disability
The median EDSS score was 6 (range, 0-8) atthe start of
treatment with mycophenolate mofetil (n=24) and 5.5
(range, 0-10)at last follow-up(ata medianof 28 months;
P=.17). Exclusion of 2 patients who underwent treat-
mentfora veryshort perioddidnotalter the medianscores.
The EDSS scores were unchanged in 15 and im-
proved in 7 (22 of 24 (91%]). The median reduction in
EDSS score was | point (range, 0-5-2.5). Fourofthese
patients no longer needed a cane. The EDSSscore wors-
enedin 2 patients (patient 3 worsenedfrom 6 to 8, and
patient 21 died after being bed boundfor 54 months).
ADVERSE EVENTS
Patient 21 died. He was a 45-year-old Hispanic man who
presented with optic neuritis and myelitis in 1999 and
had 3 additional relapsesin the sameyear. Hebegantreat-
ment with mycophenolate mofetil and prednisone in 2000,
after developing liver dysfunction with azathioprine. No
adverse effects were notedinthefirst year of treatment.
He was subsequentlylost to follow-up. Telephoneinter-
views with his family following his death indicate that
the patient continued to relapse approximately every 6
months anddied 54 monthsafter onsetof treatment with
mycophenolate mofetil. The death certificate docu-
ments the cause of death as “cardiopulmonaryfailure,
respiratorydrive failure and Devic’s disease.”
Six patients (25%) reported adverse effects: head-
ache (n=1), constipation (n=1), easy bruising (n=1),
anxiety (n=1), hair loss (n= 1), diarrhea and abdominal
pain (n=1), and low white blood cell counts that re-
quired discontinuation (n=1).
ee
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The increasing popularity of mycophenolate mofetil in
treating rheumatic disease and myasthenia gravis and in
preventing transplant rejection promptedits use for NMO.
This retrospective study summarizes the treatment ex-
perience at the MayoClinic withthis drug. Mycopheno-
late mofetil therapy was associated with an improve-
ment in the relapse rates in 19 of 24 patients (79%) and
stabilization or reduction in disability in 22 of 24 pa-
tients (91%)
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Figure. Neuromyelitis optica relapses before and after treatment with
mycophenolate mofetil (0 on the x-axis indicates the start date of treatment).
Each interrupted line on the y-axis representsa patient. The relapses of
patient 21 are distributed evenly over his mycophenolate mofetil treatment
duration owing to incomplete data.
The single previous case report of mycophenolate
mofetil in NMOdescribed a 9-year-old girl with NMO
whohad5 relapses within a 2-year period despite aza-
thioprine. Corticosteroid therapy was followed bya ver-
tebral fracture. Mycophenolate mofetil introduced 16
months after onset of NMOwasfollowed bysustained
remissionat 2 years.'!
The mainstayof treatmentfor mostpatients with NMO
is prednisone, alone or combined with azathioprine. This
approachis largely basedon
a
series of 7 patients with
NMOwhoweretreated with long-term prednisone and
azathioprine and were followed up every 2 months for
at least 18 months. Their EDSSscores improvedsignifi-
cantly and no relapses occurred for more than 18
months.”
A series of 5 patients treated with mitoxantronedur-
ing 2 years also showed improvement.'' However, 2 pa-
tients relapsed once withintheinitial 5 monthsoftreat-
ment and | patient had areversible decrease in cardiac
ejection fraction. Cardiotoxicity is a concern with mi-
toxantrone, and the duration oftreatment is limitedto
about 2 years because of restricted cumulativelifetime
dosing.
Rituximab, a monoclonal antibodyagainst CD20° B
cells,'° has been used to prevent attacks of NMO.Fol-
lowing up onaninitial report on8 patients,a recent ret-
rospective multicenter experience in 25 patients (23 of
whom wererefractoryto other medications,including |
patient treated with mycophenolate mofetil) showedthat
rituximab treatmentwas associated with reductioninre-
lapse rates andstabilized disability scores in 80% of treated
patients." However, 28%of patients had infusion-
related adverse events and 20%hadinfections that could
have beenrelated, at least in part, to immunosuppres-
sion. Twopatients died, one likely because of septice-
mia. Rituximab, therefore, was potentially beneficial but
(1) required intravenousinfusion (which maynecessi-
tate admission), (2) was associated with infection risk,
and (3) somepatients remainedrefractoryto treatment.
These factors andtherisks of significant infections from
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immunosuppression maylimit its use, especiallyasa first-
line agent in the treatment of NMOspectrumdisorders.
Mycophenolate mofetil mayalso produce serious tox-
icity. Progressive multifocal leukoencephalopathy has
been reportedin kidney, heart. and lung transplant pa-
tients andin systemic lupus erythematosus when myco-
phenolate mofetil was used in conjunction with or after
the use of other immunosuppressants.** A retrospective
cohort studyof 32 757 renal transplant recipients using
the United States Renal Data System kidneytransplant
files identified 9 cases. The incidenceof progressive mul-
tifocal leukoencephalopathyin those taking mycophe-
nolate mofetil was 14.4 cases per 100 000 person-years
at risk vs 0 for those not taking mycophenolate mofetil.
However, because 75%ofpatients in the cohort were tak-
ing mycophenolate mofetil, the putative association was
notstatisticallysignificant. No cases of progressive mul-
tifocal leukoencephalopathywere found in patients un-
dergoing mycophenolate mofetil monotherapy.” Al-
though an increasedrisk of lymphoma wasinitially
reportedin patients who underwent transplants and oc-
casionally in autoimmune disorders,” * an interna-
tional prospective registry of 6751 patients receiving my-
cophenolate mofetil and an equal number of matched
controls receiving other immunosuppressive treat-
ments did not find anassociation with lymphomainre-
nal transplant patients with lupus nephritis.’ The ad-
verse effects observed in the present study were dose
limiting in 1 patient andnecessitated change to azathio-
prinein another.
The efficacy of mycophenolate mofetil remains un-
certain. Despite anecdotal evidence supportingits effec-
tiveness in myasthenia gravis,"2 recent large random-
ized trials reported no benefit.’?*” It has not been
established whether mycophenolate mofetil is superior
to azathioprine in preventing acuterejections in recipi-
ents of cadaver kidneytransplants. ** Mycophenolate
mofetil is considerably more expensive than azathio-
prine, but less expensive than rituximab. The estimated
drug cost for | year of treatment, exclusiveof cost of ad-
ministration, is $846.80 for 150 mg of azathioprineper
day, $11 373.40 for 2000 mg of mycophenolate mofetil
per day, and $23 287.60 for four 1000-mg infusions of
rituximab per year.
The uncontrolled design of the study, the small
sample, and confounding concomitant treatments pre-
clude definitive evaluation of the efficacy of mycopheno-
late mofetil for NMOrelapse prevention. The reduction
in the posttreatmentrelapse rate could be explained by
regression to the mean.” Theeffects of EDSS score could
have been confoundedbyrecent attacks at the time of
initiation of mycophenolate mofetil treatment andeffects
on attack suppression. There was no washout period to
eliminate effect of prior therapies. Follow-up was incom-
plete, and the cause of deathin 1 patient hadto be ascer-
tained by contact withhis family andreviewof the death
certificate
Phis is a cumulative experience ofall patients with
NMO treated by 10 neurologists at 3 different MayoClinic
sites. Despite the aforementionedlimitations, this case
series provides some justification for the use of myco-
phenolate mofetil to prevent attacks of NMO. There have
been noplacebo- or active comparator—controlledtrials
in NMO. Azathioprine withor without oral prednisone,
rituximab, mycophenolate mofetil, and other immuno-
suppressants all seem effective; therefore, adverse ef-
fects and cost along with the urgencyto achieve imme-
diate immunosuppressioninfluence the choice of
treatment. Controlled trials are necessary.
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